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ABSTRACT 
This PhD thesis is a part of the study concerning non-viral nanocarriers for 
gene therapy. In modern molecular medicine, gene therapy is a very 
promising research. One issue with gene therapy is the efficient delivery of 
the genetic material into the cell. Naked DNA cannot pass freely the cell 
membrane because it is made up of very large molecules with a hydrophilic 
nature provided by the negatively charged phosphate groups; moreover it 
can be easily degraded by nucleases. For these reasons the development of 
suitable vectors for an efficient transfection is fundamental in order to 
facilitate and optimize gene transfer to targeted cells without degradation. 
One of the most important requirements in gene therapy is the development 
of safe and efficient gene delivery systems. In the past two decades viral 
vectors, such as adenovirus and retrovirus, were the most used in several 
clinical trials. Today non-viral vectors have attracted a growing interest in 
the scientific community, thanks to their preparation reproducibility, lack of 
immunogenicity and almost no size limit to the piece of DNA carried into 
cells. 
The aim of this PhD thesis was to identify and compare plasma proteins 
bound to different kind of non-viral nanovetcors commonly employed for 
gene therapy studies. The knowledge about the interaction between plasma 
proteins and nanocarriers is fundamental to understand the in vivo 
biodistribution, thus the transfection efficiency (TE).  
Protein adsorption onto nanoparticle surface (protein corona) is strongly 
affected by vector surface characteristics. In general, the primary interaction 
is thought to be electrostatic, thus surface charge of carriers is supposed to 
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play a central role in protein adsorption. Because protein corona 
composition can be critical in modifying the interactive surface that is 
recognized by cells, an insight into its formation onto lipid particles may 
serve as a fundamental predictive model for the in vivo efficiency of a lipid 
vector.  
A shotgun analytical proteomics approach was employed in all studies to 
compare human plasma protein binding capability to cationic liposomes 
(CLs), lipoplexes and protamine/DNA (P/DNA) complexes. This approach 
exploited a centrifugation-based protocol for the separation of the 
nanoparticle-protein complexes, followed by "in solution” proteolytic 
digestion of the whole protein mixtures and determination of the resulting 
peptides by nano-high performance liquid chromatography (nanoHPLC) 
coupled to a high-resolution linear trap quadrupole (LTQ) Orbitrap XL mass 
spectrometer. 
Paper I described and compared the adsorption of human plasma proteins 
bound to cationic liposomes, made of (3-[N-(N,N-dimethylaminoethane)-
carbamoyl])-cholesterol (DC-Chol) and the zwitterionic lipid 
dioleoylphosphatidylethanolamine (DOPE), and their relative DNA cationic 
lipoplexes. A shotgun proteomics approach based on HPLC coupled to high 
resolution mass spectrometry (MS) was used for an efficient identification 
of proteins adsorbed onto liposome and lipoplex surfaces. The distinct 
pattern of proteins adsorbed helped to better understand the DNA 
compaction process. The experimental evidence lead us to hypothesize that 
polyanionic DNA is associated to the lipoplex surface and can interact with 
basic plasma proteins. Such a finding is in agreement with recent results 
showing that lipoplexes are multilamellar DNA/lipid domains partially 
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decorated with DNA at their surface. Proteomics experiments showed that 
the lipoplex corona is rich of biologically relevant proteins such as 
fibronectin, histones and complement proteins. Our results provided novel 
insights to understand how lipoplexes activate the immune system and why 
they are rapidly cleared from the bloodstream. The differences in the protein 
adsorption data detected in the presented experiments could be the basis for 
the establishment of a correlation between protein adsorption pattern and the 
in vivo fate of intravenously administered nanoparticles, and will require 
some consideration in the future. 
Paper II and III investigated the liposomes made of the cationic lipid DC-
Chol DOPE and the possible effect of membrane charge density on the 
formation of the protein corona. The membrane charge density is the 
average charge per unit area of the membrane and it is controlled by the 
ratio of neutral to cationic lipid in the liposome formulation. To vary it, the 
neutral/total lipid molar ratio was changed, “diluting” the cationic lipid in 
the membrane with the neutral helper lipid. In paper II the proteomic study 
was carried out in order to portrait the protein corona composition from a 
qualitative point of view. This initial study was performed validating 
Mascot search results with the Trans-Proteomic Pipeline (TPP) platform. In 
paper III the experiment was repeated to add a label-free quantitation based 
on spectral count (SC) by Scaffold. Fibrinogen displayed higher association 
with CLs having a higher membrane charge density, while apolipoproteins 
and C4b-binding protein with CLs having a lower membrane charge 
density. These results are discussed in terms of the different lipid 
compositions of CLs and may have a deep biological impact for in vivo 
applications. Surface charge of nanoparticles is emerging as a relevant 
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factor determining the corona composition after interaction with plasma 
proteins. Remarkably, it was also shown that the charge of the protein 
corona formed around CLs is strongly related to their membrane charge 
density.  
In paper IV we investigated the compositional evolution of the protein 
corona of 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) CLs and 
DOTAP/DNA lipoplexes over a wide range of plasma concentrations (2.5-
80%). The composition of the hard corona of lipoplexes was quite stable, 
differently from that of CLs, which did evolve considerably, instead. We 
showed that the protein corona of CLs was made of both low-affinity and 
competitive-binding proteins, the relative abundance of which revealed to be 
dependent on the plasma concentration to which they were exposed. 
In paper V we examined the advantages of exploiting a P/DNA complex 
coated with a lipid envelope made of the cationic lipid DOTAP, for 
transfecting CHO (Chinese hamster ovary cells), HEK293 (human 
embryonic kidney cells), NIH 3T3 (mouse embryonal cells), and A17 
(murine cancer cells) cells. Recent studies, in fact, showed superiority of 
LPD-mediated gene transfer over conventional liposomes for delivering a 
gene to the liver. To demonstrate this evidence, we investigated complex 
formation, DNA protection ability, surface properties, nanostructure, ability 
to release DNA upon interaction with cellular lipids, and intracellular 
trafficking. 
In papers VI and VII, after investigating the physical-chemical properties 
of LDP complexes, we employed a shotgun proteomics approach to discuss 
the protein coronas of DOTAP, DOTAP/DNA and LPD complexes. In 
paper VI we carried out a qualitative study, whereas in paper VII we also 
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added a label-free quantification performed by two distinct methods: the 
spectral counting (SC), in which the number of spectra matched to peptides 
from a protein was used as a surrogate measure of protein abundance, and 
the area under the curve (AUC) or signal intensity measurement, in which 
protein abundance was derived from the extracted ion chromatograms. 
Our results could help in designing gene delivery systems, because some 
proteins could be more selectively bound than others, thus affecting the 
biodistribution of liposome nanovectors and provide a more efficient in vivo 
delivery in gene therapy applications. 
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1. INTRODUCTION AND LITERATURE REVIEW 
Gene therapy 
Gene therapy is a technique used to introduce new genetic materials to 
hosts; in recent years it has attracted a growing interest because it provides a 
tool to study gene function and its regulation, in order to explore potential 
therapeutic applications (1). Gene therapy was first conceptualized in 1947 
as “a therapeutic technique” for “correction of hereditary diseases” (2), long 
before the discovery of specific genes causing a disease and years prior to 
the elucidation of the DNA structure by Watson and Crick (3).  
In the most exploited form of gene therapy, a DNA sequence that encodes a 
functional, therapeutic gene is introduced into a target cell in order to 
replace a mutated gene. Alternatively, it is possible to use the genetic 
material to correct a mutation or induce the expression of a therapeutic 
protein drug, rather than a natural human gene. 
In gene therapy, two different approaches are possible: the somatic and the 
germ line gene therapy. In the first one, which currently represents the main 
line of basic and clinical research, the therapeutic genes are transferred into 
the somatic cells of a patient to treat a disease in a single individual. Any 
modification is not inherited by later generations. On the contrary, in the 
second one, germ cells (sperm or eggs) are modified by the introduction of 
specific genes which are integrated into their genomes. This allows the 
therapy to be heritable and passed on to later generations (4). Somatic gene 
therapy can be carried out on cells which are collected from the patient, 
modified outside the body and then transplanted back in again to the target 
tissue (ex vivo approach). Alternatively, DNA can directly be delivered into 
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the resident cells of the target tissue which is easily accessible (in vivo 
approach) (5). 
One issue with gene therapy is the efficient delivery of the genetic material 
into the cell. Naked DNA cannot freely pass the cell membrane, because it 
is made up of very large molecules with a hydrophilic nature provided by 
the negatively charged phosphate groups; moreover it can be easily 
degraded by nucleases. For these reasons the development of suitable 
vectors for an efficient transfection is fundamental in order to facilitate and 
optimize gene transfer to target cells without degradation (1).  
Vectors should have peculiar features: they should be stable, biocompatible, 
non-toxic, cost effective, but most of all, they should specifically reach 
target cells avoiding surrounding cells, integrate and then express the 
therapeutic gene (transgene) at effective levels and for extended time 
periods (5). Generally employed gene vectors can be classified into two 
main groups: viral and non-viral vectors. 
Viruses have been the first vectors employed for gene therapy, because they 
are the simplest biological agents evolved to deliver genetic information to 
cells. The efficiency in gene transfer is due to innate properties of viruses. In 
fact, viral particles (virions) posses a structure able to carry and protect the 
genetic material (DNA and RNA) during transport across the human body. 
Determinants on the surface of the virion guide the viral particle to specific 
cells minimizing immunostimulatory potential within the host. After 
infection of the cell, signals in the genetic material control gene expression 
from the virus, and in some cases viruses also have mechanisms of 
replication that allow them to be propagated in cell culture (6). For this 
reason, recombinant viruses (retrovirus, lentivirus, adenovirus, adeno-
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associated virus and herpes simplex virus) have been widely exploited as 
vectors for gene transfer (1). However, apart from these advantages, viral 
vectors also have several intrinsic drawbacks and risks: the difficulty in 
manufacture, limited opportunity for repeated administrations due to acute 
inflammatory response, limitations in transgene size, as well as the potential 
to be pathogenic or cause insertional mutagenesis. In viral vector 
development the goal is to minimize the potential risks by using only 
components of the virus necessary for transduction and expression of the 
transgene (6). 
These difficulties with viral vectors prompted the development of 
alternative gene delivery systems. The non-viral approaches comprise the 
direct injection of plasmids, a simple and reliable method because plasmids 
can be easily produced and are stable for long time spans. However TE is 
low and limited to the injection area. On the other hand, non-viral vectors 
are a valuable alternative to viruses; they are made of synthetic or natural 
compounds, which are generally less toxic and immunogenic than the viral 
counterparts, and cell or tissue specificity is achieved by binding cell-
specific functionalities on the vectors. The practical advantages of these 
systems are that they can be easily and reproducibly prepared and can be 
repeatedly administrated because of their lack immunogenicity. Moreover 
non-viral vectors can be manufactured choosing different features, such as 
charge, morphology and composition, but especially size, allowing the 
introduction and transport of large genomic fragments, including complex 
transcriptional control elements. However they are generally less efficacious 
than the viral carriers, and in several cases, the gene expression is short-
lived (paper I). 
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Liposomes 
Liposomes are self-assembled fluid supramolecular assemblies formed via 
the accumulation of lipids interacting with one another. Their main feature 
is that they are able to separate hydrophobic or hydrophilic molecules from 
the solution. These vesicles are lacking in immunogenic response, have a 
low cost, can be found in many shapes and sizes, depending on lipid 
composition, and provide differential release characteristics; for these 
reasons they have been employed to envelope and protect several types of 
therapeutic biomolecules, including DNA (7).  
Liposomes are generally formed by the self assembly of lipid molecules 
having hydrophobic tails facing each other to form a lipid bilayer and a 
hydrophilic head group facing outwards to the aqueous solution. Vesicle 
sizes fall into the nanometer to micrometer range. Liposomes can have two 
main structures. Unilamellar liposomes have a single bilayer membrane 
with an internal aqueous solution, thus separating it from the external 
medium (8). They can be small (0.02-0.2 μm), large (0.2-1 μm), or giant 
unilamellar vesicles (>1 μm). If the vesicle is quite large, other structures 
can be observed, such as the oligolamellar one, when there are only two 
concentric bilayers, and the multilamellar one, when multiple concentric 
bilayers are present (Figure 1); this latter type of liposomes is frequently 
used in pharmaceutical and cosmetic applications. Multivesicular vesicles 
are giant vesicles encapsulating smaller liposomes and have been employed 
in nanoreactor assemblies and drug delivery. Apart from multilamellar 
vesicles, the other morphologies are difficult to obtain (7). 
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Figure 1 Representation of liposome possible structures 
Liposome have an amphiphilic nature that allowed them to be extensively 
exploited for encapsulation and delivery of drugs. The main advantage of 
liposomal drug delivery systems is their ability to transport both hydrophilic 
molecules, which migrate to the inner watery core of the liposome, and 
hydrophobic ones, which are trapped within the phospholipid bilayer. In this 
way drugs are transported through a hydrophilic medium to target cells; 
here, the lipid bilayer of the liposome fuses with the cell membrane 
releasing the drug into the cell. 
Liposomes for gene delivery are usually formulated adding specific lipids, 
both cationic or neutral. The lipids employed all share a common structure, 
a positively charged hydrophilic head and hydrophobic tail(s) connected via 
a linker, which controls the relative position of hydrophobic groups and thus 
the conformational flexibility, the stability and the biodegradability of the 
resulting liposome. The positively charged head groups are generally 
amines or quaternary ammonium salts, and are able to interact and stabilize 
DNA (or other anionic biomolecules) (1). The resulting lipoplexes protect 
DNA from degradation and have an overall positive charge that allows them 
to bind more efficiently to the negatively charged cell membranes compared 
to naked DNA, with a increased cellular uptake (9; 10). In this case the 
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resulting structure is the product of different energetic interactions, such as 
van der Waals and electrostatic forces. By adding a zwitterionic lipid in the 
bilayer, the overall membrane charge density can be varied. The lipid 
composition of the liposome determines the properties of the vector (shape, 
dimension, surface charge density) and can be optimized for a better 
transfection (11). The most exploited cationic lipids for liposome production 
are DOTAP and DC-Chol (Figure 2). DOPE is a zwitterionic lipid usually 
added to destabilize the membrane at low pH values, a phenomenon which 
promotes endosomal escape. Lipids usually have 8-18 carbon atoms in their 
tails, which may be saturated or with a single double bond. The two tails are 
usually symmetric, but it has been shown that asymmetric lipid mixtures 
with both short saturated and long unsaturated carbon chains lead to 
relatively high TEs as compared to mixed formulations of symmetric 
cationic lipids (7).  
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Figure 2 Structures of the cationic lipids DOTAP and DC-Chol and of the neutral helper 
lipid DOPE 
DOTAP has a quaternary amine head group and a glycerol backbone with 
two oleoyl chains. The ester bonds, which are hydrolyzable, were added to 
make it biodegradable and reduce cytotoxicity. DOTAP is completely 
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protonated at pH 7.4 and liposomes completely made of DOTAP were 
discovered to be unsuitable for gene delivery, because the high density of 
positive charges on the surface results in a very high energy required to 
separate the DNA from the lipoplex. On the contrary, more efficient 
liposomes can be produced combining DOTAP with a neutral helper lipid, 
as seems to be the case for most cationic lipid formulations (7). 
DC-Chol contains a dimethylethylenediamine group attached to cholesterol 
moiety by an ester bond. As previously, the cholesterol group has been 
introduced to enhance the biocompatibility and the stability of lipid 
membranes in the resulting liposomes. Most importantly, the 
chloramphenicol acetyltransferase expression (CAT) assay showed a better 
transfection activity with a significant reduction in cytotoxicity. In contrast 
to cationic liposomes containing fully charged quaternary amines like 
DOTAP, DC-Chol, in a 1:1 lipid ratio with DOPE, contains a tertiary amine 
groups charged on 50% of the liposome surface at pH 7.4, which reduces 
liposome aggregation and enhances a higher transgene expression and DNA 
dissociation (7).  
DOPE is one of the most employed neutral helper lipids in liposome 
formulations. It is added to improve transfection efficiencies in many cell 
types changing liposome structure from lamellar, in which there are 
repeated layers of DNA/lipids, to an inverted hexagonal packing structure at 
low pH values, where DNA is placed inside the tubes and stabilized by 
electrostatic interactions. The hexagonal conformation is thought to 
facilitate the exit of complexed DNA from endosomal vesicles by 
destabilizing the vesicle membrane (7).  
Introduction 
 
 24 
Lipoplexes 
Cationic lipids for transfection have been selected to encapsulate DNA so 
that the interactions with the cellular membrane are favorable and 
endocytosis more efficient. The lipoplexes used in gene therapy are 
positively charged complexes of liposomes (formed by cationic lipids often 
in presence of a neutral helper) and DNA. Evidences showed that cationic 
liposomes have several advantages over viral vectors for gene therapy 
because there is no size limit for plasmid DNA transport, which is 
compacted inside the liposome and introduced into the cell by endocytosis, 
thanks to the interaction of the positively charged lipids with the negatively 
charged biological membranes (12). By choosing the lipid mixture and 
composition, lipoplexes can be made for cell-specific uptake through the 
addition of specific ligands (7).  
The mechanisms of lipoplex formation is a matter still being under 
investigation; lipoplexes are considered the product of electrostatic 
interactions between cationic charge from lipids and anionic charges from 
DNA and the elasticity forces driven by the lipid hydrophobic moiety. In 
fact, lipoplex formation is a highly dynamic event, in which cationic 
lipid/DNA complex formation is also favoured by an increase of entropy 
associated with the release of counterions from DNA and the lipid bilayers. 
Lipoplexes formation is considered determinant for the morphology and TE. 
A general two-step mechanisms has been proposed for lipoplex formation, 
in which the first step is the electrostatic binding of DNA to the liposome 
surface, and the second one is fusion and rearrangement of the liposomes, 
with the formation of short rod-like structures in which condensed DNA 
molecules are encapsulated within a lipid bilayer. The resulting complex can 
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further form string-like colloidal aggregates with ordered multilamellar 
structures (LC α), when the complexes are neutrally charged. Two models 
have been proposed for the description of cationic lipoplex structures, an 
“external” model, in which DNA is electrostatically adsorbed onto the 
surface of cationic liposomes, and an “internal” model, in which the DNA is 
surrounded by a lipid envelope. The type of structure depends on the 
lipid/DNA ratio: at low ratios, DNA is trapped into aggregated 
multilamellar structures; an excess of cationic surfactant leads to entrapment 
of the DNA molecules between the lamellas in clusters of aggregated 
multilamellar structures. 
a) b) c) 
  
 
  DNA rod  DNA rod   DNA rod 
  Cationic lipid   Cationic lipid    Lipid 
 Neutral lipid   Neutral lipid  Counterion 
Figure 3 a) the lamellar structure (LCα) of cationic lipid/DNA lipoplexes, where the DNA 
rods are located between the lipid bilayers;  
b) the inverted hexagonal structure (HCII), where DNA rods are coated by a lipid 
monolayer; the different units are arranged on a hexagonal lattice;  
c) the intercalated hexagonal structure (HI), where DNA rods are covered by three lipid 
micelles arranged on a honeycombs-like hexagonal lattice 
For cationic lipoplexes three are the most observed structures: multilamellar 
structure LC α (Figure 3a) and hexagonal structures containing inverted 
hexagonal HC II (Figure 3b) and hexagonal HI (Figure 3c).  
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Lipoplex structure can vary during transfection: in fact, it has been observed 
that lamellar structure present during the condensation and transport of the 
DNA changes to inverted hexagonal upon cell membrane contact (13). 
Lipid-polycation-DNA complexes 
LPD complexes represent a further improvement of lipoplex formulation. 
Cationic liposomes used to carry DNA form periodic multilayer structures 
with DNA chains adsorbed between lipid membranes. Once inside the cell, 
these structures protect DNA from degradation, but also often hinder 
adequate DNA release from the endosomal compartments. If this is the case, 
the lipoplex is shuttled to the lysosomes and DNA degraded by the abundant 
nucleases therein present. LPD complexes were designed to overcome this 
drawback: plasmid DNA is condensed with a polycation like protammine 
(small nuclear proteins that allow a denser DNA packaging than histones 
and are involved in spermatogenesis) and encapsulated by the lipid 
envelope. Experimental results evidenced that LPD-mediated gene transfer 
is improved with respect to conventional liposomes in the liver (14; 15). 
Protein corona, biodistribution and targeting 
Cationic lipoplexes showed to be effective in in vitro studies for transfection 
but when employed in vivo several drawbacks have emerged. Gene delivery 
vectors are usually administrated via parenteral injection, and once in the 
bloodstream they are immediately covered by plasma proteins which form a 
“protein corona” (16). The identification of those proteins with the highest 
affinity for nanoparticles with different surface composition or properties 
has become a critical aspect to investigate, in order to elucidate how protein 
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binding affects the biodistribution of the nanoparticles. Plasma proteins 
have a pivotal role in the identification of foreign bodies in the bloodstream. 
Unprotected nanoparticles are removed by macrophages within seconds 
after intravenous administration (17); the binding of proteins like opsonins 
(fibrinogen, IgG, complement factor, etc.) is recognized to enhance 
phagocytosis together with large particle sizes (>200 nm) (18; 19). On the 
contrary the binding of dysopsonins (human serum albumin HSA, 
apolipoproteins, etc.) and small sizes promote prolonged circulation time in 
blood (20). Moreover plasma proteins such as HSA, lipoproteins, fibrinogen 
and heparin can bind to lipid membranes and greatly alter lipoplex structure, 
inducing aggregation, consequently enhancing clearance or deterioration by 
nucleases and lowering the efficacy of intravenously administered cationic 
lipoplexes. Finally in the case of systemic administration, highly 
vascularized organs (heart, lung, liver, spleen) exhibit significantly higher 
expression of the transfected molecule, which is, as a consequence, cleared 
from the system (21).  
In this context the nanoparticle-protein interactions are important for 
understanding the in vivo fate of the administrated gene delivery vector, 
because this phenomenon governs the circulation, clearance rates, blood 
half-life, stability, immunogenicity, and organ biodistribution of the 
nanoparticle.  
The protein corona composition depends on the concentrations of plasma 
proteins and the kinetic and equilibrium binding constants of each protein, 
which in turn are a function of the vector features (particle size, shape, and 
surface characteristics, Figure 4). However, more recent findings have 
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revealed that the average composition of the protein corona does not reflect 
the relative abundance of proteins in human plasma (22).  
 
Figure 4 Picture displaying the equilibria between free proteins in solution, the protein 
corona and proteins on the cell membrane. In the upper part, image of silica nanoparticles 
entering a cell and polystyrene nanoparticle covered by a plasma protein corona (25) 
Proteins present with high concentrations and/or with high association rate 
constants initially bind to the lipoplex surface, but over the time they may 
be displaced by proteins with a lower concentration, lower exchange rate, 
but higher affinity, resulting in the formation of a so called “hard corona” 
(23). This corona may contain only a few proteins in a relatively immobile 
layer, with a more loosely bound layer that is less well understood. In this 
context the most abundantly associated proteins do not necessarily have the 
most profound effect, because a less abundant protein with higher affinity 
and specificity for a particular receptor may be extremely important (paper 
VII). The protein corona envelopes the particle and it is what living cells 
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actually recognize. The composition of the hard corona varies according to 
protein concentration and during distribution, from one organ to another one 
or between cellular compartments (24). However, the primary nanoparticle-
protein interaction is electrostatic, thus the surface charge of carrier is 
supposed to play a central role in protein adsorption (paper II). 
Understanding how and why plasma proteins are adsorbed to lipid particles 
would be important to elucidate delivery and uptake mechanisms. It may 
serve as a fundamental predictive model for the in vivo efficiency of the 
vector, as well as a starting point for the development of targeting strategies, 
in view of future clinical applications, but knowledge in this field is still 
limited.  
Nanoparticles covered by plasma proteins interact with the cell surface and 
are internalized by nonspecific and/or highly specific pathways, such as 
receptor-ligand interactions. The principal entering for lipoplexes is 
believed to be endocytosis, although a fusion mechanism has also been 
proposed. Here, an exchange mechanism between lipoplexes and plasma 
membranes would cause the destabilization of the lipoplex structure with 
subsequent DNA release into the cytoplasm (23). There are two main 
approaches to target nanoparticles: in one approach the surface is engineered 
so that the specific recognition/targeting molecule is displayed, whereas all 
other undesired interactions with the surrounding environment are reduced 
to a minimum (adsorption-proof nanoparticle). The other approach exploits 
the formation of the protein corona for targeting, once the correct proteins 
for location delivery have been chosen (25). Both approaches have been 
applied with success: assessed that apolipoprotein E could target a drug to 
the brain, in one case the poly(alkyl cyanoacrylate) nanoparticle was 
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covered by a surfactant that enabled to spontaneously bind that protein from 
the medium (26) in the other one it was chemically bound to the 
nanoparticle itself (27). Adsorbed proteins play a fundamental role not only 
in the second approach, but also in the first one, because the efficiency of 
the targeting molecule does depend on the effect of the biomolecules that 
they interact with on-route to the target site, thus determining for both 
approaches nanoparticle uptake, transport and sub-cellular localization.  
Shotgun proteomics approach 
In the 2000s genomics succeeded in elucidating the genome of several 
organisms; this prompted the development of other “omics” disciplines, in 
particular proteomics, the next logical step that allowed to study proteins, 
the product of genes. Proteomics gives access to the functional aspects of 
cells but for this reason proteomic studies are complicated, because, if 
compared to the genome, the proteome of an organism is much more 
dynamic, and changes in response to cellular or environmental factors are 
frequent. The proteome is orders of magnitude more complex than the 
genome due to processes such as splicing, post-translational modifications, 
protein degradation, drug perturbations and disease, which deeply change 
protein structure (28).  
Two are the possible approaches for proteomic studies, top-down 
approaches, which focus on the analysis at whole protein level, and bottom-
up approaches, which focus on the peptide level. The shotgun methods are 
bottom-up approaches and currently represent the most commonly used 
strategy for protein analysis. Typically in shotgun proteomics experiments, a 
complex protein sample is digested by a protease, usually trypsin, and 
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turned into a peptide mixture. The advantage with respect to intact protein 
analysis is that peptides are more efficiently chromatographically separated 
and sequenced by mass spectrometry with a higher sensitivity. The resulting 
peptide mixture is separated by reverse phase liquid chromatography (RP-
LC) prior to mass spectrometric analysis. Here a mass/mass (MS/MS) 
experiment is carried out, with eluting peptides fragmented by collision-
induced dissociation (CID) into characteristic ion series. The number of 
acquired MS/MS spectra is very large and assignment is performed by 
specific software solutions, which searching a protein sequences database, 
give protein identifications. For this reason shotgun proteomics allows the 
global description of complex proteome profiles, as well as the ability to 
systematically analyze dynamic proteomes (29).  
SDS-PAGE separation 
Polyacrylamide gel electrophoresis has been employed to identify and 
characterize different kinds of biological macromolecules. This technique is 
relatively simple, rapid and highly sensitive for the study of proteins. The 
principle upon which it is based is that charged molecules migrate with 
different rates when subjected to an electric field. Proteins are supported by 
a matrix, usually agarose or polyacrylamide gels. The most common 
electrophoretic technique for protein separation is sodium dodecyl sulfate 
(SDS)-polyacrylamide gel electrophoresis (SDS-PAGE), which was 
originally described by Laemmli (30). Here a denatured protein mixture is 
separated in presence of SDS which, independently of the protein mixture, 
forms negatively charged complexes in which 1 g protein binds to 1.4 g 
SDS. These complexes are rod-shaped, have a similar charge density and 
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their length is proportional to the molecular weight (MW) of the protein, 
thus proteins are separated on the basis of their size only. 
Nano-HPLC 
The most employed separation technique for proteomic analyses is HPLC, 
because it can be easily coupled with electrospray and nanoelectrospray 
ionization (ESI and nanoESI) sources, thus ensuring a high degree of 
automation and throughput. In particular, in the recent years nano-HPLC 
has attracted much attention mainly because of the higher sensitivity when 
compared to conventional HPLC methods, allowing to analyse small 
amounts of sample with none or very low dilution. Column diameters and 
stationary-phase particle size are significantly reduced and pressures 
increased, drastically improving the performance of LC and leading to the 
development of ultrahigh pressure liquid chromatography. All system 
components have been downscaled, including flow rate, connecting tubing, 
detection and injection volumes. Pumping systems have been developed for 
providing flow rates in the nl/min range, suitable for very small amounts of 
sample. HPLC system may be with and without flow splitting. In apparatus 
with flow splitting, a high pump flow rate (200-300 µl/min) is divided into 
the column flow rate (100-300 nl/min) and the rest, which is directed into 
the waste. This configuration is the most common for proteomic analyses. 
Systems without flow splitting use syringe pumps to deliver the mobile 
phase to the column. Analytical columns for proteomics research usually 
use conventional C18 stationary phase. However, the need for higher 
selectivity, sensitivity and specificity has led to three main recent 
developments. RP stationary phases were modified to operate with very low 
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or no trifluoroacetic acid (TFA), as for PepMap® columns, thus making 
mobile phases more suitable for mass spectrometric acquisitions. New 
monolithic columns have been developed, where the stationary phase 
consists of a continuous, rigid polymeric rod with a porous structure that 
enables faster separations. Finally, columns have been miniaturized and 
reduced to a chip format. In the work discussed in this thesis, RP in-house 
manufactured 15 cm fritless silica microcolumns with a 75 µm i.d were 
used.  
HPLC configurations also comprise trap columns or precolumns. Usually 
employed in column-switching modes, they enable injections of high 
volumes and highly diluted samples. They are shorter and larger than 
analytical columns (1-5 mm length and 300 µm i.d. vs 75 µm) and are used 
to load and desalt samples. They should have a high load capacity and low 
void volumes (31). 
Mass spectrometry 
Instruments should meet the increasing demand for better performance 
providing high resolution, mass accuracy, dynamic range, and tandem mass 
spectrometry capabilities coupled to automation of sample analysis. Mass 
spectrometry (MS) has become a leading technique for shotgun proteomics 
analyses because it is the most comprehensive and versatile tool currently 
available for large-scale proteomics. Here, the two main ionization 
techniques employed are the ESI and the matrix-assisted laser desorption 
ionization (MALDI).  
In the work described in this thesis a LTQ Orbitrap XL mass spectrometer 
has been employed. The LTQ Orbitrap XL is a hybrid mass spectrometer 
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that combines the orbitrap detector with an external mass analyzer, a linear 
ion trap. This allows to perform multiple levels of fragmentation (MS
n
). 
This mass spectrometer is equipped with a NSI source. It represents a 
miniaturization of the conventional ESI source, where flow rate and emitter 
tip diameter are reduced. This makes it ideal for dilute samples, with an 
increased tolerance to aqueous solvents and salts. The advantage of ESI 
source over other types of ionization techniques is that multiply-charged 
analyte ions are produced, thus high MW compounds can be observed at 
relatively low m/z values. 
After ionization, ions pass through the ion transfer tube and pressure is 
gradually reduced from atmospheric values to void (1 Torr). Ion leaving the 
ion transfer tube are focused and the pressure is further decreased (10
-5
 Torr) 
before entering the LTQ, the linear ion trap (Figure 5).  
 
Figure 5 Schematic representation of a LTQ Orbitrap XL mass spectrometer 
Ion optics use a combination of DC and RF voltage together with a vacuum 
gradient to guide ions towards the ion trap. The LTQ is a linear ion trap 
made up of two pairs of X and Y rods, as in a normal quadrupole system. In 
all scan events, the LTQ performs ion collection, regardless of mass 
(injection). After trapping, ions are ejected mass-selectively from the trap, 
ether all together (full scan mode) or after selection of specific m/z values of 
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interest (single ion monitoring and MS/MS modes). After the isolation 
process, the selected ions can be ejected and analyzed or subjected to 
fragmentation to yield product ions then ejected and analyzed.  
For detection in the orbitrap analyzer, ions coming from the LTQ are 
trapped in the C-trap, which is used to store, collisionally cool and pack ions 
before injection into the orbital trap. Here ions are electrostatically trapped 
and begin to rotate around the central electrode inducing an image current in 
the outer halves of the orbitrap. A transient is acquired and then converted 
into frequencies and m/z values by use of the Fourier transformation. The 
orbitrap is employed as a high resolution and high mass accuracy detector.  
The advantage of a hybrid LTQ orbitrap instrument is the possibility to 
work in the parallel acquisition mode. Parent ions can be analyzed in the 
orbitrap whereas the corresponding tandem mass spectra are obtained in the 
LTQ, which provides high speed and sensitivity. Fragment ions can also be 
analyzed in the orbitrap. This is a quite important aspect in shotgun studies, 
because uncertain or incorrect ion determination can lead to incorrect 
identifications (32). Moreover, the development of high-resolution and 
accurate mass spectrometry is essential for providing not only a qualitative 
description, but also a quantitative one, without compromising the quality of 
either strategy (33). 
Protein and peptide validation 
Non-targeted shotgun proteomics experiments produce a huge amount of 
raw data that need to be processed by suitable bioinformatic software for 
database searches and biostatistical analysis, in order to extract essential 
data, such as precursor ion charge state, calculation of fragment ion masses, 
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charge state deconvolution and deisotoping of fragment ions and general 
noise reduction (34). Multiple bioinformatic platforms are available. If the 
proteome of the organism being studied is known, databases of proteins 
sequences are available and downloadable in the FASTA format and are 
used for database searching. Commercial or open-source database searching 
algorithms for sequence identification of MS/MS data are available, such as 
Mascot (35), Sequest (36) and X! Tandem (37). These software match 
MS/MS spectra and precursor mass to protein sequences and include 
theoretical peptide masses in silico generated; a corresponding ion score, 
based on the percentage of sequence matched and the number of matching 
peptides, is also generated as a measure of how well the experimental 
spectra match the theoretical ones. Search engines also allow a second 
search, this time performed against a false database created by reversing or 
random scrambling the amino acid sequence of the original database (38). 
This approach is based on the assumption that decoy sequences are not 
biologically expressed and identifications are false. Identifications in the 
reverse/random database are used for calculation of a false discovery rate 
(FDR). Decoy search is an estimate of the empirical error rate, easy to be 
applied but one must take into account that the computer time is doubled 
with respect to a simple search and some reversed sequences might be 
homologous to true peptides (29). Database search for the works presented 
in this thesis have been performed using the Mascot search engine. It uses a 
FASTA file to perform three types of searches: peptide mass fingerprint 
(looks for peptide MWs expected from enzymatic digestion of a protein), 
sequence query (combination of mass data with amino acid sequences or 
physicochemical data which infer sequence or composition), MS/MS ion 
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search. The program reports peptide and protein identifications with the 
corresponding probability-based scores (35). 
After sequence data base search, protein identification can be further refined 
applying filters, such as the minimum number of unique peptides for protein 
identification and probability thresholds for protein and peptide 
identification. As for database search, protein validation can be performed 
with suitable software in order to statistically validate search results and 
ensure confidence in the protein identification. Peptides with a probability 
of correct identification below the selected error threshold are rejected. 
When results come from a decoy database searches, Bayesian statistics or 
both methods are employed for protein validation. 
The software solutions employed for validation in this work are Proteome 
Discoverer, the TPP and Scaffold.  
Proteome Discoverer is a software suit developed and commercialized by 
the mass spectrometer vendor Thermo Scientific. It comprises a series of 
tools that allow to process Thermo Scientific instrument raw data 
integrating all the different steps in a quantitative proteomics experiment 
(i.e. MS/MS spectrum extraction, peptide identification, quantification) into 
user-configurable, automated workflows. Among other possible choices, it 
integrates the Mascot search engine for protein and peptide identifications 
and it has been employed for protein validation and subsequent quantitation 
with another Thermo Scientific software, SIEVE (37). 
TPP and Scaffold are suits of software tools in which database search results 
are validated assigning peptide and protein probabilities by means of the 
Peptide (40) and ProteinProphet (41) algorithms. PeptideProphet  employs 
search scores and additional information to distinguish between correctly 
Introduction 
 
 38 
and incorrectly assigned peptides, calculating for each peptide assignment to 
an MS/MS spectrum a probability of being correct (40). Since MS/MS 
spectra are acquired from peptides and not proteins, a statistical model for 
validation of the identifications at the protein level is required. 
ProteinProphets uses PeptideProphet s results to calculate the probabilities 
for each protein of being in the sample. This probability takes into account 
if more peptides are assigned to the same protein and this grouping 
information is used to adjust the individual peptide probabilities. On the 
contrary, if peptides are shared among more proteins, a protein group is 
formed although only a subset of the proteins in a group is usually needed to 
explain the presence of all the peptides in the group (41). The TTP can also 
provide FDRs using Mayu (42). The Scaffold software does also calculate 
FDR, but in two different ways depending on whether the data has been 
searched against a decoy database or not. If a standard forward database has 
been employed for search, Scaffold uses a probabilistic method to infer 
FDR; on the contrary, if a decoy database has been employed, Scaffold uses 
an empirical method that considers the number of decoy matches (43). 
Moreover with respect to the TPP, the Scaffold software can also perform 
an additional search using the X! Tandem search engine and allows to 
perform label-free quantitation based on SCs (44).  
Label-free quantification 
LC-MS based shotgun proteomics has provided powerful tools for studying 
large scale protein expression and characterization of complex biological 
systems. The development of high resolution and high accuracy mass 
spectrometers enabled the quantitative analysis of biological samples. The 
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quantitative methods initially developed were based on stable isotope 
labelling, thus the incorporation of isotopic tags in proteins in vivo (such as 
metabolic stable isotope labelling with amino acids in cell culture, SILAC 
and 15N labelling), or in vitro, (such as isotope-coded affinity tags, ICAT, 
isobaric tag for relative and absolute quantification, iTRAQ, and 18O 
labelling). They are isotopically labelled internal standards having 
chromatographic and ionization characteristics which are highly similar to 
those of the target peptide, thus reducing variability due to ionization 
efficiency and suppression (29). However, they have potential limitations 
due to complex sample preparation, expensive reagents, the requirement for 
high sample concentration and incomplete labelling and chromatographic 
shifts that may complicate the quantification (45). Moreover this 
quantitative approach displayed a uniform distribution of percent error 
among all proteins except for very low concentrated proteins (46), but it is 
not suitable for complex, large studies, because the number of available tags 
is limited and does not allow for simultaneous quantification of several 
proteins. An alternative approach developed later performs a relative label-
free quantitation by measuring the AUC in the chromatogram or the number 
of spectra acquired for each peptide. These approaches do not show the 
above mentioned limitations and do not require any special sample 
preparation (46). Label-free methods are characterized by a higher dynamic 
range of quantification than stable isotope labelling methods, advantageous 
for screening of large and global protein changes (29).  
Relative label-free quantitation can be performed exploiting two different 
principles. One approach relies on the measurement of the AUC or signal 
intensity, in which protein abundance is derived from the extracted ion 
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chromatograms. The use of this method for relative quantitation in complex 
biological protein samples may have practical constraints: differences in 
peak intensities can be observed from run to run of the same sample and are 
caused by experimental variations, such as differences in sample preparation 
and injection. Moreover highly reproducible retention times among 
technical replicates are required because unaligned peaks lead to inaccuracy 
in quantitation but may be observed when multiple injections are performed 
onto the same column. Data collected during LC-MS/MS analysis of 
complex protein mixtures requires specific computer software to 
automatically compare the peak intensity between LC-MS. These software 
solutions detect peaks from background noise, then assign isotope patterns 
by deconvolution and align chromatograms to match retention times 
between LC-MS/MS runs (peak matching). Finally chromatographic peak 
intensities (peak area or height) are calculated and normalized, to assess for 
experimental differences in peptide analyses, and statistical significance of 
protein abundances changes are retrieved. For this thesis work the SIEVE 
software was employed. It implements the ChromAlign algorithm for 
chromatographic alignment and calculates a p-value for the expression ratio 
of each differential peak (45).  
SC is the other approach available for relative quantitation. Here the number 
of assigned peptide spectra for a protein is used to infer protein abundance. 
This method is based on the assumption that an increase in protein 
abundance typically results in an increase in the number of its proteolytic 
peptides and, as a consequence, of sequence coverage, number of identified 
unique peptides and identified total MS/MS spectra (SC) for each protein 
(48). Liu et al. demonstrated that among all the these factors of 
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identification, only SC displayed a strong linear correlation with relative 
protein abundance over a dynamic range of 2 orders of magnitude (49). The 
advantage of the SC approach over the chromatographic peak intensity 
approach is that no peak alignment is necessary, and only normalization and 
statistical analysis of SC datasets are necessary.  
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2. BACKGROUND AND AIMS 
Gene therapy represents a future perspective for treating disease. However, 
several drawbacks are still present, in particular, security, efficiency, target-
specificity of the different gene vectors. Viral vectors are efficient, but their 
extensive use is hindered by their intrinsic risks and the limited capacity to 
transport large DNA pieces. For this reason alternative non-viral vectors 
gradually acquired increasing attention, with a particular interest in 
liposome gene vectors. However, once these foreign bodies are employed in 
in vivo applications, the organisms builds up a response. Gene vectors are 
usually administrated via parenteral injection and upon contact with 
biological fluids, in particular blood, proteins begin to cover the 
nanoparticle surface forming the so called "protein corona", the composition 
of which is highly variable but of extreme importance, because it is what 
living cells actually see and determines the biodistribution of the 
nanoparticle. In fact, proteins adsorbed onto the surface are responsible for 
clearance from the bloodstream, immunologic response, cell uptake and 
targeting. Given the high interest in the development and characterization of 
liposome gene vectors, and the importance of their modification once 
introduced into a biological medium, the aim of this thesis was to study 
different types of liposome systems suitable for application in gene therapy. 
At the beginning, the DC-Chol DOPE CLs and DNA lipoplexes were 
studied. The two liposome composition have the same lipid formulation and 
differences present in their protein corona were possibly due to DNA 
presence and could help to understand if specific DNA-binding proteins 
could be found on the lipoplex surface, in order to elucidate lipoplex 
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structure, compare it with data already available in the literature and infer 
what the fate of the lipoplex would be in vivo. In the next study, the effect of 
surface charge on the nanoparticle was also investigated, in order to 
understand if this physical property of the nanovector could have a 
significant impact in the protein binding and corona composition. Apart 
from the surface charge, another aspect was considered, the effect of plasma 
protein concentration on the type and amount of protein bound on the 
surface, this time choosing DOTAP CLs and lipoplexes as a model. The 
following studies focused also on another system that showed to be 
successful in recent studies, LPD complexes. A comparison of TE was 
carried out for four cell lines using DOTAP/DNA/protamine complexes as a 
model. Then the shotgun proteomic approach was employed to understand 
the differences among these LPD complexes and the corresponding CLs and 
lipoplexes, both from the qualitative protein profile and the quantitave 
analysis; two different software solutions were compared for protein 
quantitation, based on two complete different principles for retrieving 
protein abundances, the number of SCs and the measurement of the AUC in 
the chromatogram. 
For these studies the protein-nanoparticle complexes were isolated by a 
centrifugation protocol and then the isolated pellets were analyzed both 
qualitatively and quantitatively. For the qualitative studies SDS-PAGE 
separation and evaluation of the protein profile was employed; protein 
identification was also performed by means of a shotgun proteomic 
approach on the isolated nanoparticle coronas, choosing an in-solution 
tryptic digestion, a nanoHPLC separation and peptide sequencing by high 
resolution MS spectrometry with a LTQ orbitrap XL. In the quantitative 
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studies, MS/MS data were further analyzed to retrieve relative label-free 
quantitation information, in order to give not only protein identifications, 
but also their amount differences in the original protein coronas. 
This information represents additional characterization of these liposome 
nanovectors and may be useful for developing future gene therapy 
applications, providing the basis for understanding the clearance, 
biodistribution and cell targeting in real biological systems. 
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3. MATERIAL AND METHODS 
Human plasma collection, preparation and storage 
Human whole blood plasma was obtained from the Department of 
Experimental Medicine (Sapienza University of Rome), according to 
institutional bioethics approval, by venipuncture of ten healthy 20-40 year-
old volunteers, by means of BD
TM
 P100 Blood Collection System (Franklin 
Lakes, NJ, USA) with K2EDTA anticoagulant and protease inhibitors 
cocktail. Human plasma was prepared as follows: after clot formation, the 
samples were centrifuged at 1000 x g for 5 min to pellet the blood cells, and 
the supernatant plasma was removed. After checking the absence of 
haemolysis, the plasma collected from each donor was pooled, split into 200 
μL aliquots, and stored at −80 °C in labelled Protein LoBind tubes, until 
further use. For analysis, the aliquots were thawed at 4 °C and then allowed 
to warm at room temperature (RT). 
Procedure for preparation for all kinds of nanopaticles 
DC-Chol DOPE cationic liposomes 
DC-Chol and DOPE were purchased from Avanti Polar Lipids (Alabaster, 
AL) and used without further purifications. The liposome solutions were 
prepared dissolving appropriate amounts of DC-Chol and DOPE in CHCl3 
at three different molar ratios of neutral lipid in the bilayer Φ (neutral 
lipid/total lipid, mol/mol) = 0.3, 0.5, and 0.7, keeping constant the moles of 
the cationic lipid (i.e., the overall charge). The solvent was evaporated under 
vacuum for 12 h, and the obtained lipid film was hydrated with a buffer 10 
mmol L
−1
 Tris-HCl (pH 7.4), 150 mmol L
−1
 NaCl, 1 mmol L
−1
 EDTA. 
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Small unilamellar vesicles were prepared by sonication and allowed to stay 
at 30 °C for 24 h to achieve full hydration. 
DC-Chol DOPE/DNA cationic lipoplexes 
For the preparation of lipoplexes calf thymus (CT) Na-DNA was employed. 
CT Na-DNA was solubilized in Tris-HCl buffer (1 mg mL
-1
). Sonication for 
5 min resulted in DNA fragmentation (length distribution between 500 and 
1000 base pair, as determined by gel electrophoresis). Self-assembled DC-
Chol-DOPE/DNA lipoplexes were obtained by mixing 24 mL DNA solution 
to 200 mL liposome dispersion and incubating at RT for 20 min. 
DOTAP cationic liposomes 
DOTAP was purchased from Avanti Polar Lipids (Alabaster, AL) and used 
without further purification. DOTAP CLs were thus prepared. In brief, a 
proper amount of DOTAP was dissolved in CHCl3 and the solvent was 
evaporated under vacuum for at least 24 h. The obtained lipid films were 
hydrated with the appropriate amount of Tris-HCl buffer solution (10
-2
 mol 
L
-1
, pH 7.4) to achieve the desired final concentration (1 mg mL
-1
). 
DOTAP/DNA lipoplexes  
When adequate amounts of the DNA solution were mixed with suitable 
volumes of DOTAP liposomes dispersions, self-assembled DOTAP/DNA 
lipoplexes, at single lipid/DNA volume ratio (Rv = DOTAP/DNA = 1, v/v), 
were obtained. At this volume ratio, lipoplexes exhibited the lowest 
colloidal dimensions (about 200 nm), and were positively charged (about 50 
mV). 
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LPD complexes  
Negatively charged P/DNA microspheres were prepared at a 
protamine/DNA weight ratio (Rw) of 0.5. LPD complexes were prepared by 
mixing P/DNA microspheres with DOTAP small unilamellar vesicles at a 
single lipid/DNA volume ratio (Rv = DOTAP/DNA= 1, v/v). At this volume 
ratio, LPD systems exhibited the lowest colloidal dimensions (about 200 
nm), and were positively charged (about 45 mV). 
The characterization of the resulting vesicle dispersions and samples was 
made by means of size and zeta potential (ζp) measurements, respectively. 
Size and zeta potential measurements 
All sizing and zeta potential measurements were made on a Zetasizer Nano 
ZS90 (Malvern, UK) at 25°C with a scattering angle of 90.0°. Sizing 
measurements were made on the neat vesicle dispersions, whereas the 
samples were diluted 1/10 with distilled water for ζp measurements.  
Table 1 Zeta-potential and hydrodynamic radius for the different nannoparticles 
under investigation 
Type of nanoparticle 
Zeta-potential  
(ζp) mV 
Hydrodynamic radius  
(RH) nm 
DC-Chol DOPE (Φ = 0.3) ~ 60.1 ± 1.2 102 ± 4  
DC-Chol DOPE (Φ = 0.5) ~ 56.3 ± 1.3  109 ± 2 
DC-Chol DOPE (Φ = 0.7) ~ 55.7 ± 1.3 105 ± 1 
DC-Chol DOPE/DNA (Φ = 0.5) ~ 48.1 ± 1.4  120 ± 3  
DOTAP ~ 55.1 ± 1.2 61.2 ± 2.5 
DOTAP/DNA ~ 42.3 ± 1.1 125.5 ±4.5 
LPD complexes ~ 47.5 ± 1.3 200 ± 1.5 
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Table 1 shows the resulting mean values for ζp and size (reported as 
hydrodynamic radius, RH) obtained across the experiments described in 
papers I-VII for all the nanoparticles studied. 
Incubation of CLs, lipoplexes and LPD complexes 
For all experiments performed plasma protein binding to nanoparticles was 
studied by incubating each type of the nanoparticles considered (1 mg mL
−1
) 
in 10 mmol L
−1
 Tris-HCl (pH 7.4), 150 mmol L
−1
 NaCl and 1 mmol L
−1
 
EDTA with 1:1 v/v amount of plasma in an ice bath for 1 h. Thereafter, the 
incubation was carried on at 25 °C for 1 h to promote aggregation. The 
sample was centrifuged at 15000 x g for 10 min to pellet the liposome- 
protein complexes. The pellet was washed with 250 μL 10 mmol L−1 Tris-
HCl (pH 7.4), 150 mmol L
−1
 NaCl and 1 mmol L
−1
 EDTA, using a vortex 
mixer, transferred into a new Protein LoBind tube, and centrifuged again to 
pellet the liposome-protein complexes; this procedure was repeated twice. 
The tubes were changed after each washing step to minimize contamination 
of plasma proteins bound to the tubes. A plasma aliquot not incubated with 
nanoparticles was subjected to the same procedure as control to verify the 
absence of protein precipitation. 
Centrifugation was chosen for the separation of the nanoparticle-protein 
complexes because this method does not destroy the complex nor induce the 
binding of additional proteins, since we were working on protein strongly 
adsorbed onto the nanoparticles, the so-called “hard corona”, whose 
biological macromolecules have a high affinity for the nanoparticle surface. 
To achieve this we used stringent washing conditions after centrifuging the 
plasma incubated with nanoparticles to obtain the pellet of the 
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nanoparticle/protein complex. We also used a short centrifugation time, just 
2 min, to avoid sedimentation of large proteins, formation of protein 
aggregates, and co-precipitation. This procedure was chosen according to 
previous studies showing that under controlled conditions, washing and 
centrifugation, the nanoparticle/protein complexes are not destroyed nor any 
binding of additional proteins is induced (paper IX). 
One-dimensional polyacrylamide gel electrophoresis 
For separation by SDS-PAGE, proteins were eluted from the particles by 
adding SDS-PAGE sample buffer to the pellet and boiling the solution. A 
12% polyacrylamide gel was employed to separate the proteins as reported 
elsewhere (paper IX). Coomassie PhastGel Blue R-350 was used to stain 
the gels with gentle agitation, in accordance with the manufacturer’s manual 
(GE Healthcare, Milan, Italy). All experiments were conducted four times to 
ensure the reproducibility of the particle/protein complex pellet sizes, 
general pattern, and band intensities on the 1D gels. To determine the MWs 
of proteins after an electrophoretic run, protein MW markers were used. The 
MWs were finally obtained by means of Kodak dedicated software 
(Rochester, NY).  
Proteomics experiments 
In-solution trypsin digestion 
A shotgun proteomics approach was used to analyze and compare human 
plasma protein binding capability with two different kinds of cationic 
liposomes, two types of lipoplexes and LPD complexes. The 
nanoparticle/protein complexes were resuspended in 8 mol L
-1
 urea solution 
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in 50 mmol L
-1
 NH4HCO3 and incubated with 200 mmol L
-1
 DTT at 37 °C 
for 1 h, under slight agitation, to denature proteins adsorbed onto liposomes, 
lipoplexes and LPD complexes. Afterwards, 200 mmol L
-1
 IAA were added 
to the samples and incubated at RT for 1 h in the dark. Subsequently, 200 
mmol L
-1
 DTT were added and incubated at 37°C for 1 h, under slight 
agitation, to consume any leftover alkylating agent and to avoid trypsin 
alkylation. The sample solutions were then diluted with 50 mmol L
-1
 
NH4HCO3 to obtain a final 1 mol L
-1
 urea concentration. Reconstituted 
trypsin solution (20 mg mL
-1
 in 50 mmol L
-1
 NH4HCO3) was added to 
ensure a minimum enzyme-to-substrate ratio of 1:20. Digestion of the 
protein samples was performed rotating overnight at 37°C and quenched the 
next day by adding formic acid. Digested samples were desalted by using a 
SPE C18 column (Bond Elut 1cc LRC-C18, VARIAN, Palo Alto, CA, 
USA) conditioned with ACN and rinsed with 0.1% TFA. Peptides were 
eluted from the SPE column with ACN:H2O (50:50, v/v) containing 0.05% 
TFA and were dried in a Speed-Vac SC 250 Express (Thermo Savant, 
Holbrook, NY, USA). Each sample was re-constituted with a suitable 
volume of a 0.1% formic acid solution. Digested samples were stored at 
−80°C until analysis. 
NanoHPLC-MS analysis 
NanoHPLC was performed using a Dionex Ultimate 3000 instruments 
(Dionex, Sunnyvale, CA, USA) consisting of a nanopump with degasser, 
and a loading pump connected to a thermostatted microwell-plate 
autosampler. Sample was on-line enriched on a 300 μm i.d. × 5 mm 
Acclaim PepMap 100 C18 (5 μm particle size, 100 Å pore size) μ-
precolumn (Dionex), employing a premixed mobile phase H2O:ACN 98:2 
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(v/v; phase C) containing 0.1% (v/v) HCOOH at a flow rate of 10 μL min−1. 
Peptides injected were separated on a Biobasic 18 (5 μm particle size, 300Å 
pore size) 75 μm i.d. × 100 mm, 15 μm tip picofrit column (Thermo 
Scientific, Bellefonte, PA, USA) operated at a flow rate of 250 nL min
−1
. 
Phase A was H2O and phase B was ACN, both containing 0.1% (v/v) 
HCOOH. A 120-min gradient was used: after an isocratic step at 5% B for 5 
min, B was linearly increased to 30% within 75 min; afterwards, B was 
increased to 80% within 5 min, and to 95% within the following 10 min to 
rinse the column. Finally, B was reduced to 5% over 1 min and the column 
re-equilibrated for 24 min. 
The nanoHPLC system was coupled to an LTQ-Orbitrap XL hybrid mass 
spectrometer (Thermo Fisher Scientific, Bremen, Germany) via a nanoESI 
ion source, operated in positive ionization mode, with spray and capillary 
voltage set at 2.90 kV and 42 V, respectively, and capillary temperature set 
at 180 °C. Full MS spectra were acquired in profile mode in the m/z range 
350-1800 in the orbitrap with resolution set at 60000, whereas data-
dependent MS/MS scan of the five most intense monoisotopic peaks in the 
spectra (top five strategy) was operated with CID activation at low 
resolution in the LTQ. Rejection of +1 and unassigned charge states was 
enabled. All MS/MS spectra were collected using a 35% normalized 
collision energy and an isolation window of 2m/z. Ion trap and orbitrap 
maximum ion injection times were set to 1000 and 200 ms, respectively. 
Automatic gain control was used to prevent overfilling of the ion traps and 
was set to 5×10
5
 for full FTMS scan, and 1×10
4
 ions in MS
n
 mode for the 
LTQ. To minimize redundant spectral acquisitions, dynamic exclusion was 
enabled with a repeat count of 1 and a repeat duration of 30 s. The whole 
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LC/MS system was managed by the Xcalibur software (v.2.07, 
ThermoFisher Scientific). Five technical replicates per sample were 
performed. 
Data processing and statistical validation 
For all experiments carried out on the various types of nanoparticles, thermo 
RAW data files were submitted to Mascot Deamon (v2.2.04, Matrix 
Science, London, UK) using the Thermo-Finnigan LCQ/DECA RAW file 
data import filter to perform database searches against the non-redundant 
Swiss-Prot database (v57.15; Homo sapiens taxonomy restriction, 20266 
sequences, papers I-VI) and IPI human database (version 3.79, paper VII). 
For the database search, trypsin was specified as the proteolytic enzyme 
with a maximum of two missed cleavages. Carbamidomethylation was set 
as fixed modification of cysteine, whereas oxidation of methionine was 
chosen as variable modification. The monoisotopic mass tolerance for 
precursor ions and fragmentation ions were set to 10 ppm and 0.8 Da, 
respectively. Charge states of +2, or +3 were selected as precursor ions. 
Regarding statistical data analysis for validation of peptide and protein, in 
papers I, II, VI we used a recently developed statistical open source 
software, the TPP. Peptide identification and protein assignment were 
statistically validated submitting the Mascot result files (.dat files) in the 
open source TPP software (Seattle Proteome Center, SPC, Proteomics 
Tools: http://tools.proteomecenter.org/software.php). After conversion of 
the output Mascot files in the .pepXML format, the PeptideProphet  and 
ProteinProphet tools (40; 41; 50), included in TPP, were employed.  
In paper III, in order to validate protein identifications derived from 
MS/MS sequencing results, the Mascot output files were submitted to the 
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commercial software Scaffold (v3.1.2, Proteome Software, Portland, 
Oregon, USA; http://www.proteomesoftware. com/) (44), which also 
employs a independent implementation of the Bayesian statistical 
algorithms developed by the Institute for Systems Biology, i.e. 
PeptideProphet and ProteinProphet (40; 41; 50). Scaffold tool to integrate 
Mascot identification results with X! Tandem search engine results 
(performed in automatic with the same parameters set for Mascot) was used. 
In paper VII we used two different software solutions for label-free 
comparative analysis: SIEVE and Scaffold. In the case of the analysis with 
SIEVE, Proteome Discoverer software (version 1.3.0.339; Thermo Fisher 
Scientific) was used to validate identification of Mascot results. Proteins 
containing at least two identified peptides were accepted. SIEVE software 
(version 1.3; Thermo Fisher Scientific) was used to execute differential 
quantitative analysis on validated proteins. Alignment and framing (peak 
detection) were performed as follows: data were processed in the interval 
13-80 min of the chromatographic separation (also processed for peptide 
identification), frames from MS/MS scans were used, a maximum of 
200000 frames was set together with 105 as signal threshold, and peptides 
with MZStart 400 and MZStop 1800, MZWidth 0.01, and RTWidth 2.5 
were used. 
Scaffold (version 3.1.2; Proteome Software, Portland, OR, USA) was also 
used to validate MS/MS based peptide identifications that could be 
established at greater than 95% probability as specified by the 
PeptideProphet algorithm. Protein identifications were accepted if they 
could be established at greater than 99.0% probability by the ProteinProphet 
algorithm and contained at least two unique peptides. Proteins that 
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contained shared peptides and could not be differentiated on the basis of 
MS/MS analysis alone were grouped to satisfy the principles of parsimony. 
FDR was found to be 0.1% for proteins and 0.5% for peptides. Unweighted 
spectrum counts (USC) were used to assess the consistency of experimental 
replicates in quantitative analysis, and normalized spectrum counts (NSC) 
was used to retrieve protein abundance. The SC normalization is an option 
available in Scaffold by means of which SCs are multiplied by a fractional 
amount across samples, so that the total number of spectra are the same 
within each category and then across all categories. Fisher’s exact test was 
used to identify significant differences and to calculate p-values. Ratios 
between NSCs were used to perform differential quantitative analysis. 
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4. RESULTS AND DISCUSSIONS 
The results discussed in this section were initially reported in papers I-VII. 
In papers I, II and III we investigated the binding of human plasma 
proteins to the surface of liposomes composed by the cationic lipid DC-Chol 
and the zwitterionic lipid (neutral helper lipid) DOPE. At the beginning, the 
features of this liposome formulation were analyzed and compared to those 
of the corresponding lipoplex system, then the attention was focused on the 
effect of membrane charge density on the binding of plasma proteins for 
liposomes with different neutral lipid/total lipid ratios, in order to have 
liposomes with three different membrane charge densities (Φ = 0.3, 0.5, 
0.7). The resulting protein coronas have been characterized both 
qualitatively and quantitatively. The analysis of the observable protein 
patterns was interesting because this type of knowledge could help to better 
understand the DNA compaction process. Moreover this study might open 
up the way to understand molecular phenomena occurring upon lipoplex-
protein interactions in vivo. Evidences in a recent study (22; 51) showed that 
clusters of multilamellar lipoplexes connected by DNA can coexist with 
DNA adsorbed onto unbroken vesicles. The interaction between 
nanoparticles and plasma proteins is mainly electrostatic, however several 
other factors influence the detailed nature of the protein corona. Among 
them, size, shape and surface hydrophilicity/hydrophobicity are fundamental 
features which determine the composition of the corona.  
In the first study (paper I) two systems were initially compared, i.e. DC-
Chol DOPE CLs (Φ = 0.5) and its DOPE/DNA lipoplex counterpart, in 
order to evaluate the effect of DNA presence. With this respect, our ζp 
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results (Table 1) showed that DC-Chol DOPE CLs and DC-Chol 
DOPE/DNA lipoplexes did not exhibit remarkable differences. These data 
were not enough to describe the exact structure. For this purpose, the two 
coronas were compared, because if the lipoplex structure were only 
multilamellar, the resulting protein profile would be the same for the 
liposome and the lipoplex. In fact in this type of structure, DNA molecules 
are enveloped by the lipid bilayer; on the contrary, in a cluster-like structure 
the two coronas would be different because DNA is also exposed on the 
surface and available for protein binding. A shotgun proteomics strategy 
was employed for the characterization of the two types of corona. Peptide 
and protein identifications were statistically validated submitting the Mascot 
result files to the TPP software. Here the peptide and protein probability 
thresholds were set at 0.7 and 0.9, respectively, for both liposomes and 
lipoplexes data sets. The related values for the error rate and sensitivity were 
0.6, 84.4% for liposomes and 0.8, 83.0% for lipoplexes. Protein 
identifications were accepted if at least two unique tryptic peptides were 
present. Applying these conditions, 110 and 125 proteins were identified as 
adsorbed onto liposome and lipoplex surface, respectively, with 99 proteins 
being in common (Figure 6).  
As Table 2 shows, individual proteins or protein classes, among which 
HSA, various Igs, apolipoproteins, fibrinogen, proteins of the complement 
pathways and other proteins, were identified. The most abundant protein in 
plasma, HSA, was found to be associated both with DC-Chol-DOPE CLs 
and DC-Chol-DOPE/DNA lipoplexes (paper IX).  
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Figure 6 Venn diagram showing the 
distribution of TPP validated proteins for 
DC-Chol-DOPE CLs and lipoplexes 
Figure 7 Charge calculated at pH 7 for the 
proteins identified in the protein corona of 
DC-Chol-DOPE LCs and DNA lipoplexes. 
■ positively charged proteins; ■ negatively 
charged proteins 
Concerning Igs, they were identified as part of the protein corona found 
around different nanoparticles and are involved in several biological 
processes (e.g. allergic reaction, immunity response and anaphylactic 
shock). IgG is also involved in transport across the placenta as well as in the 
opsonization process (52). Apolipoproteins represent the main constituents 
of the protein corona of particles with hydrophobic surface (23; 53). 
Furthermore, they are involved in the lipid and cholesterol transport 
throughout bloodstream (54) and, as such, are expected to greatly influence 
the intracellular trafficking, fate and transport of nanoparticles inside cells 
and body. The fibrinogen, a glycoprotein that is converted by thrombin into 
fibrin during blood coagulation, interacts with foreign surfaces and induces 
attachment of immune cells such as monocytes, macrophages and 
neutrophils. As a result, apoptosis is delayed and antibody-dependent cell 
cytotoxicity and phagocytosis are increased (55; 56). 
 
Common CLs Lipoplex 
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Table 2 Proteins identified exclusively on the surface of CLs and lipoplexes, including 
their probability, sequence coverage, unique peptides and charge calculated at pH 7  
Protein ID Protein name Protein 
probability 
Coverage 
% 
Unique 
peptides 
Charge 
at pH 7 
Liposomes      
 Protein transport protein 
Sec16A 
0.9234 0.6 3 −51.3 
 CD5 antigen-like 0.9846 18.7 4 −11.3 
 Apolipoprotein M 0.9873 9 2 −3.8 
 Angiotensinogen 0.9999 8.9 2 −5.8 
 Ig k chain V-II region 
TEW 
0.9904 32.7 2 −0.9 
 Coagulation factor V 0.9623 1.1 2 −40.6 
 CD9 antigen 0.9889 15.4 2 0.4 
 Ubiquitin-conjugating 
enzyme E2 H 
0.908 15.3 2 −13.3 
 Apolipoprotein F 1 8.8 3 −6.7 
 Collectin-11 1 29.2 6 −6.3 
 Protein Z-dependent 
protease inhibitor 
0.9995 7.9 2 4.1 
Lipoplexes      
 Ras-related protein Rab-
27B 
0.9248 10.1 2 −2.9 
 Putative nucleoside 
diphosphate kinase 
0.9983 19 2 3.8 
 Histone H2B type 1-K 1 34.9 4 18.6 
 Serum deprivation-
response protein 
0.9913 12.5 4 −18.3 
 Plasminogen 0.9308 3.7 2 3.4 
 Complement C5 1 4.8 6 −9.8 
 Kininogen-1 1 25.6 14 6.8 
 Band 3 anion transport 
protein 
0.9934 3.6 2 −27.7 
 Fibronectin 1 4.4 7 −45.3 
 Complement component 
C8 a chain 
0.9991 7.9 2 −3.7 
 Complement component 
C8 g chain 
0.9953 16.3 2 3.1 
 Histone H1.4 1 16.9 4 58.9 
 Complement component 
C7 
0.9797 3.8 2 −6.6 
 Heat shock cognate 71 
kDa protein 
1 23.1 8 −11.4 
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 Solute carrier family 2, 
facilitated glucose 
transporter member 3 
0.9999 8.1 3 0.4 
 Keratin, type I 
cytoskeletal 10 
1 25.7 8 −14.2 
 Lipopolysaccharide 
binding prot 
0.9573 6 2 −1.7 
 Myosin regulatory light 
polypeptide 9 
1 55.8 8 −11.1 
 Peroxiredoxin 6 0.9869 16.1 2 −1.4 
 Protein disulfide-
isomerase A3 
0.9963 18.2 3 −4.0 
 Coronin-1A 0.9984 13.4 3 −1.9 
 F Actin capping prot. Sub. 
a 
0.9832 14 3 −7.2 
 Nucleosome assembly 
prot 1 like 1 
0.9207 14.3 3 −52.6 
 Clathrin heavy chain 0.9036 1.6 2 −33.2 
 Adenylyl cyclase-
associated protein 1 
1 29.5 6 5.8 
 Latent transforming G.F. b 
bind 
0.9328 3.1 3 −36.8 
The nanoparticles studied were lipid nanovectors and for these systems the 
main interaction with plasma proteins was electrostatic; so this finding was 
striking because it was an evidence that lipoplex surface was different from 
that of pure CLs. The condensation of DNA on the lipid surface was a 
possible explanation for this phenomenon and was in agreement with the 
measures of ζp. 
In order to elucidate the correlation between the nanoparticle surface charge 
and protein corona compositions, the charges at pH 7 for all the identified 
proteins was calculated using a specific software (http://www.scripps.edu/~ 
cdputnam/protcalc.html, values are listed in Table 1). Figure 7 shows the 
fraction of negatively (blue) and positively (red) charged proteins in the 
overlap of the two protein coronas. As evident, the proteins common to both 
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coronas are principally negative (66%), an expected result because both DC-
Chol-DOPE CLs and DC-Chol-DOPE/DNA lipoplexes are positively 
charged nanoparticles. The same consideration performed taking into 
account the unique proteins (i.e. those that are not common) gives a 
different result: in this case, the percentage of negatively charged proteins 
was found to be about 77% and 65% for liposomes and lipoplexes, 
respectively. On the other hand, the average charge of the proteins found in 
the coronas was -11 for DC-Chol-DOPE CLs and -6 for DC-Chol-
DOPE/DNA lipoplexes. On average, the presence of more positively 
charged proteins in the lipoplex corona indicated that their surface was, at 
least locally, negatively charged. All these data showed that polyanionic 
DNA was associated with the lipoplex surface and could interact with 
positively charged plasma proteins. The evaluation of the lipoplex corona 
showed that it was rich of histones and complement proteins, which are 
DNA-binding protein, the presence of which further supported that a part of 
DNA was bound to the lipid surface. In particular, histones H1 and H2B 
type 1-K were identified exclusively in the lipoplex corona, suggesting that 
DNA was adsorbed at the lipoplex membrane and recognized by specific 
DNA-binding proteins as these. Complement proteins make up the 
complement system, a part of the immune system that contributes to clear 
pathogens from an organism (57). Their presence on the DNA-rich surface 
of lipoplexes was in very good agreement with the existence of a domain 
with DNA-binding activity in these proteins (58) and explains why 
lipoplexes are often rapidly cleared from the bloodstream and delivered to 
the Kupffer cells in the liver: indeed they form transmembrane channels on 
the surface of intruding pathogenic cells and cause lysis. Finally, another 
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protein found only on the lipoplex corona was fibronectin, which also has a 
DNA-binding domain. This is interesting because fibronectin can bind top 
cellular components known to promote the lipoplex-cell interaction and thus 
facilitate cell adhesion and internalization. This is supported by a work in 
which fibronectin was added to the surface or in solution with the lipoplexes 
and could enhance the substrate-mediated gene transfer efficiency (59).  
After a qualitative characterization of the protein corona of DC-Chol-DOPE 
CLs and lipoplexes, the next step was to evaluate the effect of charge 
density on the nanoparticle surface (papers II and III), which is one of the 
known features affecting transfection, in order to evaluate if any difference 
could be established in the protein corona, both qualitatively and 
quantitatively. The membrane charge density is the average charge per unit 
area of the membrane and can be varied changing the ratio between the 
neutral and the cationic lipid employed in the liposome preparation (in this 
case, DOPE and DC-Chol, respectively). Three different molar ratios were 
chosen, Φ = 0.3, 0.5, and 0.7, keeping constant the moles of cationic lipid 
(i.e., the overall charge). In these studies the issue concerning biological and 
technical variability was analyzed. The reproducibility of MS analysis in 
proteomics depends upon variations in sample preparation, proteolytic 
digestion, on-line separation of peptides and MS data acquisition, analysis 
and interpretation (60). To minimize biological variability and consider only 
the variables due to the analytical protocol and methodology, a pool of 
plasma has been employed, because blood composition may change 
significantly from one person to another one, resulting in different 
interactions with the nanoparticles (23). This was adopted for all the 
experiments of this study. Moreover, for these experiments, three 
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experimental replicates, with five technical replicates each, were performed 
for each sample, in order to assess the experimental reproducibility, 
resulting in 15 data files for each CL formulation. The proteolytic digestion 
was controlled using a freeware, RawMeat, that allowed to visualize 
different information, such as the charge distribution in the full MS spectra 
of precursor ions. What could be established was that mass charge varied 
from +2 to +6, with +2 and +3 charge precursors being about 85% of the 
total, and +4 charge precursors representing another 10%; the absence of 
higher charge states indicated a satisfactory digestion for the all the samples 
analyzed. RawMeat also allowed to evaluate the retention time 
reproducibility among technical replicates by checking the alignment 
overlaying the total ion current of all the samples belonging to the same CL 
formulation. Good reproducibility was also obtained comparing retention 
times of some selected peaks for samples belonging to different CL 
formulations, if the same chromatographic column was used. The qualitative 
study of the nanoparticle corona was performed validating Mascot search 
results with the TPP platform, setting the peptide and protein probability 
thresholds at 0.7 and 0.9, respectively. The related FDR values and 
sensitivity were, respectively, 0.5% and 86.9% for CLs with Φ = 0.3; 0.6% 
and 89.0% for CLs with Φ = 0.5; and 0.6% and 90.7% for CLs with Φ = 0.7. 
Protein identifications were accepted if at least two unique tryptic peptides 
were present. With these criteria, the proteins identified in the corona of CLs 
with Φ = 0.3, 0.5, and 0.7 were, respectively, 133, 128, and 143, with a total 
of 169 proteins, 106 of which being in common (Figure 8a). 
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a) b) 
  
Figure 8 Venn diagrams for the three CLs formulations showing the distribution of all 
identified proteins in: a) the qualitative (paper II) and b) quantitative (paper III) 
experiment 
As in the previous study, the majority of the 106 proteins were common to 
the three CL formulations and were involved in the immune or 
inflammatory processes (acute phase), blood coagulation, including platelet 
activation and degranulation, or in lipid transport functions (e.g., 
apolipoproteins). 
The CLs with Φ = 0.7 were able to bind more proteins and, as a 
consequence, were also the nanoparticles having the highest percentage of 
proteins exclusively adsorbed onto their surface (16% vs 7.5% and 5.4% of 
CLs with Φ, respectively, 0.3 and 0.5). This result was likely due to the 
different CL characteristics because the moles of cationic lipids were fixed, 
whereas the moles of neutral lipids was varied to obtain the different Φ 
values, and CLs with higher Φ possess a larger surface area. On the other 
hand, to a higher Φ corresponds a smaller σM that, differently from our 
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initial hypothesis, seemed to have not a determinant role in protein 
adsorption.  
After the study of the analytical reproducibility and qualitative analysis of 
the plasma proteins adsorbed onto the three different CLs, the experiment 
was repeated to add a label-free quantitative analysis based on SC (paper 
III). In this case, the validation of protein identifications was performed 
using the Scaffold software, also exploiting the X! Tandem search engine to 
increase confidence. Minimum peptide identification probability was set at 
95% (the highest available value), whereas protein identification probability 
was set at 99%, with each identification accepted if at least two unique 
peptides were present. The original Mascot search was made against a 
standard forward database so, applying the just mentioned filters, a FDR < 
0.1% was calculated, and a total of 177 proteins were identified; in 
particular, 152 proteins were identified for Φ = 0.3 CLs and 143 for both Φ 
= 0.5 and Φ = 0.7 CLs, with 117 proteins being in common (Figure 8b). 
These results were slightly different from the ones obtained from the first 
experiment, but this difference could be assigned to subtle modifications in 
the validation algorithms implemented by the two software programs, as 
well as the additional X! Tandem second search. The aim of this work was 
to quantify both major and minor proteins forming the corona because such 
a knowledge could help in developing future predicting models for 
nanoparticle surface chemistry interactions and biodistribution. For protein 
quantitative analysis, the Scaffold software normalization of the SCs and 
various statistical tests, to identify significant abundance differences in two 
or more categories, were employed. Quantitative data showed that CLs with 
Φ = 0.3 and Φ = 0.5 had a similar protein abundance for almost all the 
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identified proteins, leading to the conclusion that the composition of these 
two CL formulations was roughly the same. More difference emerged from 
the comparison between the coronas of Φ = 0.3 CLs and Φ = 0.7 CLs, and 
for such a reason the following discussion of protein differences will be 
restricted to the comparison of these two CL fromulations only. In order to 
evaluate the actual contribution of each protein to the hard corona 
composition, another correction was adopted over the mean values of the 
NSCs for the three experimental replicates (61). This correction expressed a 
relative protein quantity and represented a normalization that considered the 
mass of each protein, and was calculated as follows (Equation 1). 
       (
(     ⁄ ) 
∑ (     ⁄ ) 
 
   
)       (1) 
The MWNSCk is the percentage MW-normalized NSC for protein k (i.e. the 
relative protein abundance in the ‘hard corona’) (61), and MW is the MW in 
kDa for protein k. The quantitative analysis of the identified protein was 
performed, however it should be noted that the protein abundance did not 
necessarily reflect the biological impact of the nanoparticle. In fact, less 
abundant proteins bound to the nanoparticle surface can have a significant 
effect and can take part to several biological processes. However proteins, 
the relative abundance of which is extremely low, were not expected to be a 
determining factor for the fate and impact of the nanoparticle (61-63). In 
order to simplify data interpretation and evaluate only proteins with larger 
relative abundances, the attention was restricted to proteins with a 
MWNSCk ≥ 1. Relative abundances of protein satisfying such criterion is 
reported in Figure 9. The results appeared dependent upon the lipid 
composition, which was the main difference, since size and the ζp of CLs 
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with Φ = 0.3 and 0.7 were quite similar (Table 1). To better decipher data, 
we calculated the relative protein abundance ratio, R, defined as the ratio 
between the MWNSCk of Φ = 0.3 CLs and Φ = 0.7 CLs, considering 
significant only R > 2 and R < 0.5. This highlighted that fibrinogen was 
more associated with Φ = 0.3 CLs (R > 2) than all other identified proteins. 
On the other side, apolipoproteins and C4b-binding protein alpha chain are 
most abundantly associated with Φ = 0.7 CLs (R < 0.5, Figure 10). 
Considering that Φ = 0.7 CLs were richer in DOPE that Φ = 0.3 CLs, 
phospholipid-lipoprotein binding represented a general feature of lipid-
based nanoparticles in physiological conditions. In fact, the results showed 
that apolipoproteins had hydrophilic phospholipids that could better interact 
with the phospholid moiety of DOPE rather than with the less hydrophilic 
head group of DC-Chol. Significant quantities of opsonins (in particular 
fibrinogen, which was abundant in Φ = 0.3 CLs, but also IgG, and 
complement factors), were detected and were supposed to promote rapid 
clearance from the bloodstream; on the contrary the binding of dysopsonins 
(in particular apolipoproteins were found abundant in Φ = 0.7 CLs corona) 
promotes prolonged circulation time in blood (61-63). The presence of 
apolipoproteins on CL surfaces was also associated with a enhanced 
interaction with low-density lipoprotein receptors, which facilitates the 
transport across the blood-brain barrier. The presence of C4b-binding 
protein, prevalent in Φ = 0.7 CLs, was not in contradiction with this 
suggestion because it has as inhibitory role in the complement system. This 
specific adsorption on CLs with different Φ was also confirmed by the lists 
of unique proteins for the two systems. 
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Proteins bound to CLs with Φ = 0.7 (the most lipophilic nanopartciles 
characterized) were associated with the liver (a lipid-rich organ) and 
involved in blood coagulation process and complement pathway. On the 
contrary, the proteins that were found only in the Φ = 0.3 CL coronas have 
binding functions and are localized mostly in cytoplasm. However, the 
relative protein abundance of such "exclusive proteins" was lower than 1% 
in both the coronas. In this case, too, the charges at pH 7.4 of those proteins 
with MWNSCk ≥ 1 either in the corona of CLs with Φ = 0.3 or in that of 
CLs with Φ = 0.7 were calculated (http://www.scripps.edu/~cdputnam/ 
protcalc.html). The relative charge, a measure of the relative amount of the 
charge on the protein corona, was calculated by multiplying the total charge 
on the protein k, qk, for its relative protein abundance, MWNSCk (Equation 
2). 
 ( )  ∑          ( )
 
    (2) 
The relative charge of both the coronas was negative; with Q (Φ = 0.3) < Q 
(Φ = 0.7): it confirmed that the cationic surface interacted prevalently with 
negatively charged proteins. Moreover, considering that Φ = 0.3 CLs were 
more positively charged than Φ = 0.7 CLs, it could be established that the 
charge of the protein corona and the membrane charge density of cationic 
lipid membranes were strongly related to each other. Φ = 0.7 CLs had a 
larger amount of DOPE with a resulting electrostatic repulsion barrier that 
was low enough to be overcome by basic proteins; short-range attractive van 
der Waals forces could thus prevail over electrostatic repulsion, thereby 
inducing membrane aggregation and nanoparticle clustering, as also has 
been experimentally observed. 
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Once established that the amount of DOPE in the CL formulations could 
deeply influence the surface properties and the membrane charge density of 
cationic membranes, the effect of plasma concentration on the resulting 
protein corona was investigated, this time for DOTAP CLs and lipoplexes 
(paper IV). In fact, recent studies demonstrated that the actual composition 
of the hard corona of silica nanoparticles varied significantly with protein 
concentration (61). The choice of DOTAP CLs was made because they 
represented an excellent model systems of lipid nanoparticles in which a 
DNA/polycation core is coated with a lipid envelope (64-66). This aspect is 
quite interesting because it allowed to investigate the differences observed 
when nanovectors are used in in vivo studies instead of in in vitro studies, 
highlighting the effect of a real biological environment, with important 
consequences useful in future application of lipid-based gene vectors. Both 
CLs and lipoplex suspensions were incubated with different plasma 
concentrations (2.5, 5, 10, 20, 50, and 80%). In order to evaluate the 
differences in protein bound to the corona, a separation by SDS-PAGE was 
performed, to which a shotgun protein identification and quantitation was 
also added. Initially, a preliminary physical-chemical characterization of 
both DOTAP CLs and DOTAP/DNA lipoplexes was carried out. Sizing and 
ζp measurements showed that DOTAP CLs were small, positively charged 
vesicles (RH = 61.2 nm; ζP potential = 55.1 ± 1.2 mV). DOTAP/DNA 
lipoplexes were larger, instead, (RH = 125.5 nm), with a lower surface 
charge (ζp = 40.0 ± 1.1 mV). Synchrotron small-angle X-ray scattering 
(SAXS) intensity was used to investigate the structure, and indicated that 
CLs were simple unilamellar vesicles, whereas DOTAP/DNA lipoplexes 
were multilamellar onion-like structures, where DNA rods were densely 
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packed within more than 30 lipid bilayer/DNA monolayer aggregates, in 
agreement with the accepted model of the DNA-induced restructuring of 
CLs upon lipoplex formation (67). Data also confirmed the recent 
suggestion that lipoplexes are hybrid structures in which DNA chains could 
also be exposed on the surface (68), a fact which was expected to influence 
the nature of the protein corona. From the SDS-PAGE analysis it was 
evident that the increase in plasma concentration affected the pattern of 
proteins adsorbed onto the corona, in particular for DOTAP CLs (Figure 
11a), whereas for lipoplexes the intensity of the protein bands seemed 
directly proportional to the increase of plasma concentration (Figure 11b). 
The differences among different gel runs were evaluated calculating the 
total band intensities of proteins recovered from DOTAP CLs (61) (Figure 
11c) and DOTAP/DNA lipoplexes (Figure 11d).  
For DOTAP CLs the total amount of protein was maximum at ~20% plasma 
and decreased at lower and higher plasma concentrations, a trend explained 
taking into account that the most abundant proteins (i.e., those binding at 
lower plasma concentrations) were progressively displaced by those with a 
higher affinity (16; 24; 61; 63; 69; 70). Aggregation of CLs was another 
possible explanation (24). The trend of total band intensity for 
DOTAP/DNA lipoplexes was quite different and increased with plasma 
concentration (Figure 11d), probably because more proteins of the same 
type bound at higher concentrations. DNA molecules affected the protein 
corona even at low plasma concentration because being partially exposed 
allowed them to be available for protein adsorption. 
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Figure 11 For 2.5 - 80% plasma concentrations, SDS-PAGE gels of proteins found in the 
corona of: a) DOTAP CLs, and b) DOTAP/DNA lipoplexes. Most abundant proteins are 
marked with numbers. At the bottom the histograms for the corresponding total band 
intensity are reported for: c) DOTAP CLs, and d) DOTAP/DNA lipoplexes. 
The comparison among the gel band total intensities for a certain plasma 
concentration between the two systems highlighted that the intensity was 
higher for CLs than for lipoplexes, which meant that the lipid membrane 
area of CLs that was available for binding was larger than that of the 
lipoplexes, in agreement with the results of the preliminary physical-
chemical characterization of lipoplexes as a multilamellar structure. Indeed, 
multilamellarity (71-73), is a factor known to reduce the fraction of the lipid 
available on the outer surface for binding. To further support this 
observation, the total intensity of each lane at a fixed plasma concentration 
from the gel reported in Figure 11b was divided by the total intensity of the 
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corresponding lane from the gel reported in Figure 11d. The calculated ratio, 
RI, is reported in Figure 12.  
 
Figure 12 Plots showing a) RI ratio as a funtion of plasma concentration, and b) total 
intensity from Figure11b vs RCA  
At the lowest plasma concentration (2.5%), RI was found to be ~25, in 
agreement with the ratio of the exposed surface area for DOTAP CLs to that 
of the DOTAP/DNA lipoplexes. This ratio was kept constant in the 
experiment, nevertheless RI decreased with the increase of plasma 
concentration. Moreover, although the ratio of the plasma concentration to 
the total particle surface (RCA, area mL
-1
) was not constant throughout the 
experiment, the two investigated regions were practically contiguous, and 
plotting the total intensity of each lane from the gels reported in Figure 
11a,b against RCA did not show any clear trend. (Figure 12b).  
The interpretation of the data reported in Figure 12a was complicated by the 
fact that the exposed surface area of CLs is 30-fold larger than that of 
lipoplexes and the effective area per protein decreased with increasing 
protein concentration; other determining factors complicating data 
interpretation were the particle size, different for CLs and lipoplexes, and 
the nature of the surfaces, which for CLs were completely lipid, whereas for 
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lipoplexes DNA molecules were also present. All these aspects deeply 
affected the composition of the resulting protein corona in the different 
conditions for the two systems, and a quantitative comparison was not easy. 
In particular, a semiquantitative densitometry analysis was performed and 
the relative densitometry results as portrayed in Figure 13a for DOTAP CLs 
and Figure 13b for the corresponding lipoplexes. For the five major bands of 
Figure 11a, b, the intensity of each protein band was divided by the total 
intensity of the lane, and the same process was also carried out as a function 
of the plasma concentration during incubation (Figure 13a). From this 
analysis two groups of proteins could be found, low-affinity (LA) proteins, 
the relative amount of which showed a decreasing trend in the corona, and 
competitive-binding (CB) proteins, the relative amount of which had an 
increasing trend in the corona with increasing plasma concentration. For this 
reason, the formation of the corona for DOTAP CLs did not appear to be 
stable, with its composition probably affected by a cooperative phenomenon 
(61). However, for DOTAP/DNA lipoplexes, the relative intensities of all 
bands did not change significantly increasing from 2.5 to 80% plasma 
concentration, and the protein composition remained largely unchanged. 
The shotgun proteomics part of the experiments provided the identification 
of the proteins found in selected bands, which were cut from the gels and 
sequenced. As in previously described studies, the most abundant plasma 
proteins (albumin, fibrinogen, complement C5, apolipoprotein A-I, 
transferrin, vitronectin, and fibronectin) were identified for both systems. 
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Figure 13 For the different plasma concentrations, after 1 h incubation, plots showing the 
relative amounts of proteins marked in Figure 11a, b for: a) DOTAP CLs, and b) DNA 
lipoplexes. The proteins for which the relative amount decreased with increasing plasma 
concentration were labeled low-affinity (LA) proteins; the proteins for which the relative 
amount increased with plasma concentration are labeled competitive-binding (CB) proteins  
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However, in the corona of DOTAP/DNA lipoplexes a larger amount of 
immunoglobulins was detected. They are mainly basic proteins and their 
presence revealed that the surface charge of lipoplexes could locally be 
negatively charged, probably due to DNA on the surface, as also supported 
by sizing, ζp and SAXS measurements. Histones were also unique of the 
lipoplex corona. 
One common issue with liposome nanovectors is that the multilamellar 
structure of lipoplexes provides protection during transport, but also often 
hinders an adequate DNA release when inside the cell, with DNA trapped in 
the endosome and then degraded in the lysosomes (9; 74; 75). In order to 
increase transfection, lipoplexes were modified, condensing plasmid DNA 
with a polycation and forming lipid/DNA/polycation (LDP) complexes (76), 
which had successful results in delivering a gene to the liver with respect to 
more traditional liposome gene vectors (15).  
The next studies carried out were set in this context, and demonstrated that 
the TE of P/DNAcomplexes coated with a lipid envelope made of DOTAP 
is 3-20 times higher than that of DOTAP/DNA lipoplexes, which were 
considered as a comparison model, and evaluated for transfection CHO, 
HEK293, NIH 3T3, and A17 cells (paper V, Figure 14).  
Moreover, the encapsulation of precondensed DNA in the lipid envelope 
would have been a mean by which the interaction between DNA and basic 
serum proteins would be reduced (15; 65-66; 75-78). In order to elucidate 
this enhanced TE, several aspects were studied. The stabilization of these 
complexes was one issue to consider, and required the understanding of the 
factors that govern amphiphile-DNA interactions and subsequent complex 
formation. 
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Figure 14 TE of lipoplexes and LPD complexes at lipid/DNA ratio 2. Luciferase activity is 
reported as relative light units mg
-1
 protein in cell lysate. 
 
Figure 15 Plots showing the diameter (a) and zeta-potential (b) for lipoplexes (circles) and 
LPD complexes (triangles) as a function of lipid/DNA volume ratio Rv. 
When the complex is formed, reentrant condensation and charge inversion 
(73; 79), occurred for both systems (Figure 15), but in the case of LPD 
complexes charge and size saturation occurred at RV values smaller than 
those observed for lipoplexes; this meant that the complete encapsulation of 
P/DNAcore by a lipid envelope required a lower amount of cationic lipid 
than that for the formation of a similar lipoplex with the same amount of 
DNA. For this reason LPD complexes have an advantage over conventional 
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lipoplexes because they are potentially less toxic than for in vivo 
applications.  
The enhanced TE of LPD complexes was also influenced by the capability 
of the nanovector to overcome a series of biological barriers (membrane, 
cytoplasmic compartment, nucleus) (80). This capability depends upon the 
physical-chemical properties of the vector, such as size (81-84), ζp (85; 86), 
nanostructure (71, 87), propensity to be disintegrated by anionic lipids (73, 
79, 87-91) and ability to release DNA both in the cytosol and in the nucleus. 
However, no significant difference was observed for the ζp of LPD 
complexes and lipoplexes (ζp = 47.5 and 44.4 mV, respectively) or for their 
size, which could influence the uptake mechanisms (80), because both 
systems were larger than 200 nm and were supposed to enter via caveolae-
mediated pathways.  
More differences were expected in the fuse mechanisms with the cell 
membrane. Here, when the nanovector reaches the membrane, anionic 
cellular lipids begin to laterally diffuse into the complex neutralizing 
cationic lipids (92). Cationic/anionic mixed bilayers form and weaken the 
electrostatic attraction between cationic lipids and DNA, and when the 
positive lipoplex charge is neutralized, DNA can be released (92). SAXS 
measurements showed that DNA was not located in the lipid envelope of 
LPD complexes, but trapped inside the nanoparticle core. For this reason 
anionic cellular lipids could interact with LPD cationic lipids without 
competition with DNA, resulting in a more efficient DNA cytoplasmic 
release than normal lipoplexes, as observed by confocal microscopy 
experiments (Figure 16). 
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Figure 16 Confocal microscopy images of CHO-K1 cells 4 h after treatment with: a) LPD 
complexes , and b) lipoplexes; in the case of LPD complexes, the green-fluorescent NBD-
DOTAP and red-fluorescent DNA have different localizations, with DNA spread into the 
cytoplasm; on the contrary, in the case of liposomes, a colocalization was observed, 
suggesting that lipoplexes remained intact 
 
Figure 17 SAXS patterns for: a) LPD complexes, and b) lipoplexes, at DNA volume ratio 
Rv = 2; Sharp periodical peaks represented alternating lipid bilayers DNA/monolayer; the 
arrow-marked peak indicated the one-dimensional ordering of DNA placed between the 
lipid bilayers 
Moreover, SAXS measurements have highlighted that LPD complexes were 
made of about 10 lipid layers in a highly swollen state, while lipoplexes 
were more ordered multilamellar structures in which 30 alternating lipid/ 
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DNA layers were present (Figure 17). This could help the fusion process for 
LPD complexes because the number of lipid layers to be peeled off is 
inferior. 
LPD complexes, as well as several other nanovectors used in gene delivery, 
are usually administrated intravenously; for this reason, after their 
preliminary physical-chemical characterization, LPD complexes were 
compared to simple DOTAP CLs and their corresponding lipoplexes, this 
time focusing the attention on the effect of their exposure to plasma. In fact 
the type of protein corona which is formed is essential for an adequate 
distribution in vivo. The proteomic study was initially qualitative: with 
Mascot search results submitted to the TPP for protein identification 
validation (paper VI). In this work the experimental and analytical 
reproducibility of the method described for the isolation and analysis of 
proteins adsorbed onto these systems was evaluated. In fact in proteomic 
studies it is frequent that the analysis of the same sample under the same 
experimental conditions can lead to the identification of a different protein 
set for each experiment (93-95). Usually it is very rare to observe a 100% 
overlap between two chromatographic runs even for the same sample, 
especially for very complex samples, where the degree of overlap can reach 
only about 20%. For this reason, the presence (or absence) of a protein in a 
sample can be a consequence of incomplete determination and may not 
reflect real biological difference between samples. To tackle this issue, three 
experimental replicates were performed, with five technical replicates each. 
Chosen a peptide and protein probability threshold for validation, in the best 
case (experimental replicate 1 of CLs), the false-positive rate is very low 
(error rate of 0.3%), with an extremely high percentage of correct 
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identifications (95.4%) (Table 3). On the other hand, in the worst instance 
(experimental replicate 2 of LPD complexes), the false-positive rate is also 
quite low 0.7%, with a percentage of correct identifications which was still 
good (81.0%). The agreement between experimental and technical replicates 
showed that the experiment had a high degree of reproducibility, with very 
similar sensitivities and error rates (Table 3).  
Table 3 Protein identification sensitivity and error rates as calculated on the 5 technical 
replicates by the TPP, setting peptide probability ≥ 0.75 and protein probability ≥ 0.90 
Experimental  
replicate 
Sensitivity Error rate 
CLs   
1 95.4% 0.3% 
2  92.5% 0.5% 
3 93.7% 0.4% 
Lipoplexes   
1  88.8% 0.6% 
2  91.2% 0.6% 
3  94.2% 0.7% 
LPD complexes   
1 87.5% 0.8% 
2  81.0% 0.7% 
3 86.2% 0.7% 
The percentage of overlap among the experimental replicates was also 
calculated and is reported in Table 4. Identified proteins for the three lipid 
vectors were classified for each experimental replicate, reporting the 
corresponding percentage of the total, number of proteins that did or did not 
overlap among the experimental replicates and the number of proteins 
uniquely identified in a single replicate. This classification showed that the 
number of proteins overlapping among the three systems in the three 
experimental replicates was very high, certainly because protein samples 
were not too complex and the number of chromatographic runs was quite 
high. Another aspect emerged from this comparison: the variation of protein 
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identifications was significantly larger for LPD complexes, indicating that 
the type of proteins adsorbed onto the surface of LPD complexes changed 
slightly between experimental replicates, probably because the presence of 
protamine could make the nanoparticles dynamically unstable. On the 
contrary  the percentages of overlap among the three experimental replicates 
were very close to each other in the case of CLs and lipoplexes, because 
they were more stable systems (Table 4). 
Table 4 Proteins overlapping among the three systems under investigation as validated 
from five technical replicates (the percentage of the total of proteins which were identified 
in each experimental replicate is also reported in brackets)  
 Exp. replicate Combined Overlap 
Only exp. 
replicate 
 1 2 3  Yes No 1 2 3 
CLs 
90 
(85.7%) 
95 
(90.5%) 
94 
(89.5%) 
105 82 13 1 5 7 
Lipoplexes 
176 
(84.6%) 
186 
(89.4%) 
168 
(80.8%) 
208 140 26 9 10 7 
LPD 
complexes 
135 
(85.4%) 
110 
(69.6%) 
116 
(73.4%) 
158 92 47 26 6 15 
The number of proteins identified for the three lipid vectors is depicted in 
Figure 18. Lipoplexes bound the largest number of proteins, 208, whereas 
only 105 were identified on the corona of CLs and 158 in the corona of LPD 
complexes. This could be a consequence of lipoplex structure and partial 
exposure of DNA on the surface, which made it available for binding of 
proteins, such as DNA-binding proteins and/or basic proteins that otherwise 
would not interact with simple cationic lipid membranes. The number of 
proteins bound to the surface of the LPD complexes was intermediate 
between those of CLs and lipoplexes. A possible explanation of this 
observation could be that, although in LPD complexes plasmid DNA was 
condensed with protamine and encapsulated within the lipid envelope, a 
Results and Discussion 
 
 85 
fraction of precondensed DNA used for preparation might be subtracted by 
cationic lipids, resulting in some intermediate structure in which DNA was 
still available to protein binding. This suggestion was also supported by a 
large percentage of overlap between lipoplexes and LPD complexes. 
 
Figure 18 Venn diagram showing identified 
proteins for DOPE CLs, lipoplexes and LPD 
complexes 
Figure 19 Venn diagrams showing the 
proteins validated by Proteome Discoverer  
Established that the experimental conditions were suitable for differential 
proteomic analysis, the analysis of the protein corona of the three systems 
was possible. The experiment was repeated, this time with the aim of 
exploiting label-free quantitation approaches to add a quantitative 
description of the differences in protein forming the corona of the three 
nanovectors under investigation (paper VII). By means of Proteome 
Discoverer, 306 proteins were validated, in particular 104 for CLs, 227 for 
lipoplexes, which resulted to have the richest protein corona, and 186 for 
LPD complexes (Figure 19). 
Lipoplexes had nearly twice as much protein identifications as CLs but only 
approximately 20% more proteins than the corresponding value for LPD 
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complexes. CLs and LPD complexes had nearly the same number of 
identifications, with that of LPD complexes being only 1.8 times that of 
CLs. The Venn diagram highlighted another aspect: only 59 proteins were 
shared among all samples; 71 proteins were common to lipoplexes and LPD 
complexes, a number which was 10 times and approximately 5 times the 
protein overlap for lipoplexes and CLs, and for LPD complexes and CLs, 
respectively. Comparisons for relative quantitative analysis were performed 
on two samples at a time considering the shared proteins only. For SIEVE 
analysis the change in abundance was expressed as the ratio of protein 
signal intensity measured for two samples. Changes were considered 
significant if the coefficient of variance was lower than 10%, the p-value 
was lower than 0.001, Mascot score was higher than 25, and peptides had 
unique protein assignment. Moreover, signal intensity (abundance) ratios 
had to be higher than 2 or lower than 0.5 with a CV lower than 0.33. This 
reduced the number of proteins found to satisfy the above conditions in the 
analysis to 9 for lipoplexes vs CLs, 2 for LPD complexes vs CLs, and 17 for 
lipoplexes vs LPD complexes. Results are shown in Table 5. 
Table 5 Results of SIEVE quantitative analysis showing signal intensity ratios with CV < 
10%, p-value < 0.001, Mascot score > 25, peptides unique assignment, and abundance ratio 
higher than 2 or lower than 0.5 with a CV < 0.33.  
 
Protein name 
Abundance ratio 
 Lipoplexes/Cls 
LPD 
complexes/ 
CLs 
LPD 
complexes/ 
lipoplexes 
 HSPA5 protein   0.20±0.04 
 Serum amyloid A-4 protein   0.16±0.04 
 Prothrombin (Fragment) 0.010±0.003   
 PLG Plasminogen  4.5±1.5 0.44±0.09 
 
C4b-binding protein alpha 
chain 
0.04±0.01   
 Apolipoprotein E  (1.3±0.2) 0.29±0.03 
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 Apolipoprotein A-II   0.33±0.06 
 Apolipoprotein C-II   0.7±0.1 
 Apolipoprotein B-100 2.7±0.1 (0.59±0.07) 0.29±0.02 
 
Complement C1q 
subcomponent subunit C 
  0.003±0.001 
 Complement C9 (1.8±0.3)
[a] 
 0.28±0.04 
 Platelet factor 4 (1.6±0.4)
[a]
  0.07±0.01 
 Apolipoprotein(a) 2.2±0.2  0.49±0.06 
 Complement C5   (2.6±1.0) 
 
Lipopolysaccharide-binding 
protein 
3.0±0.6  0.20±0.06 
 Profilin-1 13±4  0.18±0.05 
 
Serum 
paraoxonase/arylesterase 1 
(2.0±1.6)
[a]
 0.010±0.003  
 Thrombospondin-1   0.12±0.02 
 Vitronectin (1.5±0.1)
[a]
  0.15±0.01 
 Talin-1 2.1±0.3  0.09±0.01 
 Histone H4   0.33±0.07 
 Complement C3 (Fragment) 2.1±0.4 (0.9±0.2)  
 
Complement component 6 
precursor 
0.45±0.06   
[a] Proteins that do not satisfy SIEVE’s criteria but do for Scaffold’s 
 
Figure 20 Correlation plots for DOTAP CLs and LPD complexes 
For Scaffold analysis the experimental replicate were analyzed 
independently, combining all technical replicates in one analysis using 
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Scaffold’s MuDPIT option. The reproducibility among replicate 
experiments was checked comparing the USC for each protein and 
Pearson’s product was calculated showing that the experimental replicates 
were highly reproducible (Figure 20). For validation the chosen probability 
parameters were at least 95% for peptide and 99% for protein 
identifications, with each protein identification accepted if at least two 
unique peptides were present. Grouping proteins that could not be 
distinguished, a total of 268 proteins were validated with 0.1% protein FDR 
and 0.5% peptide FDR. USC were used to assess the consistency of 
experimental replicates in quantitative analysis, and NSC were used to 
retrieve protein abundances. Scaffold normalization consists in multiplying 
by a fractional amount across samples, so that the total number of spectra 
are the same within each category and then across all categories. To 
establish if any difference was statistically significant the Fisher’s exact test 
was used to calculate p-values. Results obtained with this validation 
approach were consistent with the former obtained by Proteome Discoverer: 
again, the lipoplex protein corona was the richest in qualitative composition, 
whereas that of the CLs was the poorest; protein number ratios for one 
sample to another were also very close to those found in Proteome 
Discoverer analysis. 82 proteins are common among all the samples, as well 
as proteins shared between lipoplexes and LPD complexes, which was 
approximately 20 times and 7 times protein overlap between lipoplexes and 
CLs, and between LPD complexes and CLs, respectively (Figure 21).  
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Figure 21 Venn diagram showing the proteins validated by Scaffold 
From the NSCs, for each protein the mean value (with the corresponding 
standard deviation) was calculated and used for comparing two samples at a 
time, each time taking into account shared proteins only. Differences were 
considered significant if the Fisher's p-value was smaller than 0.001 and the 
NSC ratio higher than 2 or lower than 0.5, with a coefficient of variance 
lower than 0.33. In this way 22 proteins were found to be quantitatively 
different for lipoplexes vs CLs, 17 for LPD complexes vs CLs and 12 
lipoplexes vs LPD complexes (Table 6). 
Table 6 Results of Scaffold quantitative analysis showing NSC ratios for proteins having a 
p-value < 0.001, abundance ratio higher than 2 or lower than 0.5 and a CV < 0.33.  
 
Protein name 
Abundance ratio 
 
Lipoplexes/ 
Cls 
LPD  
complexes/ 
CLs 
LPD  
complexes/ 
lipoplexes 
 Complement component C8 gamma chain  3.8±0.6 2.1±0.6 
 Prothrombin (Fragment)
 
(0.01±0.004)
[b] 
  
 Plasminogen   (1.6±0.5)
[b]
 
 
cDNA FLJ55673, highly similar to Complem. 
fact. B 
 2.1±0.3 2.5±0.3 
 Properdin   2.39±0.23 
 C4b-binding protein alpha chain 0.09±0.01   
 Apolipoprotein A-I 2.3±0.5 5.1±0.7 2.3±0.3 
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 Apolipoprotein E 3.0±0.6 3.4±0.6 (1.1±0.3)
[b]
 
 Apolipoprotein C-III  2.9±0.4 2.2±0.3 
 Isoform 1 of Fibrinogen alpha chain 0.13±0.03 0.26±0.02 2.0±0.4 
 Apolipoprotein B-100 2.8±0.3 3.0±0.5 (1.6±0.5)
[b]
 
 Complement C1q subcomponent subunit A   0.03±0.01 
 Complement C1q subcomponent subunit C   0.06±0.02 
 Complement component C9 2.8±0.6 3.6±0.8 (1.3±0.3)
[b]
 
 Protein AMBP 0.13±0.02   
 Platelet basic protein 4.8±0.5   
 Platelet factor 4 4.2±0.8   
 Apolipoprotein(a) 2.4±0.2 4.0±0.4 (1.7±0.1)
[b]
 
 Complement C5   2.7±0.8 
 Lipopolysaccharide-binding protein 3.3±0.9 2.42±0.56  
 Isoform HMW of Kininogen-1  0.14±0.03  
 PFN1 Profilin_1   (0.4±0.1)
[b]
 
 Isoform 2 of Phospholipid transfer protein   0.48±0.06 
 Serum paraoxonase/arylesterase 1 0.09±0.02 0.08±0.02  
 Isoform 1 of Vinculin 3.1±0.1   
 Isoform 1 of Clusterin 0.38±0.06 0.5±0.1  
 Inter-alpha-trypsin inhibitor heavy chain H1 0.17±0.02 0.34±0.08  
 Inter-alpha-trypsin inhibitor heavy chain H1   2.0±0.6 
 Vitamin K-dependent protein S  0.15±0.04  
 Isoform 1 of Integrin alpha-IIb 2.5±0.5   
 Fibrinogen beta chain 0.10±0.02 0.19±0.03  
 Thrombospondin-1 2.4±0.4   
 Vitronectin 2.5±0.3  (0.5±0.1)
[b]
 
 Talin-1 3.9±0.7  (0.08±0.05)
[b]
 
 Isoform 2 of Filamin-A 10±2  0.18±0.06 
 Hyaluronan-binding protein 2 2.2±0.4   
 Complement C3 (Fragment) (1.27±0.06) 2.4±0.1  
[a] Number of isoforms with shared peptides that could not be differentiated and were 
grouped together 
[b] These proteins do not satisfy Scaffold's criteria but do for SIEVEs’s 
Both NSC Scaffold and AUC SIEVE analyses revealed that the quantitative 
differences among the tree coronas were approximately 10% of the 
validated proteins. Assuming the two methods of quantitation to be 
complementary, the relative amount (signal intensity and abundance ratio) 
of validated proteins for which at least one method has identified a 
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significant difference are compared in Figure 22. A good correlation for 
LPD complexes vs CLs and LPD complexes vs lipoplexes was observed, 
whereas a lower correlation was found for lipoplexes vs CLs. 
 
Figure 22 Graphs comparing relative protein abundance ratios as calculated by SIEVE or 
Scaffold; only proteins present in significant different amounts by either of the two 
programs are shown; Pearson's product are also reported 
However, the correlation was substantially increased limiting the attention 
to only those proteins identified by both methods with a significant 
difference, irrespective of the CV (Figure 23). 
r = 0.60 
r = 0.88 
r = 0.82 
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Figure 23 Plots comparing the significant relative abundance ratios of SIEVE vs Scaffold 
for lipoplexes vs CLs (a) and LPD complexes vs lipoplexes (b)
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5. CONCLUSIONS 
Because nanoparticle interactions with plasma proteins strongly affect the 
biodistribution of the vectors in the body, a deep understanding of these 
interactions could be useful in developing nanocarriers with surface, size 
and shape able to drive them to target organs. 
Thanks to the study carried out in paper I it was possible to understand the 
DNA compaction process in the lipoplexes. The distinct pattern of protein 
adsorbed onto liposome and lipoplex surfaces showed the existence of 
hybrid structures in which the polyanionic DNA is associated with the 
lipoplex surface and could interact with positively charged plasma proteins. 
Our results suggested that lipoplexes were multilamellar onion-like system 
with DNA sandwiched between opposing lipid bilayers, but coexisted with 
other multilamellar complexes or with intact vesicles stuck together by 
DNA.This result was supported by the type of proteins adsorbed onto 
lipoplexes, such as histones and complement proteins, which are DNA-
binding proteins. 
Subsequently in papers II and III we studied the effect of membrane 
charge density and demonstrated a preferential adsorption for some classes 
of proteins. Our results showed that lipid composition did control the 
surface properties of nanoparticles and could entirely change the nature of 
the biologically active proteins in the corona, with subsequent possibly 
relevant biological impacts. 
Once established that the amount of DOPE in the CL formulations could 
deeply influence the surface properties and the membrane charge density of 
cationic membranes, the effect of plasma concentration on the resulting 
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protein corona was investigated, this time for DOTAP CLs and lipoplexes 
(paper IV). We showed that the protein corona of CLs was made of both 
low-affinity and competitive binding proteins, the relative abundance of 
which changes with the plasma concentration. Such effects might be so 
striking because the biological response to lipid gene vectors with DNA 
cargo confined in their interior space may change dramatically as the 
amount of protein in the environment changes. The protein corona of 
lipoplexes changed in abundance but not in composition. We concluded that 
the evolution of protein corona passing from in vitro to in vivo conditions 
could be affected by the presence of DNA. This aspect should be carefully 
considered for the rational design of lipid gene vectors. 
The next study (paper V) showed that LPD complexes were more efficient 
in transfecting cells if compared to the corresponding lipoplexes, probably 
because of the different packaging when complexes with DNA were 
formed. In the LPD complexes DNA was condensed with a polycation and 
encapsulated by a lipid envelope. This kind of structure represented an ideal 
strategy to shield the mutual interactions between DNA and basic serum 
proteins for in vivo applications but, most importantly, LPD complexes 
showed a enhanced capacity to release their DNA payload, while lipoplexes 
remained largely intact and accumulated at the cell nucleus. 
The last two studies (papers VI and VII) compared the protein coronas 
adsorbed onto DOTAP, DOTAP/DNA lipoplexes and LPD complexes. The 
protein coronas resulted to be different in terms of qualitative composition. 
These studies confirmed that the protein coronas of lipoplexes and LPD 
complexes were more variable than those of CLs, whereas small differences 
were detected between those of lipoplexes and LPD complexes. 
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All results could help in designing gene delivery systems, because some 
proteins could be more selectively bound than others, and their presence 
could be exploited for the biodistribution of the nanoparticles in vivo, in 
order to target to specific cells or tissues and provide a more efficient and 
effective gene therapy.  
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The distribution of drug delivery systems into the body is affected by plasma proteins
adsorbed onto their surface. Furthermore, an exact understanding of the structure and
morphology of drug carriers is fundamental to understand their role as gene delivery systems.
In this work, the adsorption of human plasma proteins bound to cationic liposomes and to
their relative DNA lipoplexes was compared. A shotgun proteomics approach based on HPLC
coupled to high resolution MS was used for an efficient identification of proteins adsorbed
onto liposome and lipoplex surfaces. The distinct pattern of proteins adsorbed helps to better
understand the DNA compaction process. The experimental evidence leads us to hypothesize
that polyanionic DNA is associated to the lipoplex surface and can interact with basic plasma
proteins. Such a finding is in agreement with recent results showing that lipoplexes are
multilamellar DNA/lipid domains partially decorated with DNA at their surface. Proteomics
experiments showed that the lipoplex corona is rich of biologically relevant proteins such as
fibronectin, histones and complement proteins. Our results provide novel insights to
understand how lipoplexes activate the immune system and why they are rapidly cleared from
the blood stream. The differences in the protein adsorption data detected in the presented
experiments could be the basis for the establishment of a correlation between protein
adsorption pattern and in vivo fate of intravenously administered nanoparticles and will
require some consideration in the future.
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1 Introduction
The development of safe and efficient drug delivery systems
is one of the critical steps in achieving the full potential of
the gene therapy in the treatment of many inherent and
acquired diseases [1–3]. The majority of gene therapy
experiments and clinical trials currently use viral delivery
systems [4–6], but several aspects need to be improved for
achieving therapeutic benefit in patients. These include
better efficiency and reliability of procedures for the
manufacture of virus, freedom from helper virus contam-
ination [7], avoidance of immunogenicity of the viral particle
itself and ways of overcoming the limitation of transgene
size [8–10]. In several of these respects, non-viral delivery
systems have clear advantages over viral delivery systems
such as preparation reproducibility, lack of immunogenicity
and almost no size limit to the piece of DNA carried
into cells. Cationic liposomes (CLs) are the most promising
non-viral candidates for in vitro and in vivo gene delivery
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applications [11–13]. Regarding the barriers to in vivo
transfection, the inhibitory effect of plasma proteins binding
to lipoplex surface nanoparticles has been reported. The
immunological response to pathogens and foreign bodies is
activated by specific plasma proteins that contribute to their
clearance by the reticuloendothelial system, particularly in
the liver. Plasma proteins such as albumin, lipoproteins,
fibrinogen and heparin can bind to lipid membranes,
causing aggregation of lipoplexes. Recent ground-breaking
studies focused on what cells and organs barrier actually see
when interacting with a nanoparticle dispersed in a biolo-
gical medium [14]. Nanoparticles covered by plasma
proteins interact with the cell surface and are internalized by
nonspecific and/or highly specific pathways, such as recep-
tor–ligand interactions. This protein-mediated binding can
also affect the structure arrangement of the membrane itself
[15]. It has been shown that such particle–biomolecule
complexes can be physically isolated from the surrounding
medium and studied in detail, without altering their struc-
ture. The way by which nanoparticles are processed by cells
is strongly regulated by the identity and lifetime of proteins
adsorbed on their surface. Most cellular internalization
mechanisms are receptor-mediated. Therefore, a nano-
particle bare or covered by proteins that are not recognized
by cell receptors cannot be efficiently engulfed by cells.
Interestingly, the hard corona can evolve significantly as one
passes from protein concentrations appropriate to in vitro
cell studies to those present in in vivo studies [16]. A better
knowledge of proteins adsorbed on nanoparticle surface is
an urgent task for comprehending their biological respon-
ses. Moreover, the comprehension of the correlation
between protein adsorption and in vivo organ distribution
can be exploited to realize liposomes targeting different
tissues. Since the adsorption of plasma proteins occurs at
the surface level, proteomics technique is expected to clarify
the surface properties of both CLs and lipoplexes.
In the present study, we have investigated the binding of
human plasma proteins on the surface of lipoplexes made of
the cationic lipid 3-[N-(N,N-dimethylaminoethane)-carba-
moyl] cholesterol (DC-Chol), the neutral ‘helper’ lipid
dioleoylphosphatidylethanolamine (DOPE) and DNA. DC-
Chol-DOPE CLs were regarded as a control of the experi-
ment. Since DC-Chol-DOPE/DNA lipoplexes and DC-
Chol-DOPE CLs share the same lipid composition, this
approach will also help us towards identifying proteins
absorbed on the lipoplex surface as a consequence of the
presence of complexed DNA. Proteins solely and specifically
bound to lipoplex surface are extremely important because
they determine the biological identity of lipoplexes in vivo.
For this purpose, we have employed a shotgun proteomics
approach with a nano-HPLC system coupled to a high
resolution Orbitrap linear quadrupole ion trap (LTQ)-XL
mass spectrometer. This combined approach is expected to
develop a workflow specifically geared toward the efficient
identification of protein adsorbed onto nanoparticles
surface.
2 Materials and methods
2.1 Reagents and chemicals
The cationic lipid DC-Chol and the zwitterionic lipid DOPE
were purchased from Avanti Polar Lipids (Alabaster, AL).
Calf thymus (CT) Na-DNA was purchased from Sigma-Aldrich
(St. Louis, MO). All organic solvents were purchased from
Carlo Erba Reagents (Milan, Italy). Sodium chloride, iodoacet-
amide, EDTA, TRIS, polyacrylamide, DTT and ammonium
bicarbonate were acquired from GE Healthcare (Amersham
Biosciences, Uppsala, Sweden). Ultrapure water was
obtained from distilled water by a Milli-Q system (Millipore
Billerica, MA, USA). Protein LoBind tube were obtained from
Eppendorf (Hamburg, Germany). Porcine trypsin (modified,
sequencing grade) was commercialized by Promega (Madi-
son, WI, USA).
2.2 CL preparation
Appropriate amounts of DC-Chol and DOPE were solved in
CHCl3 at a molar ratio of zwitterionic lipid in the bilayer was
F5 (neutral lipid/total lipid) (mol/mol)5 0.5. First, the
solvent was removed by a gentle stream of nitrogen. To
ensure solvent removal, samples were kept under vacuum
for 12 h. The lipid film was hydrated with a solution
10mmol/L Tris-HCl, pH 7.4, 150mmol/L NaCl, 1mmol/L
EDTA (dissolving buffer).
The obtained liposome suspensions (1mg/mL) were
sonicated to clarity and stored at 301C for 48 h to achieve full
hydration.
2.3 Lipoplexes preparation
CT Na-DNA was employed. CT Na-DNA was solubilized in
Tris-HCl buffer (1mg/mL). Sonication for 5min resulted in
DNA fragmentation (length distribution between 500 and
1000 base pair, as determined by gel electrophoresis). Self-
assembled DC-Chol- DOPE/DNA lipoplexes were obtained by
mixing 24mL of DNA solution to 200mL of liposome disper-
sion and incubating at room temperature (RT) for 20min.
2.4 Size and f potential measurements
Size and z potential (zp) measurements of both CLs and
lipoplexes were determined by a Zetasizer Nano ZS90
(Malvern, UK) at 251C with a scattering angle of 90.01. The
neat vesicle dispersions was used for sizing measurements,
while 1/10 diluted samples were employed for zp measure-
ments. For each sample, five measurements were replicated
and averaged. All the data showed an unimodal distribution.
The polydispersity index was directly calculated by the
apparatus software.
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2.5 Human plasma samples
Human whole blood was obtained from the Experimental
Medicine Department (‘Sapienza’ University of Rome) by
venipuncture of healthy volunteers aged 20–40 years, using
BD
TM
P100 Blood Collection System (Franklin Lakes, NJ,
USA) with K2EDTA anticoagulant and protease inhibitors
cocktail. After clot formation, blood samples were centrifu-
gated at 1000 g for 5min to pellet the blood cells. The
supernatant plasma was collected and, after checking the
absence of hemolysis, was pooled to keep down differences
between individuals and reduce the overall subject-to-subject
variation. Then pooled plasma was aliquoted and stored at
801C in labeled Protein LoBind tubes to ensure plasma
stability during storage. Before analysis, plasma aliquots
were thawed at 4 1C and then warmed at RT.
2.6 CL and lipoplex incubation with plasma and
centrifugation
Aliquots of 200mL of plasma were incubated with 200mL of
CL suspension (1mg/mL) in the dissolving buffer at 371C for
1 h. The same procedure was used for lipoplexes. A robust
centrifugation (15 000 g for 10min) was used to pellet the
nanoparticle–protein complexes. Each pellet was washed with
250mL of the dissolving buffer, vortexed and then was
transferred into a new Protein LoBind tubes. After washing,
samples were newly centrifuged to remove proteins other
than those constituting the hard protein corona. This proce-
dure was repeated twice. After each washing step, tubes were
changed to reduce contamination from plasma proteins.
Figure 1 shows the protein profile adsorbed onto liposome
and lipoplex surface after SDS-PAGE.
2.7 In-solution trypsin digestion
The nanoparticle–protein complexes were resuspended in
40mL of 8mol/L urea solution in 50mmol/L NH4HCO3 and
2mL of 200mmol/L DTT and were incubated at 371C for 1 h,
under slight agitation, to denature proteins adsorbed onto
liposome and lipoplex surface. Afterwards, 8mL of 200mmol/
L iodoacetamide were added to the samples, and then they
were incubated at RT for 1 h in the dark. Subsequently, 8mL
of 200mmol/L DTT were added and incubated at 371C for
1 h, under slight agitation, to consume any leftover alkylating
agent and to avoid trypsin alkylation. The sample solutions
were then diluted with 50mmol/L NH4HCO3 to obtain a
final urea concentration of 1mol/L. Reconstituted trypsin
solution (20mg/mL in 50mmol/L NH4HCO3) was added to
ensure a minimum enzyme-to-substrate ratio of 1:20. The
samples were allowed to digest rotating overnight at 371C and
the digestion was quenched by adding formic acid. Digested
samples were desalted by using a SPE C18 column (BOND
ELUT 1CC LRC-C18, VARIAN, Palo Alto, CA, USA) condi-
tioned with acetonitrile and rinsed with 0.1% TFA. Peptides
were eluted from the SPE column with 0.5mL of ACN/H2O
(50:50, v/v) containing 0.05% TFA and were dried in a Speed-
Vac SC 250 Express (Thermo Savant, Holbrook, NY, USA).
Each sample was re-constituted with 100mL of the 0.1%
formic acid solution. Digested samples were stored at 801C
until analysis.
2.8 NanoHPLC-MS analysis
A HPLC/MS system consisting of a Dionex Ultimate
3000 nano-LC system (Sunnyvale CA, USA) connected to a
LTQ-Orbitrap XL mass spectrometer (Thermo Fisher
Scientific, Bremen, Germany) equipped with a nanospray
ion source was used to analyze tryptic peptides. Peptide
mixtures were resolved on a Hypersil Gold C18 column
(particle size 5mm, 150 0.18mm) at a flow rate of 1mL/min.
The LC gradient was optimized to detect the largest set of
peptides, using H2O/formic acid (99.9:0.1, v/v) as phase A
and ACN/formic acid (99.9:0.1, v/v) as phase B. A 120min
gradient from 2 to 90% B was used. After an isocratic step at
2% B for 5min, B was linearly increased to 35% in 80min;
afterwards, B was increased to 90% B in 5min. To rinse the
column such percentage was held constant for 2min.
Finally, the B content was to 2% over 2min, and the column
was re-equilibrated for 20min. The loading pump for peptide
enrichment was conducted at a flow-rate of 6mL/min by
premixed mobile phases H2O/ACN (98:2, v/v) with
0.1% formic acid. A 10mL aliquot of sample was injected.
The mass spectrometer was operated in the data-dependent
mode to automatically switch between Orbitrap-MS and
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Figure 1. Proteins adsorbed onto DC-Chol-DOPE CLs (lanes B–E,
respectively) and DC-Chol-DOPE/DNA lipoplexes (lanes F–I,
respectively) surface were mixed with electrophoretic sample
buffer, and boiled for 5 min prior to the electrophoretic run at
200 V constant voltage for 35 min. The proteins were visualized
using Coomassie PhastGel Blue R-350. Lanes A and J are protein
molecular weight markers (kDa).
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LTQ-MS/MS acquisition (m/z range 350–1800, resolution
60 000) using the ‘TOP5 strategy’. In brief, a scan cycle was
initiated with a full scan of high mass accuracy in the
Orbitrap analyzer that was followed by MS/MS scans in the
linear ion trap on the five most intense precursor ions with
dynamic exclusion of previously selected ions. This dynamic
exclusion consisted of two MS/MS spectra acquisitions of
the most abundant ion for a period of 30 s and then
excluding this ion for the followed fragmentations for 100 s.
The activation type used was CID with a normalized colli-
sion energy set at 35V. The experimental design provided
replicate MS runs on the same sample. The runs, called
technical replicates, help assess the additional variation
introduced into the measurements by the experimental
procedure and can increase the number of identified
proteins. Therefore, a total of five LC-MS/MS runs for each
sample (liposomes and lipoplexes) were analyzed.
2.9 Data processing and statistical validation
For database search, raw data files obtained from Xcalibur
software were submitted in MASCOT Deamon (version 2.2.04,
Matrix Science, London, UK) using the ThermoFinnigan
LCQ/DECA RAW file data import filter. Data were searched
against human entries in the SwissProt protein database
(version 57.15, 20 266 sequences). Trypsin was specified as
the proteolytic enzyme with a maximum of two missed clea-
vages, and fixed modification (carbamidomethyl) on cysteine
(157.0215Da), and variable modifications (oxidation) on
methionine (115.9949Da) were set for all searches. The
monoisotopic mass tolerance for precursor ions and frag-
mentation ions were set to 10ppm and 0.8Da, respectively.
Charge states of 12 or 13 were selected as precursor ions.
Peptide identification and protein assignment were
statistically validated submitting the MASCOT result files
(.dat) in the open source Trans-Proteomic Pipeline (TPP)
software (Seattle Proteome Center, SPC, Proteomics
Tools: http://tools.proteomecenter.org/software.php). After
conversion of the output MASCOT files (.dat) in
the.pepXML format, the PeptideProphet and and Protein-
Prophet tools [17–19], included in TPP, were employed.
Protein identifications have been submitted to the
proteomics identifications database PRIDE, accession
numbers 15915 and 15916.
3 Results and discussion
3.1 Size and fp measurements
Size and zp measurements showed that DC-Chol-DOPE CLs
are cationic vesicles (zp5 55.171.1mV) quite small in size
(hydrodynamic radius, RH, around 65nm). Narrow particle
size distribution (polydispersity index 5 0.2) showed lipo-
some suspensions to be monodisperse. The mix of DNA and
CLs induced the formation of larger size lipoplexes
(RH120 nm). Surface charge DC-Chol-DOPE/DNA lipo-
plexes was slightly lower than that of free liposomes (zp5
48.171.4mV). Such finding is most likely to be due to
partial neutralization of the positive charge of cationic lipids
by poly-anionic DNA.
3.2 Separation of nanoparticle–protein complex
from plasma by centrifugation
In this study, we used centrifugation as a method of
separation of the nanoparticle–protein complex because,
according to previous findings [20], standard durations of
washing and centrifugation give reproducible results. To
date, most studies have used centrifugation as the method of
separation of particle-associated proteins [21]. In particular,
stringent washing conditions, suitable to investigate the so-
called ‘hard corona’ [21, 22], were used. Therefore, three
washes with the dissolving buffer were performed to remove
all weakly bound proteins. Sedimentation of large proteins,
formation of protein aggregates and co-precipitation were
avoided by selecting a short centrifugation time (2min).
Despite the three vigorous washes, many proteins were
identified (Table 1). Such finding indicates that most
proteins of the protein corona remained tightly bound to
liposomes The presence in the corona of proteins whose
concentration in plasma is not high suggests that the
interaction between liposomes and some plasma proteins is
not dependent on their concentration, but it depends on
their affinity for liposome surface, different for each protein.
3.3 Statistical data analysis for validation of peptide
and protein identification using TPP
Following MASCOT searching of acquired MS/MS spectra,
rather than interpreting the data solely on the basis of
filtering by database search engine output scores (threshold
approach), MASCOT output files were submitted to the
recently developed statistical open source software, the TPP.
PeptideProphet and ProteinProphet, the two new statistical
tools of TPP, designed for such a purpose, were applied to
peptide and protein identification, respectively. Figure 2
summarizes the data workflow for this process. Because the
sensitivity (percentage of total correct identifications
remaining after restricting data at a given probability
threshold) and error rates (percentage of total false identi-
fication) for any data set modeled are directly related and are
affected by the probability threshold set to filter the data sets,
setting more or less stringent probability threshold is
possible. The peptide and protein probability thresholds for
running PeptideProphet and ProteinProphet were set at 0.7
and 0.9, respectively, for both sample data sets (liposomes
and lipoplexes). The related values for the error rate and
sensitivity were 0.6, 84.4% for liposomes and 0.8, 83.0% for
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lipoplexes. Protein identifications based on mass spectra
correlating to at least two unique tryptic peptides were
considered valid identifications. Applying these conditions,
110 and 125 proteins were identified as adsorbed onto
liposome and lipoplex surface, respectively, with an overlap
of 99 proteins. Further information on protein identification
is provided in Supporting Information.
3.4 Serum proteins adsorbed onto nanoparticle
surface
The shotgun proteomics strategy has been already adopted
to identify the proteins adsorbed onto DC-Chol-DOPE CLs
and onto DC-Chol-DOPE/DNA lipoplexes [20]. As Table 1
shows, individual proteins or protein classes, including
HSA, various Igs, apolipoproteins, fibrinogen, proteins of
the complement pathways and other proteins were identi-
fied. Our results confirm previous observations that nano-
particles can bind several classes of plasma proteins in
various amounts [22]. In fact, upon exposure to biological
fluids, nanoparticles are first covered by the most abundant
plasma proteins that are subsequently replaced by the
higher affinity ones [21]. HSA, the most abundant protein in
plasma, was found to be associated both with DC-Chol-
DOPE CLs [20], and DC-Chol-DOPE/DNA lipoplexes. Igs,
identified as part of the protein corona around different
nanoparticles, are involved in many biological processes, e.g.
Table 1. Proteins identified exclusively onto liposome or lipoplex surface with the main search result parameters obtained after TPP
validation, and their relative positive/negative charge at pH 7
Protein ID Protein name Protein
probability
Coverage
%
Unique
peps
Charge
pH 7
Liposomes
O15027|SC16A_HUMAN Protein transport protein Sec16A 0.9234 0.6 3 51.3
O43866|CD5L_HUMAN CD5 antigen-like 0.9846 18.7 4 11.3
O95445|APOM_HUMAN Apolipoprotein M 0.9873 9 2 3.8
P01019|ANGT_HUMAN Angiotensinogen 0.9999 8.9 2 5.8
P01617|KV204_HUMAN Ig k chain V-II region TEW 0.9904 32.7 2 0.9
P12259|FA5_HUMAN Coagulation factor V 0.9623 1.1 2 40.6
P21926|CD9_HUMAN CD9 antigen 0.9889 15.4 2 0.4
P62256|UBE2H_HUMAN Ubiquitin-conjugating enzyme E2 H 0.908 15.3 2 13.3
Q13790|APOF_HUMAN Apolipoprotein F 1 8.8 3 6.7
Q9BWP8|COL11_HUMAN Collectin-11 1 29.2 6 6.3
Q9UK55|ZPI_HUMAN Protein Z-dependent protease inhibitor 0.9995 7.9 2 4.1
Lipoplexes
O00194|RB27B_HUMAN Ras-related protein Rab-27B 0.9248 10.1 2 2.9
O60361|NDK8_HUMAN Putative nucleoside diphosphate kinase 0.9983 19 2 3.8
O60814|H2B1K_HUMAN Histone H2B type 1-K 1 34.9 4 18.6
O95810|SDPR_HUMAN Serum deprivation-response protein 0.9913 12.5 4 18.3
P00747|PLMN_HUMAN Plasminogen 0.9308 3.7 2 3.4
P01031|CO5_HUMAN Complement C5 1 4.8 6 9.8
P01042|KNG1_HUMAN Kininogen-1 1 25.6 14 6.8
P02730|B3AT_HUMAN Band 3 anion transport protein 0.9934 3.6 2 27.7
P02751|FINC_HUMAN Fibronectin 1 4.4 7 45.3
P07357|CO8A_HUMAN Complement component C8 a chain 0.9991 7.9 2 3.7
P07360|CO8G_HUMAN Complement component C8 g chain 0.9953 16.3 2 3.1
P10412|H14_HUMAN Histone H1.4 1 16.9 4 58.9
P10643|CO7_HUMAN Complement component C7 0.9797 3.8 2 6.6
P11142|HSP7C_HUMAN Heat shock cognate 71 kDa protein 1 23.1 8 11.4
P11169|GTR3_HUMAN Solute carrier family 2, facilitated glucose
transporter member 3
0.9999 8.1 3 0.4
P13645|K1C10_HUMAN Keratin, type I cytoskeletal 10 1 25.7 8 14.2
P18428|LBP_HUMAN Lipopolysaccharide binding prot 0.9573 6 2 1.7
P24844|MYL9_HUMAN Myosin regulatory light polypeptide 9 1 55.8 8 11.1
P30041|PRDX6_HUMAN Peroxiredoxin 6 0.9869 16.1 2 1.4
P30101|PDIA3_HUMAN Protein disulfide-isomerase A3 0.9963 18.2 3 4.0
P31146|COR1A_HUMAN Coronin-1A 0.9984 13.4 3 1.9
P52907|CAZA1_HUMAN F Actin capping prot. Sub. a 0.9832 14 3 7.2
P55209|NP1L1_HUMAN Nucleosome assembly prot 1 like 1 0.9207 14.3 3 52.6
Q00610|CLH1_HUMAN Clathrin heavy chain 0.9036 1.6 2 33.2
Q01518|CAP1_HUMAN Adenylyl cyclase-associated protein 1 1 29.5 6 5.8
Q14766|LTBP1_HUMAN Latent transforming G.F. b bind 0.9328 3.1 3 36.8
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allergic reaction, immunity response and anaphylactic
shock. IgG is also involved in transport across the placenta
as well as in the opsonization process [23]. Apolipoproteins
are the main constituents of the protein corona of particles
with hydrophobic surface [21, 24]. Furthermore, they are
involved in the lipid and cholesterol transportation
throughout bloodstream [25] and, as such, are expected to
greatly influence the intracellular trafficking, fate and
transport of nanoparticles inside cells and animal body. The
fibrinogen, a glycoprotein that is converted by thrombin into
fibrin during blood coagulation, interacts with foreign
surfaces and induces attachment of immune cells such as
monocytes, macrophages and neutrophils. As a result of
fibrinogen action, apoptosis is delayed and antibody-depen-
dent cell cytotoxicity and phagocytosis are increased [26, 27].
Other acute-phase proteins were recognized in the protein
corona suggesting that the nanoparticle–protein complex
can activate various inflammatory responses. Most proteins
related to the complement pathways that promotes neutro-
phil attachment to different surfaces were also identified
[28]. It has been reported that classical pathways of the
complement system can be activated by polystyrene latex
particles modified with hydroxyethyl acrylate [29] and non-
functionalized double-walled carbon nanotubes [30].
In Fig. 3 a general evaluation of the degree of similarity
of the protein coronas around DC-Chol-DOPE CLs and DC-
Chol-DOPE/DNA lipoplexes is presented where the fraction
of proteins that are unique for each system (light gray) as
well as the fractions detected on both of them (dark gray) are
reported. More than 88% of the corona for CLs is constituted
by proteins that are also in lipoplex corona. On the other
hand, this percentage decreases to 74% of proteins for
lipoplexes, which bind more identified proteins than lipo-
somes. Since the first interaction between lipid nanovectors
and plasma proteins is electrostatic, this finding is a striking
confirmation that lipoplex surface is different from that of
pure CLs. Bearing in mind that the lipid composition of CLs
and lipoplexes is identical, such surface modification is
probably due to the DNA condensation on the lipid surface.
Thus, DNA may affect the biological impact of nanoparticles
by modifying the composition of their protein corona. This
is a key issue that must be evaluated in nanomedicine and
nanosafety studies in vivo.
To find out a correlation between surface charge of lipid
nanoparticles and composition of protein coronas, the
charges at pH5 7 of all the proteins identified was calcu-
lated by a dedicated software (http://www.scripps.edu/
cdputnam/protcalc.html) and the values are listed in
Table 1.
Figure 4A shows the fraction of negatively (dark gray)
and positively (light gray) charged proteins in the overlap of
the two protein coronas. As evident, the proteins common to
both coronas are principally negative (66%). This is an
expected result because both DC-Chol-DOPE CLs and DC-
Chol-DOPE/DNA lipoplexes are positively charged nano-
particles that preferentially interact with oppositely charged
proteins. Even though the relative abundance of identified
proteins could not be determined, the strategy used in
Fig. 4A might be useful to investigate how the surface
charge properties of lipid nanoparticles influence the
composition of the protein corona. Indeed, the relative
protein abundance is not expected to reflect the biological
impact; in terms of the biological response, the most
abundantly associated proteins do not necessarily have the
strongest effect. A less abundant protein with high affinity
and specificity for a particular receptor may instead be a key
100
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Figure 3. Percentage of proteins that are unique for each system
(dark gray) as well as the fractions detected on both of them
(light gray).
LC-MS/MS Spectra
Mascot
database search
PeptideProphetTM peptide
b bili ipro a t es
ProteinProphetTM protein 
probabilities
Protein identification list
Figure 2. Acquired MS/MS spectra were submitted to MASCOT
for searching protein sequence database. MASCOT results were
subsequently converted to pepXML by MASCOT2XML, and
evaluated by PeptideProphet. The resulting files were then
analyzed by ProteinProphet, resulting in a single list of identified
proteins.
3354 A. L. Capriotti et al. Proteomics 2011, 11, 3349–3358
& 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
player. It is therefore essential to develop methods, as that
presented in this investigation, to identify both major and
minor particle-associated proteins. The picture is different
when unique proteins (i.e. that are not in common) are
considered (Fig. 4B). In this case, the percentage of negative
proteins was found to be about 77 and 65% for liposomes
and lipoplexes, respectively. On the other hand, the average
charge of the proteins found in the coronas was 11 for
DC-Chol-DOPE CLs and 6 for DC-Chol-DOPE/DNA
lipoplexes. Aside from being a quantitative result, this
finding is in agreement with zp measurements showing that
DC-Chol-DOPE CLs are more positively charged (zp5
55.171.1mV) than DC-Chol-DOPE/DNA lipoplexes (zp5
48.171.4mV). On average, the presence of more positively
charged proteins in the lipoplex corona indicates that their
surface is, at least locallynegatively charged. In previous
investigations [31, 32], we have provided unambiguous
evidence that DC-Chol-DOPE/DNA lipoplexes are onion-like
structures made of tenths of alternating lipid and DNA
layers. The most likely explanation of such observation is
that a fraction of DNA is associated with the lipoplex surface
and could interact with basic plasma proteins by charge
attraction. This suggestion is supported by the recent study
[31] showing that clusters of multilamellar lipoplexes
connected by DNA coexist with DNA-decorated unbroken
vesicles. Even though electrostatics plays a key role in the
interaction of nanoparticles with plasma proteins, many
other factors can influence the detailed nature of the
nanoparticle protein corona. Among them, size, shape and
surface hydrophilicity/hydrophobicity can affect the
composition of the corona. With this respect, our DLS and
zp results showed that DC-Chol-DOPE CLs and DC-Chol-
DOPE/DNA lipoplexes did not exhibit remarkable differ-
ences. Thus, minor changes, if any, in the above-mentioned
chemical-physical properties could not be used to explain
the observed differences in their corona composition.
Growing evidence suggests that the adsorbed protein layer is
a determining factor for the cellular uptake, trafficking and
biodistribution of lipoplexes. A detailed knowledge of
proteins specifically bound to lipoplexes might open up the
way to understand molecular phenomena occurring upon
lipoplex–protein interactions in vivo. Furthermore, a precise
definition of these proteins is a vital piece of information for
developing an effective and correctly addressed strategy of
gene delivery. To address this issue, we mainly focused on
the proteins present in the corona of lipoplexes. Some
proteins were specifically found on the lipoplex corona
(Table 1). The most significant ones were: (i) fibronectin; (ii)
HSP70; (iii) histones; (iv) complement proteins. Fibronectin
was not found on the liposome corona; thus it makes sense
that this protein interacts with DNA molecules adsorbed at
the lipoplex surface. This suggestion is in plain agreement
with the existence of a DNA-binding domain in the fibro-
nectin molecule. Fibronectin is a high-molecular weight
(440 kDa) protein involved in many biological processes
such as cell adhesion, growth, migration and differentiation.
Cellular fibronectin is assembled into the extracellular
matrix and binds to membrane-spanning receptor proteins
called integrins. In addition to integrins, fibronectin also
binds extracellular matrix components such as collagen,
fibrin and sulfate proteoglycans. Since the latter cellular
components are known to promote the lipoplex–cell inter-
action, it could be hypothesized that fibronectin could also
play a role in facilitating the lipoplex cell adhesion and
internalization. According to this suggestion, some authors
recently reported on the surface-mediated delivery of lipo-
plexes mixed with fibronectin [33]. The inclusion of fibro-
nectin on the surface or in solution with the lipoplexes was
found to enhance the substrate-mediated gene transfer
efficiency.
HSP70 are a class of functionally related proteins whose
expression is increased when cells are exposed to elevated
temperatures or other stress. Among other functions,
extracellular and membrane-bound HSPs are involved in
binding antigens and presenting them to the immune
system [34]. HSPs are useful as immunologic adjuvants in
boosting the response to a vaccine [35]. Histone H1 (P10412)
and H2B type 1-K (O60814) were identified. They are highly
alkaline proteins found in eukaryotic cell nuclei, which
package and order the DNA into structural units called
nucleosomes. More in detail, Histone H1 is one of the most
abundant proteins in the nucleus of eukaryotic cells. It has
long been known as the ‘linker histone’, because it links the
chromatosomal DNA that goes between the nucleosomes.
Histone H2B type 1-K is one of the proteins involved in the
structure of chromatin in eukaryotic cell. Aside from
biological interpretations, finding Histone H1 and Histone
H2B type 1-K in the lipoplex corona (and not in the lipo-
some corona) is a striking confirmation of our suggestion
that DNA is adsorbed at the lipoplex membrane is recog-
nized by specific DNA-binding proteins.
Some other proteins found in the lipoplex corona were
identified as immune-response proteins. Among them, the
most relevant ones seemed to be the complement proteins.
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Figure 4. Fraction of negatively (dark gray) and positively (light
gray) charged proteins.
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Complement proteins make up the complement system, a
part of the immune system that ‘complements’ the ability of
antibodies and phagocytic cells to clear pathogens from an
organism [36]. Complement activation by the classical
pathway occurs when the rst component of complement,
C1, binds, mainly via charge interactions to immune
complexes (containing IgG or IgM) or directly to a non-Ig
target surface. Remarkably, we observe that C1 was
identified both on the liposome and the lipoplexes corona.
Recent studies [37] have shown that C1 interacts
favorably with phospholipids in CLs. According to these
findings, our proteomics results are likely to suggest that
those complement proteins that have been found in
both the coronas are most likely to be bound to the lipid
surface. On the other side, C5 (P01031), C7 (P10643) and
the a (P07357) and g (P07360) chain of C8 (Table 1) were
found only on that of lipoplexes. Our proteomics
results showing that these complement proteins are
present at the DNA-rich surface of lipoplexes are in very
good agreement with the existence of a domain with
DNA-binding activity in the complement proteins [38].
From a biological point of view, complement proteins
identified on the lipoplex corona play a key role in the
activation of the alternative complement pathway. In parti-
cular, C5b initiates the membrane attack pathway, which
leads to the formation of the membrane attack complex,
consisting of C5b, C6, C7, C8 and polymeric C9, that is the
cytolytic end-product of the complement cascade. It forms a
transmembrane channel on the surface of intruding
pathogenic cells, which causes their osmotic lysis and their
final killing. In the context of gene delivery, it has reported
that Kupffer cells and other macrophage cell types clear
complement-coated pathogens. Thus, our proteomic results
showing that lipoplexes are coated by several complement
proteins might contribute to explain why lipoplexes are
often rapidly cleared from the bloodstream and delivered to
the Kupffer cells in the liver.
Recent in vivo studies [37, 38] have shown that the
sequential injection of CLs and DNA strongly reduces the
uptake by the liver and results in higher level of activity with
respect to preformed CLs–DNA complexes. To explain
results, the authors suggested that sequential injection of
CLs and DNA might inhibit the binding of some opsonin
proteins, thus reducing stimulation of phagocytosis by
reticuloendothelial system. Remarkably, our results support
such hypothesis because complement proteins were detec-
ted only in the corona of lipoplexes and not in the corona of
CLs. This observation could, at least in part, explain the
superior efficiency of transfection strategies based on such
sequential injection.
Opsonization remains a severe obstacle to in vivo
transfection and significant challenges remain before lipo-
plex-mediated gene delivery technique can be used techno-
logically. Among unreturned questions, how lipoplexes can
suppress the immune response is a mandatory task for
successful gene delivery applications. However, to respond
such query it is necessary to deeply understand the lipoplex-
induced immune response. In the future, a precise char-
acterization of the lipoplex protein corona composition, as
that reported in this study, shall be used to attain quanti-
tative data on the dynamics of the protein corona [39, 40].
Such knowledge will be extremely useful for a multitude of
protein nanoscience applications.
4 Concluding remarks
The current work is the first study aiming to identify and
compare proteins that bind onto DC-Chol-DOPE CLs and
onto DC-Chol-DOPE/DNA lipoplexes. A distinct pattern of
protein adsorbed onto liposomes and lipoplexes surface, as
suggested by the results, helps to better understand the
DNA compaction process. The experimental evidence leads
us to hypothesize that poly-anionic DNA is associated with
the lipoplex surface and can interact with positively charged
plasma proteins. Our results are in agreement with the
existence of clusters composed of multilamellar DNA/lipid
domains coexisting with other multilamellar complexes or,
alternatively, with intact vesicles stuck together by DNA.
Even more remarkably, we have shown that the lipoplex
corona is rich of histones and complement proteins. The
former are DNA-binding proteins and their presence on the
lipoplex surface confirms our suggestions that a part of
DNA is bound to the lipid surface. Complement proteins
compose the complement system, a part of the immune
system that works against intruding pathogenic cells.
Therefore, our results provide novel insights to understand
how lipoplexes activate the immune system and why they
are rapidly cleared from the blood stream. Since these
proteins were found to be specifically bound to the lipoplex
surface and not to the liposome one, new delivery strategies
that protect delivered DNA making it inaccessible to plasma
proteins are highly desirable.
Future work will be performed in that direction. In
addition, these results show that shotgun proteomics
analysis of proteins adsorbed onto nanoparticles surface can
be useful in the design of better drug carriers for specific
target cells or tissues. The differences in the protein
adsorption data detected in the presented experiments could
be the basis for the establishment of a correlation between
protein adsorption pattern and in vivo fate of intravenously
administered nanoparticles.
The authors have declared no conflict of interest.
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Abstract The knowledge about the interaction between
plasma proteins and nanocarriers employed for in vivo
delivery is fundamental to understand their biodistribution.
Protein adsorption onto nanoparticle surface (protein
corona) is strongly affected by vector surface character-
istics. In general, the primary interaction is thought to be
electrostatic, thus surface charge of carrier is supposed to
play a central role in protein adsorption. Because protein
corona composition can be critical in modifying the
interactive surface that is recognized by cells, characteriz-
ing its formation onto lipid particles may serve as a
fundamental predictive model for the in vivo efficiency of
a lipidic vector. In the present work, protein coronas
adsorbed onto three differently charged cationic liposome
formulations were compared by a shotgun proteomic
approach based on nano-liquid chromatography–high-reso-
lution mass spectrometry. About 130 proteins were identi-
fied in each corona, with only small differences between the
different cationic liposome formulations. However, this
study could be useful for the future controlled design of
colloidal drug carriers and possibly in the controlled
creation of biocompatible surfaces of other devices that
come into contact with proteins into body fluids.
Keywords Cationic liposomes .Mass spectrometry.
Nanoparticles . Plasma . Protein corona
Introduction
One of the problems posed by liposomes as carriers for
drug delivery and gene therapy is a rapid clearance from
the blood circulation. Various aspects of liposome
architecture strongly influence the clearance behavior.
Positively charged liposome containing equimolar
amounts of cholesterol are particularly stable, as well as
liposomes containing amphipathic phosphatidylethanol-
amine. During the last few decades, cationic liposomes
(CLs) and their complexes with DNA (lipoplexes) have
attracted a lot of scientific interest as their advantages as
gene delivery vectors were recognized and they became
the most widely used synthetic nanocarriers of genes
both in vitro and in vivo, and the object of extensive
physical–chemical characterizations [1–4].
A critical obstacle for extensive clinical application of
lipid-mediated transfection (lipofection) is its low transfec-
tion efficiency. Among the potential factors regulating
lipofection, membrane charge density of lipid bilayers,
σM, has been identified as a key parameter regulating
nanoparticle activity in vitro [5], and the existence of an
optimal membrane charge density, σM
*, for in vivo
transfection studies was demonstrated.
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However, despite the success for in vitro transfection,
nanocarriers often exhibit significant drawbacks when used
for in vivo delivery. When nanoparticles enter in contact
with human plasma, proteins compete for their surface
leading to a rich protein “corona” that potentially dictates
the fate in vivo [6, 7]. In general, the primary nanoparticle–
protein interaction is electrostatic, thus surface charge of
carrier is supposed to play a central role in protein
adsorption. Because protein binding to nanoparticles can
be critical in modifying the interactive surface that is
recognized by cells, understanding how and why plasma
proteins are adsorbed to lipid particles may serve as a
fundamental predictive model for the in vivo efficiency of
a lipidic vector. This is a point of great general interest,
even though only marginally addressed so far, in view of
future clinical application of lipoplexes. Therefore, the
knowledge of the adsorbed proteins could be useful in the
screening of new liposomal formulations which result
more biocompatible.
In this study, we investigated the liposomes made of the
cationic lipid (3-[N-(N,N-dimethylaminoethane)-carbamoyl])-
cholesterol (DC-Chol), and the zwitterionic lipid dioleoyl-
phosphatidylethanolamine (DOPE). The possible effect of
membrane charge density on the composition of adsorbed
protein coronas was also studied. The membrane charge
density is the average charge per unit area of the membrane
and it is controlled by the ratio of neutral to cationic lipid in
the liposome formulation. Thus, it was varied by changing
the neutral/total lipid molar ratio, “diluting” the cationic lipid
in the membrane.
Liquid chromatography coupled on-line with electro-
spray ionization–mass spectrometry (LC/ESI-MS) is the
technique of choice when analyzing proteins and peptides
in biological samples. In particular, the most employed
proteomics strategy is the “shotgun” approach which is
based on the LC/ESI-MS analysis of tryptic digests of a
whole protein sample.
In recent years, great impulse to proteomics has been
provided by the improved performances of newly available
mass spectrometers and chromatographic instrumentation,
resulting in higher sensitivity, speed of analysis, and mass
accuracy [8, 9]. However, the huge amount of data
obtainable with these new analytical instrumentations have
also required the development of dedicated softwares for
handling and filtering the results.
In the present work, a shotgun proteomics approach
based on high-resolution MS (by an Orbitrap instrument)
coupled to nanoLC system was employed to identify the
proteins adsorbed onto liposome surface after incubation
with human plasma. Data were then submitted to a suitable
result statistical validation.
Even if LC/MS has been already applied for investigating
interactions between nanoparticle and proteins [6, 7, 10–12],
this is the first study comparing three differently charged CL
formulations.
Experimental
Chemicals and reagents
The cationic lipid DC-Chol and the neutral “helper” lipid
DOPE were purchased from Avanti Polar Lipids (Alabaster,
AL, USA).
Ethylenediaminetetraacetic acid (EDTA), tris (hydroxy-
methyl)aminomethane (Tris), sodium chloride, 1,4-dithio-
threitol (DTT), iodoacetamide (IAA), ammonium
bicarbonate, urea, trifluoroacetic acid (TFA) were purchased
from Sigma Aldrich (St. Louis, MO, USA). All organic
solvents were the highest grade available from Carlo Erba
Reagents (Milan, Italy).
Ultrapure water was produced from distilled water by a
Milli-Q system (Millipore Corporation, Billerica, MA,
USA). Protein LoBind tube were obtained from Eppendorf
(Hamburg, Germany). Modified porcine trypsin, sequencing
grade, was commercialized by Promega (Madison,WI, USA).
Solid-phase extraction (SPE) C18 cartridges were from
BOND ELUT (Varian, Palo Alto, CA, USA).
Cationic liposomes preparation
DC-Chol and DOPE were used without further purifica-
tions. The liposome solutions were prepared solving
appropriate amounts of DC-Chol and DOPE in CHCl3 at
three different molar ratios of neutral lipid in the bilayer of
Φ (neutral lipid/total lipid, mol/mol)=0.3, 0.5, and 0.7,
keeping constant the moles of cationic lipids (i.e., the
overall charge). The solvent was evaporated under vacuum
for 12 h, and the obtained lipid film was hydrated with a
buffer 10 mmol L−1 Tris–HCl (pH 7.4), 150 mmol L−1
NaCl, 1 mmol L−1 EDTA. Small unilamellar vesicles were
prepared by sonication and allowed to stay at 30 °C for
24 h to achieve full hydration.
Size and zeta potential measurements
All sizing and zeta potential (ζp) measurements were made
on a Zetasizer Nano ZS90 (Malvern, U.K.) at 25°C with a
scattering angle of 90.0°. Sizing measurements were made
on the neat vesicle dispersions, whereas the samples were
diluted 1/10 with distilled water for ζp measurements. For
all samples investigated, the data show a unimodal
distribution and represent the average of at least five
different measurements carried out for each sample. The
polydispersity index (pdi) was directly calculated by the
apparatus software.
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Human plasma samples
Human plasma samples were obtained from Department of
Experimental Medicine (Sapienza University of Rome)
according to institutional bioethics approval. Sample of
human whole blood were obtained by venipuncture of ten
healthy volunteers aged 20–40 years, by means of BDTM
P100 Blood Collection System (Franklin Lakes, NJ, USA)
with K2EDTA anticoagulant and protease inhibitors cock-
tail. Human plasma was prepared as follows: after clot
formation, the samples were centrifuged at 1,000 RCF for
5 min to pellet the blood cells, and the supernatant plasma
was removed. After checking the absence of hemolysis, the
plasma from each separate donor was pooled, split into
200 μL aliquots, and stored at −80 °C in labeled Protein
LoBind tubes, until further use. For analysis, the aliquots
were thawed at 4 °C and then allowed to warm at room
temperature.
Incubation of cationic liposomes with human plasma
Plasma protein binding to nanoparticles was studied by
incubating 200 μL of CL suspension in 10 mmol L−1 Tris–
HCl (pH 7.4), 150 mmol L−1 NaCl, 1 mmol L−1 EDTAwith
200 μL of plasma as already described [12]. The incubation
was carried on at 37 °C for 1 h to promote aggregation. The
sample was centrifuged at 15 kRCF for 10 min to pellet the
CL–protein complexes. The pellet was washed with 250 μL
of 10 mmol L−1 Tris–HCl (pH 7.4), 150 mmol L−1 NaCl,
1 mmol L−1 EDTA, using a vortex mixer, transferred into a
new Protein LoBind tube, and centrifuged again to pellet
the liposome–protein complexes. The entire procedure was
repeated twice. The tubes were changed after each washing
step to minimize contamination of plasma proteins bound to
the tubes. A plasma aliquot not incubated with CLs was
subjected to the same procedure as control to verify the
absence of protein precipitation. Three experimental repli-
cates were performed for each of the three CL formulations
to ensure the reproducibility of the particle–protein complex
formation.
Tryptic digestion and peptide desalting
After the incubation of nanoparticles with plasma, the
obtained pellet was resuspended in 40 μL of 8 mol L−1 urea
in 50 mmol L−1 NH4HCO3 (pH=7.8). Afterwards, the
proteic solution was reduced with 2 μL 200 mmol L−1 DTT,
alkylated with 8 μL 200 mmol L−1 IAA, and added with
another 8 μL 200 mmol L−1 DTT. Finally, the sample
solution was diluted with 50 mmol L−1 NH4HCO3 to obtain
a final urea concentration of 1 mol L−1 and digested
overnight with 2 μg of trypsin at 37 °C. The enzymatic
reaction was stopped by adding TFA.
Digested sample was desalted using a SPE C18 silica
cartridge. The cartridge was attached to a vacuum manifold
apparatus, washed with 1 mL of acetonitrile, and condi-
tioned with 1 mL of H2O 0.1% (v/v) TFA. Then the tryptic
digest was passed through the SPE column, and the
peptides were slowly eluted with 500 μL of water/
acetonitrile (50:50, v/v) 0.05% TFA.
After eluate lyophilization in a Speed-Vac SC 250
Express (Thermo Savant, Holbrook, NY, USA), the sample
was re-constituted with 100 μL of 0.1% (v/v) HCOOH. All
samples were stored at −80 °C until analysis.
LC/MS conditions
NanoLC was performed using a Dionex Ultimate 3000
instruments (Dionex, Sunnyvale, CA, USA) consisting of a
nanopump with degasser, and a loading pump connected to
a thermostatted microwell-plate autosampler.
Sample was enriched on-line on a 300 μm i.d. × 5 mm
Acclaim PepMap 100 C18 (5 μm particle size, 100Å pore
size) μ-precolumn (Dionex), employing a premixed mobile
phase H2O:CH3CN 98:2 (v/v; phase C) containing 0.1% (v/v)
HCOOH at a flow rate of 10 μL min−1. A 5-μL aliquot of
sample was injected.
Peptides were separated on a Biobasic 18 (5 μm particle
size, 300Å pore size) 75 μm i.d. × 100 mm, 15 μm tip
picofrit column (Thermo Scientific, Bellefonte, PA, USA)
operated at a flow rate of 250 nL min−1. Phase Awas H2O
and phase B was CH3CN, both containing 0.1% (v/v)
HCOOH. A 120-min gradient was used: after an isocratic
step at 5% B for 5 min, B was linearly increased to 30%
within 75 min; afterwards, B was increased to 80% within
5 min, and to 95% within the following 10 min to rinse the
column. Finally, B was reported to 5% over 1 min and the
column re-equilibrated for 24 min.
The nanoLC system was coupled to an LTQ-Orbitrap XL
hybrid mass spectrometer (Thermo Fisher Scientific, Bremen,
Germany) via a nanoelectrospray ion source, operated in
positive ionization mode, with spray and capillary voltage set
at 2.90 kVand 42 V, respectively, and capillary temperature set
at 180 °C.
Full MS spectra were acquired in profile mode in the m/z
range 350–1,800 in the Orbitrap with resolution set at
60,000, whereas data-dependent MS/MS scan of the five
most intense monoisotopic peaks in the spectra (top five
strategy) was operated with collision-induced dissociation
activation at low resolution in the LTQ. Rejection of +1,
and unassigned charge states was enabled. All MS/MS
spectra were collected using a normalized collision energy
of 35%, and an isolation window of 2m/z. Ion trap and
Orbitrap maximum ion injection times were set to 1,000
and 200 ms, respectively. Automatic gain control was used
to prevent overfilling of the ion traps and was set to 5×105
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for full FTMS scan, and 1×104 ions in MSn mode for the
LTQ. To minimize redundant spectral acquisitions, dynamic
exclusion was enabled with a repeat count of 1 and a repeat
duration of 30 s.
The whole LC/MS system was managed by Xcalibur
software (v.2.07, ThermoFisher Scientific).
Five technical replicates per sample were performed.
Data analysis
Thermo RAW data files were submitted to Mascot Deamon
(v2.2.04, Matrix Science, London, UK) using the Thermo-
Finnigan LCQ/DECA RAW file data import filter to
perform database searches against the nonredundant
Swiss-Prot database (v57.15;Homo sapiens species restriction,
20,266 sequences).
For the database search, trypsin was specified as the
proteolytic enzyme with a maximum of two missed
cleavages. Carbamidomethylation was set as fixed modifi-
cation of cysteine, whereas variable modification was
oxidation of methionine. The monoisotopic mass tolerance
for precursor ions and fragmentation ions were set to
10 ppm and 0.8 Da, respectively. Charge states of +2, or +3
were selected as precursor ions.
Peptide identification and protein assignment were
statistically validated submitting the Mascot result files
(.dat) in the open source Trans-Proteomic Pipeline (TPP)
software (v4.4 Vuvuzela, Seattle Proteome Center, Proteomics
Tools: http://tools.proteomecenter.org/software.php). After
conversion of the output Mascot files (.dat) in the .pepXML
format, the PeptideProphet and ProteinProphet tools [13–15]
included in TPP, were employed.
Results and discussion
DLS and zeta potential measurements
DLS and zeta potential measurements showed that DC-
Chol–DOPE CLs are positively charged vesicles with the
following ζp values: 60.1±1.2 mV for Φ=0.3; 56.3±
1.3 mV for Φ=0.5; and 55.7±1.3 mV for Φ=0.7. The
hydrodynamic radius, RH, is ranged between 105 and
110 nm. Narrow particle size distribution (pdi=0.2) showed
liposome suspensions to be monodisperse.
Separation of nanoparticle–protein complex from plasma
The suitability of centrifugation as a method of separation
of the nanoparticle–protein complex, followed by suitable
washing stringent conditions for characterizing the so-
called hard corona has been already discussed in previous
works [6, 12].
LC/MS condition optimization
For data-dependent MS/MS scan, the top five acquisition
strategy was chosen, allowing the selection of the five most
intense peaks (above a set threshold) in the spectrum for
MS/MS analysis. Therefore, it is important to assure
separation in those parts of chromatogram where most
peptides are eluted, to avoid discarding some precursors.
Peptide separation was optimized on the base of identified
proteins; then, the Thermo RAW files were submitted to the
freely available software RawMeat (v2.0, VAST Scientific,
http://vastscientific.com/rawmeat/), a data quality assess-
ment tool designed for Thermo MS data. By the aid of
RawMeat, that compares the time dependent effects with
MS and MS/MS chromatogram, the suitability of chro-
matographic separation was verified, in particular observing
the top N spacing graph, showing the number of precursors
selected per scan cycle.
Repeatibility and reproducibility
Proteomics experiments are sensitive to both biological and
technical variability, and recently the degree in variability
from analysis-to-analysis for even relatively simple com-
plex biological samples has been illustrated and discussed
[16, 17].
Lack of reproducibility of MS results in proteomics can
be caused by variations in sample preparation, proteolytic
digestion, on-line separation of peptides, and MS data
acquisition, analysis and interpretation. Additionally, some
intrinsic properties of LC/MS/MS contribute to the problem
such as the stochastic nature of peptide sampling [8].
The main parameters affecting repeatability and repro-
ducibility between samples were investigated.
In order to analyze only the variables due to the
analytical protocol and methodology, all plasma samples
were aliquots from a pool of plasma obtained from ten
different donors, thus avoiding any biological variability. In
fact, blood composition can vary substantially, leading to
different interactions between nanoparticles and proteins for
different individuals [6].
The low complexity of samples under investigation
allowed to employ a shotgun proteomics approach without
needing any prefractionation step, this greatly reduced
protein/peptide variable losses.
To assess variability due to sample preparation, three
experimental replicates were performed. Figure 1 shows,
for each CL formulation, the number of proteins identified
analyzing the data obtained from each of the three single
experiments (five LC/MS runs per sample) and from the
three experiments considered all together (15 LC/MS runs
in total). The proteins identified in all the three experiments
respect to the total for CLs with Φ=0.3, 0.5, and 0.7 were,
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respectively, 94/133 (71%), 92/128 (72%), and 96/143
(67%).
Another critical parameter in proteomics analysis is the
enzyme amount needed to obtain a complete proteolytic
digestion of the sample. The RawMeat charge distribution
graph showed the presence in the full MS spectra of
precursors with mass charge varying from +2 to +6, with +2
and +3 charge precursors representing about 85% of the
total, and +4 charge precursors another 10%, indicating a
satisfactory digestion yield in all the samples analyzed.
Technical variation is purely related to the analytical
techniques being used, because every measurement tech-
nique has some intrinsic sources of variability that cannot
be totally eliminated. However, technical replicates of the
same sample allow to improve analysis precision. Indeed,
replicate analyses of the same sample have been demon-
strated to improve confidence in protein and peptide
identifications [9, 18]. Therefore, five technical replicates
were performed for all the samples (three samples for each
CL formulation).
Retention time reproducibility was assessed by overlay-
ing the total ion current of all the samples belonging to the
same CL formulation and checking the alignment with
RawMeat software. Good reproducibility was also obtained
comparing retention times of some selected peaks eluting at
different retention times present in samples belonging to
different CL formulations, if the same chromatographic
column was used.
At the end of each sample technical replicate batch,
potential sample carryover was assessed by analyzing blank
injections.
As regards MS data acquisition, repeatability and
reproducibility between samples was evaluated comparing
the number of MS and MS/MS scans, as well as average
intensity of the full MS spectra in all the LC/MS runs.
Results are reported in Table 1 and show that the mean
number of scans presents in all cases a relative standard
deviation below 5%.
As reported by Köcher et al. [8], until recently, there
have been no common rules for MS-based protein
identification. Responding to the concerns of the scientific
community regarding high numbers of false-positive pro-
tein identifications in the literature, common guidelines
were adopted by some scientific journals specialized in
proteomics [19, 20]. However, these guidelines are mainly
recommendations and are currently only required for
publication in some proteomics journals, whereas they do
not apply for publishing MS data in the majority of
scientific journals. One of the most important requirements
within these guidelines is to report the false discovery rate
(FDR), a number estimating the uncertainty of protein
identification. Among the different existing approaches on
how calculate FDR [13, 15, 21, 22], the TPP software was
employed to statistical validate peptide identification and
protein assignment.
Protein identification and statistical data analysis by TPP
software
After protein identification by Mascot search engine, the
resulting output files (15 files for each CL formulation)
were submitted to the statistical open source software
TPP. The two new statistical tools of TPP, i.e., Peptide-
Prophet and ProteinProphet, designed for such a purpose,
were applied to peptide and protein identification,
respectively.
Because the sensitivity (percentage of total correct identi-
fications remaining after restricting data at a given proba-
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of the three single experiments
(five LC/MS runs per sample)
and analyzing the three experi-
ments all together (15 LC/MS
runs in total)
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bility threshold) and error rates (percentage of total false
identification) for any dataset modeled are directly
related and are affected by the probability threshold set
to filter the datasets, it is possible setting more or less
stringent probability threshold. The peptide and protein
probability thresholds for running PeptideProphet and
ProteinProphet were set at 0.7 and 0.9, respectively, for
all sample data sets. The related values for FDR and
sensitivity were, respectively, 0.5% and 86.9% for CLs
with Φ=0.3; 0.6% and 89.0% for CLs with Φ=0.5; and
0.6% and 90.7% for CLs with Φ=0.7.
Following HUPO recommendation, protein identifica-
tion was considered valid only if based on mass spectra
correlating to at least two unique tryptic peptides. Applying
these conditions, the proteins identified as adsorbed onto
surface of CLs with Φ=0.3, 0.5, and 0.7 were, respec-
tively, 133, 128, and 143, for a total of 169 proteins, with
106 common proteins (see Fig. 2). Proteins identified only
in one CL formulation are reported in Table 2. Details
about all the identified proteins are provided in Electronic
Supplementary Material.
Plasma proteins adsorbed onto liposome surface
Most of the 106 proteins common to the three CL
formulation are related mainly to the immune or inflamma-
tory (acute phase) response and to the blood coagulation
processes, including platelet activation and degranulation,
or in lipid transport functions (e.g., apolipoproteins).
As can be seen in Fig. 2 and Table 2, only few proteins
had an exclusive binding with only one CL formulation.
Among proteins belonging only to corona of CLs with Φ=
0.3, all the proteins but keratin (most likely deriving from a
contamination during sample preparation) were identified
with up to three unique peptides. The same situation
occurred for proteins adsorbed onto CLs with Φ=0.5, except
for tubulin beta-1 chain, identified with 13 unique peptides.
Tubulin is the major constituent of microtubules, and is a
heterodimer of alpha and beta chains. However, we did not
find any explanation for this preferential interaction with
CLs with Φ=0.5, either from the biological or electrostatic
point of view.
The CLs with Φ=0.7 were able to bind more proteins
and, as a consequence, were also the nanoparticles having
the highest percentage of proteins adsorbed exclusively
onto their surface (16% versus 7.5% and 5.4% of CLs with
Φ, respectively, 0.3 and 0.5). This result is likely due to the
different CL characteristics: because the moles of cationic
lipids are fixed whereas the moles of neutral lipids is varied
to obtain the different Φ values, CLs with higher Φ possess
a larger surface area. On the other hand, to a higher Φ
corresponds a smaller σM that, differently from our initial
hypothesis, seems to have not a determinant role in protein
adsorption. The proteins identified with the highest number
of unique tryptic peptides were ceruplosamin (16), phos-
pholipid transfer protein (PLTP) (14), antithrombin-III (9),
=0.3 =0.5
=0.7
Fig. 2 Venn diagram representing the total number of proteins
identified onto surface of cationic liposomes with Φ=0.3, 0.5 and
0.7, and the relative overlaps
Table 1 Mean values and relative standard deviation (RSD) of the
number of MS and MS/MS scans, and spectrum average intensity
obtained, for each of the three cationic liposome formulations, in the
five technical replicates of single experiments and considering all the
three experimental replicates
Φ 03 0.5 0.7
MS scan MS2 scan Avg int MS scan MS2 scan Avg int MS scan MS2 scan Avg int
Exp 1 (5 runs) Mean1 4103 5056 2.2×10
6 3914 5307 2.3×106 3574 6608 6.7×106
RSD1% 2.7% 2.7% 3.8% 0.6% 1.0% 5.8% 0.9% 0.5% 4.0%
Exp 2 (5 runs) Mean2 3903 5200 2.4×10
6 3862 5294 2.1×106 3645 6272 5.6×106
RSD2% 0.7% 1.4% 3.5% 0.3% 0.6% 3.1% 0.6% 0.7% 2.3%
Exp 3 (5 runs) Mean3 3818 4990 1.7×10
6 3755 5105 1.6×106 3646 5912 4.5×106
RSD3% 0,4% 0,4% 2.0% 0.9% 1.4% 1.1% 2.0% 2.6% 5.9%
Total (15 runs) Mean 3941 5082 2.1×106 3843 5235 2.0×106 3622 6264 5.6×106
RSD% 3.5% 2.4% 15.7% 1.9% 2.1% 15.4% 1.5% 4.9% 17.2%
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serum amyloid A protein (8), alpha-1-antichymotrypsin (7),
and transthyretin (7).
Among these six proteins, four belong to the same
biological processes of the most of 106 common proteins.
In fact, PLTP is involved in cellular lipid metabolic process
and lipid transport, and has been shown to interact with
apoliprotein A-I and A-II [23]; recently [24], it has been
observed that the level of PLTP in plasma increases during
Table 2 Proteins identified in only one cationic liposome formulation with the relative main identification parameters and charge at pH 7
Uniprot protein ID Protein name Protein prob Coverage% Unique peps Charge (pH 7)
Φ=0.3
O43866 CD5L_HUMAN CD5 antigen-like 1 26.5 3 −11.4
P02747 C1QC_HUMAN Complement C1q subcomponent subunit C 0.9962 11.0 2 4.2
P06733 ENOA_HUMAN Alpha-enolase 0.9816 17.7 3 1.3
P11597 CETP_HUMAN Cholesteryl ester transfer protein 0.9969 5.7 2 −7.9
P25705 ATPA_HUMAN ATP synthase subunit alpha, mitochondrial 0.9999 10.5 3 9.6
P35908 K22E_HUMAN Keratin, type II cytoskeletal 2 epidermal 1 68.5 32 3.8
P48735 IDHP_HUMAN Isocitrate dehydrogenase [NADP], mitochondrial 0.9827 6.2 2 10.9
P55072 TERA_HUMAN Transitional endoplasmic reticulum ATPase 0.9175 3.7 2 −22.8
Q9BWP8 COL11_HUMAN Collectin-11 1 17.3 3 −6.3
Q9ULV4 COR1C_HUMAN Coronin-1 C 0.9951 12.0 2 0.5
Φ=0.5
O00299 CLIC1_HUMAN Chloride intracellular channel protein 1 0.9309 12.0 2 −7.5
P60174 TPIS_HUMAN Triosephosphate isomerase 0.9966 16.9 2 −0.2
P61158 ARP3_HUMAN Actin-related protein 3 0.9964 7.9 2 −7.1
P62937 PPIA_HUMAN Peptidyl-prolyl cis–trans isomerase A 0.9999 19.4 2 1.8
P68366 TBA4A_HUMAN Tubulin alpha-4A chain 1 37.1 3 −21.2
Q15942 ZYX_HUMAN Zyxin 0.9715 9.8 2 −3
Q9H4B7 TBB1_HUMAN Tubulin beta-1 chain 1 46.8 13 −18.2
Φ=0.7
P00450 CERU_HUMAN Ceruloplasmin 1 22.5 16 −32.5
P00747 PLMN_HUMAN Plasminogen 1 16.2 5 3.4
P01008 ANT3_HUMAN Antithrombin-III 1 35.8 9 −1
P01011 AACT_HUMAN Alpha-1-antichymotrypsin 1 30.0 7 −9.9
P01625 KV402_HUMAN Ig kappa chain V–IV region Len 0.9998 23.7 2 0.9
P01861 IGHG4_HUMAN Ig gamma-4 chain C region 1 49.5 3 1.4
P02735 SAA_HUMAN Serum amyloid A protein 1 66.4 8 −0.4
P02745 C1QA_HUMAN Complement C1q subcomponent subunit A 0.9985 20.4 2 7.3
P02766 TTHY_HUMAN Transthyretin 1 68.0 7 −3.9
P04217 A1BG_HUMAN Alpha-1B-glycoprotein 1 18.8 3 −11.4
P05155 IC1_HUMAN Plasma protease C1 inhibitor 1 18.0 4 −2.7
P05546 HEP2_HUMAN Heparin cofactor 2 1 14.6 4 −0.7
P19652 A1AG2_HUMAN Alpha-1-acid glycoprotein 2 1 31.3 5 −7.5
P25787 PSA2_HUMAN Proteasome subunit alpha type-2 1 17.1 2 0.8
P25789 PSA4_HUMAN Proteasome subunit alpha type-4 1 20.7 3 1.8
P36955 PEDF_HUMAN Pigment epithelium-derived factor 0.9006 11.2 2 −3.2
P39060 COIA1_HUMAN Collagen alpha-1(XVIII) chain 0.9995 5.3 2 −22.8
P43652 AFAM_HUMAN Afamin 0.9887 7.3 2 −10.9
P49720 PSB3_HUMAN Proteasome subunit beta type-3 1 8.8 2 −0.7
P55058 PLTP_HUMAN Phospholipid transfer protein 1 38.9 14 0
P81605 DCD_HUMAN Dermcidin 0.9956 22.7 2 −0.6
Q00610 CLH1_HUMAN Clathrin heavy chain 1 0.9082 1.4 2 −33.2
Q6Q788 APOA5_HUMAN Apolipoprotein A-V 1 5.5 2 −4.7
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acute inflammation, and complex formation with clusterin,
coagulation factors and complement factors were demon-
strated by immuno-isolation and shotgun proteomics.
Serum amyloid A protein is a major acute phase reactant
and an apolipoprotein of the HDL complex; and alpha-1-
antichymotrypsin is also involved in acute phase response.
Antithrombin-III is the most important serine protease
inhibitor in plasma that regulates the blood coagulation
cascade.
Different biological processes are interested for trans-
thyretin (transport and hormone activity), and ceruloplasmin
that is the major copper-carrying protein in the blood, and in
addition plays a role in iron metabolism.
The eight proteins identified adsorbed only onto CLs
with Φ=0.3 and 0.7, a deeper analysis of the number of
unique peptides related to the proteins showed that, indeed,
for seven, the differences were not very significant (e.g.,
five proteins were also present in CLs with Φ=0.5 with
only one unique peptide and thus discarded). However, the
tubulin beta chain, identified with 12 and 5 unique peptides,
respectively, in CLs with Φ=0.3 and 0.7, was totally absent
in CLs with Φ=0.5.
This protein is related to apoptosis and defense response
processes.
Regarding the protein overlaps between CLs with Φ=0.3
and 0.5, and between CLs with Φ=0.5 and 0.7, as well as
proteins common to all CL formulations, in most cases, a
logical trend (i.e., the number of unique peptides and
sequence coverage) is observed.
The biochemical rationale for some adsorbed proteins onto
one or more of the CLs studied is hardly understandable.
Protein interaction between them and with other molecules is
a very complex phenomenon and, in this scenario, some
unexpected specific interactions could be simply due to casual
events rendering the surface “antigenic” for a specific protein.
Nevertheless, this interaction might cause consequences at
level of liposome to target cell interaction.
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with plasma components, that lead to the formation of a “protein corona” onto CL
surface. The interactions between nanoparticles entering the body and biomolecules have
an essential role for their biodistribution. Because the knowledge of proteins adsorbed
onto vector surface could be useful in the screening of new, more efficient and more
biocompatible liposomal formulations, the behavior of three CLs with different membrane
charge densities was investigated. The proteins of the three coronas were identified by
nano-liquid chromatography–tandem mass spectrometry, and quantified with label-free
spectral counting strategy. Fibrinogen displayed higher association with CLs with high
membrane charge density, while apolipoproteins and C4b-binding protein with CLs with
low membrane charge density. These results are discussed in terms of the different lipid
compositions of CLs and may have a deep biological impact for in vivo applications. Surface
charge of nanoparticles is emerging as a relevant factor determining the corona composi-
tion after interaction with plasma proteins. Remarkably, it is also shown that the charge
of the protein corona formed around CLs is strongly related to their membrane charge
density.
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NanoLC–MS/MS1. Introduction
Gene therapy, consisting in the introduction of new genetic
materials to hosts, is attracting a growing interest to study
gene function and its regulation, to establish and most of all
to explore potential therapeutic applications to various ac-
quired or inherited diseases [1] caused by the defect of the ab-
sence of one or more genes. Therefore, the development of
suitable vectors for an efficient transfection is of fundamental
importance in gene therapy.
Starting from the first application in 1987 [2], cationic lipo-
some (CL)-mediated gene transfer has been the most; fax: +39 06 490631.
1.it (C. Cavaliere).
r B.V. All rights reservedextensively investigated and commonly used nonviral gene
delivery approach [1,3–6]. Several different lipids, all sharing
the common structure, i.e. positively charged hydrophilic
head and hydrophobic tail connected via a linker, have been
developed and tested for lipofection. The positively charged
head group (generally amines or quaternary ammonium
salts) serves to interact with DNA (lipoplexes) or other anionic
biomolecules, while the hydrophobic part is the “helper” lipid.
The structure of CL (including surface charge density and coli-
pid) strongly affects its transfection efficiency [1].
However, one of the major problems using nanovectors for
drug or gene delivery is their interaction with blood.
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blood circulation. Indeed, when nanoparticles enter into blood
circulation, plasma proteins are adsorbed onto their surface to
form a “protein corona” [7–12]. These interactions with blood
biomolecules have been shown to have an essential role in
nanoparticle biodistribution [10], and clearance behavior is
strongly affected by nanocarrier architecture [11,13]. There-
fore, protein binding to nanoparticles can be critical in modi-
fying the interactive surface that is recognized by cells
[14,15], and understanding how and why plasma proteins
are adsorbed to lipid particles may serve as a fundamental
predictive model for the in vivo efficiency of the vector, in
view of future clinical applications.
Because the knowledge of plasma proteins adsorbed onto
vector surface could be useful in the screening of new, more
efficient and more biocompatible liposomal formulations, in
a previous work [16] we investigated the behavior of three
CLs with different membrane charge densities. In particular,
we characterized from the qualitative point of view the
three protein coronas by nano-liquid chromatography–tan-
demmass spectrometry (nanoLC–MS/MS). No significant dif-
ferences were found in the composition of protein coronas.
However, some quantitative differences could be inferred
from the Exponentially Modified Protein Abundance Index
(emPAI) values [17] provided by the search engine Mascot.
For this reason, we decided to perform a quantitative analysis
to have a deeper insight and better investigate about a possi-
ble specific absorption of plasma proteins onto the different
CL surfaces.
MS-based quantitative proteomics can be performed
employing both stable isotope labeling and label-free ap-
proaches [18–20]. Labeled methods allow the simultaneous
quantification of several samples, however present also
some drawbacks, such as incomplete labeling, sample dilution
(rendering difficult the detection of low abundance proteins),
and are associated with high costs. For these reasons, label-
free strategies are widely used in biomarker studies [21].
Label-free MS measurement of peptides (and therefore of
their parent protein) relies on peak intensity measurements
(comparing the directMS signal intensity for any given peptide
on the basis of its retention time, and m/z ratio) or spectral
counting (SC) [22–24]. In SC approach, the number of acquired
MS/MS spectra matching to a specific peptide is considered
an indicator of its abundance in a given sample [20,23]. SCs of
peptides associatedwith a protein are then summed and com-
pared across the samples, often after normalization.
In the present work, a label-free quantification of plasma
proteins adsorbed onto the surface of the three liposome for-
mulations previously investigated was performed. According
to recent findings [25], CLs are excellent model systems of
lipid nanoparticles in which an inner core made of DNA pre-
condensed by oppositely charged macromolecules (e.g. poly-
cations, cationic proteins etc.) is coated with a lipid envelope.
After nanoLC–MS/MS analysis and Mascot database search,
protein identification was statistically validated with Scaffold
software. The same software was also used to evaluate quan-
titative differences between the three protein coronas with
SC method.
Very recently, a few papers on MS-based quantification of
protein coronas on different nanoparticle surfaces have beenpublished [11,12,26], however this is the first study on quanti-
fication of the plasma proteins adsorbed onto different CLs.2. Material and methods
2.1. Chemicals and standards
All chemicals were purchased from Sigma Aldrich (St. Luis, Mo,
USA) unless otherwise stated. The sequencing grade modified
trypsin was from Promega (Madison, WI, USA). All organic sol-
ventswere thehighest gradeavailable fromCarlo Erba Reagents
(Milan, Italy). Ultrapure water (resistivity 18.2 MΩ cm) was
obtained by an Arium water purification system (Sartorius,
Florence, Italy).
The cationic lipid 3β-[N-(N′, N′-dimethylaminoethane)-
carbamoyl])-cholesterol (DC-Chol), and the neutral lipid dio-
leoylphosphatidylethanolamine (DOPE) were purchased from
Avanti Polar Lipids (Alabaster, AL, USA).
Solid phase extraction (SPE) C18 cartridges were BOND
ELUT (Varian, Palo Alto, CA, USA).
2.2. Preparation of cationic liposomes
The solutions of liposomes were prepared as already de-
scribed [16] by solving suitable amounts of DC-Chol and
DOPE in CHCl3, keeping constant the moles of cationic lipids,
to obtain three different molar ratios of neutral lipid in the bi-
layer Φ (neutral lipid/total lipid, mol/mol)=0.3, 0.5, and 0.7.
After solvent removal (under vacuum for 12 h), the result-
ing lipid film was hydrated with 10 mmol L−1 Tris–HCl pH
7.4, 150 mmol L−1 NaCl, 1 mmol L−1 EDTA (buffer A). Small
unilamellar vesicles were prepared by sonication and allowed
to stay at 30 °C for 24 h to achieve full hydration.
The characterization of the resulting vesicle dispersions
and samples was made by means of size and zeta potential
measurements, respectively [16].
2.3. Samples
Sample of humanwhole blood were obtained by venipuncture
of ten healthy volunteers aged 20–40 years; K2EDTA anticoag-
ulant and protease inhibitors cocktail were immediately
added. Human plasma (HP) samples were prepared at the
Department of Experimental Medicine (Sapienza Università
di Roma) in accordance with the institutional bioethics code.
HP from each donor was pooled, split into aliquots, and
stored at −80 °C in Protein LoBind tubes (Eppendorf, Hamburg,
Germany) until further use. For analysis, the aliquots were
thawed at 4 °C and then allowed to warm at room temperature.
2.4. Human plasma-cationic liposome incubation
Incubation of HP with CLs was conducted as described in a
previous work [27]. Briefly, 200 μL of HP were incubated with
200 μL of CL suspension in buffer A, at 37 °C for 1 h. After cen-
trifugation (15,000 RCF for 10 min) the pellet, constituted by
CL-protein complexes, was washed twice with 250 μL buffer
A. For each of the three CL formulations, three experimental
replicates were performed.
Table 1 – Size (D), polidispersity (pdi), and ζ Potential (ζP) of
DC-Chol-DOPE liposomes at three different molar ratios of
neutral lipid in the bilayer, Φ, before and after incubation
with human plasma (HP).
DC-Chol-DOPE DC-Chol-DOPE/HP
Φ=0.3
D (nm) 102±4 450±23
pdi 0.243 0.459
ζP (mV) 54.3±0.7 −9.0±0.9
Φ=0.5
D (nm) 109±2 360±31
pdi 0.212 0.345
ζP (mV) 56.3±1.3 −11.4±0.8
Φ=0.7
D (nm) 105±1 1761±400
pdi 0.239 0.513
ζP (mV) 60.5±1.3 −27.4±0.7
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The protein–nanoparticle complex pellet was redissolved in
40 μL of 8 mol L−1 urea in 50 mmol L−1 NH4HCO3 (pH=7.8). Af-
terwards, protein tryptic digestion was conducted following
the protocol already described elsewhere, employing 2 μg of
trypsin [16].
The digestion was stopped by adding TFA. Then, the
resulting peptide mixture was passed through a SPE C18 silica
cartridge for desalting, washed and eluted with 500 μL of
water/acetonitrile (50:50, v/v) 0.05% TFA.
After solvent removal in a Speed-Vac apparatus (mod. SC
250 Express; Thermo Savant, Holbrook, NY, USA), sample res-
idue was reconstituted with 100 μL H2O 0.1% (v/v) HCOOH. All
samples were stored at −80 °C until analysis.
2.6. NanoLC–MS/MS analysis
NanoLC systemwasDionexUltimate 3000 (Dionex, Sunnyvale,
CA, USA), equipped with a degasser and a thermostatted
microwell-plate autosampler.
Peptides were preconcentrated injecting 5 μL aliquot of
sample onto a 300 μm i.d.×5 mm Acclaim PepMap 100 C18
(5 μm particle size, 100 Å pore size) μ-precolumn (Dionex);
the loading pump was then operated for 5 min with H2O:
CH3CN 98:2 (v/v) containing 0.1% (v/v) HCOOH at flow-rate of
10 μL min−1. Peptide mixture was separated on a Biobasic 18
(5 μm particle size, 300 Å pore size) 75 μm i.d.×100 mm,
15 μm tip picofrit column (Thermo Scientific, Bellefonte, PA,
USA) operated at a flow rate of 250 nL min−1. Phase A was
H2O and phase B was CH3CN, both with 0.1% (v/v) HCOOH.
After an isocratic step at 5% B for 5 min, B was linearly in-
creased to 30% within 75 min; then, B was increased to 80%
within 5 min, and to 95% within the following 10 min to
rinse the column.
Mass spectrometry detection was performed by an LTQ-
Orbitrap XL instrument (ThermoFisher Scientific, Bremen,
Germany) with a nanospray source, operated in positive ion
mode. Spray and capillary voltage were set at 2.90 kV and
42 V, respectively; capillary temperature was 180 °C.
Full MS spectra were acquired in profile mode in the m/z
range 350–1800 in the Orbitrap with resolution set at 60,000,
whereas data-dependent MS/MS scan of the 5 most intense
monoisotopic peaks in the spectra (top 5 strategy) was operat-
ed with collision-induced dissociation (CID) activation at low
resolution in the LTQ. Rejection of +1, and unassigned charge
states was enabled. All MS/MS spectra were collected using a
normalized collision energy of 35%, and an isolation window
of 2m/z. Automatic gain control was used to prevent overfill-
ing of the ion traps, and dynamic exclusion was enabled to
minimize redundant spectral acquisitions.
The whole LC–MS system was managed by Xcalibur soft-
ware (v.2.07, ThermoFisher Scientific).
Five technical replicates per sample were performed.
2.7. Data analysis
Thermo RAW data files were submitted to Mascot Deamon
(v2.3.2, Matrix Science, London, UK) using the ThermoFinni-
gan LCQ/DECA RAW file data import filter to perform databasesearches against the nonredundant UniProtKB/Swiss-Prot da-
tabase (release 57.15 of 2 March 2010; Homo sapiens species
restriction, 20,266 sequences).
For the database search, trypsin was specified as the pro-
teolytic enzyme with up to two missed cleavages. Carbamido-
methylation of cysteine and oxidation of methionine were set
as fixed and variable modification, respectively. Themonoiso-
topic mass tolerance for precursor ions and fragmentation
ions was set to 10 ppm and 0.8 Da, respectively.
To validate protein identifications derived from MS/MS se-
quencing results, theMascot output files (.dat) were submitted
in the commercial software Scaffold (v3.1.2, Proteome Soft-
ware, Portland, Oregon, USA; http://www.proteomesoftware.
com/) [28], that employs independent implementation of
Bayesian statistical algorithms developed by the Institute for
Systems Biology, i.e. PeptideProphet™ and ProteinProphet®
[29–31]. Scaffold tool to integrate Mascot identification results
with X!Tandem search engine results (performed in automatic
with the same parameters settled for Mascot) was used.3. Results and discussion
3.1. Size, polidispersity and charge of CLs
Size, polidispersity (pdi), and ζ Potential (ζP) of DC-Chol-DOPE
CLs at the three differentmolar ratios of neutral lipid in the bi-
layer were measured before and after incubation with HP
(Table 1). Dynamic light scattering and ζP measurements
showed that all the three DC-Chol-DOPE CLs investigated are
positively charged vesicles (ζP in the range 54.3–60.5 mV)
with a hydrodynamic radius (RH) around 100 nm. Narrow par-
ticle size distribution (pdi ~0.2) showed CL suspensions to be
monodisperse. After incubation with plasma, formation of
larger size nanoparticles (depending on CL typology) occurred.
The very large RH increase of CLs with Φ=0.7 after incubation
with plasma shows that a more pronounced aggregation phe-
nomenon occurred [14,32].
Fig. 1 – Venn diagram reporting the number of proteins
identified onto the surface of the three cationic liposome
formulations.
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Optimization of parameters affecting LC–MS/MS analysis, as
well as repeatability and reproducibility between samples,
has been already illustrated [16].
Because the focus of the work is the evaluation of quantita-
tive differences in protein coronas of the differently charged
CL formulations, and it is known that difference in blood com-
position can lead to different interactions between nanoparti-
cles and proteins [7], the biological variability was avoided by
pooling HP samples from all the ten donors.
Three experimental replicates were performed for each CL
typology, and five technical replicates were carried out for
each sample. To assure good chromatogram alignment and
retention times reproducibility between the three experi-
ments of each CL formulation, as well as between all the
three CL formulation experimental batches, it was fundamen-
tal to use the same chromatographic column.
3.3. Protein identification
The resulting output files obtained by Mascot search engine
(15 files for each CL formulation) were submitted to the soft-
ware Scaffold. Peptide identification assigned by Mascot was
verified using the X!Tandem database searching program (in-
tegrated into Scaffold) to increase the confidence. Then, the
software probabilistically validated these peptide identifica-
tions and derived corresponding protein probabilities using
PeptideProphet and ProteinProphet, respectively.
Scaffold results were filtered applying the condition to con-
sider valid only protein identifications based on mass spectra
correlating to at least two unique tryptic peptides. Minimum
peptide identification probability was set at 95% (the highest
available value), whereas protein identification probability
was set at 99%. Applying these filters, a false discovery rate
(FDR) <0.1% was obtained, and a total of 177 proteins were
identified in the protein coronas of the three CL formulations,
152 for CLs with Φ=0.3, and 143 for both CLs with Φ=0.5 and
0.7, with 117 proteins in common (as shown in Fig. 1). Further
details on identification parameters and the full list of proteins
and peptides can be found in Supplementary Tables S1 and S2.
In the previous work [16], data obtained from Mascot were
statistically validated with the open source Trans-Proteomic
Pipeline (TPP) software (v4.4 Vuvuzela, Seattle Proteome Center,
Proteomics Tools: http://tools.proteomecenter.org/software.
php), that employs the PeptideProphet andProteinProphet algo-
rithms, the same successively adopted by Scaffold. In that case,
applying for all sample data sets 70% and 90% as peptide and
protein probability thresholds, the proteins identified as
adsorbed onto surface of CLs with Φ=0.3, 0.5, and 0.7 were, re-
spectively, 133, 128, and 143, for a total of 169 proteins, with
106 common proteins. The different results obtained in the pre-
sent work are very likely due to the slight modifications of the
algorithms and to the employment of X!Tandem as second
search engine (see Supplementary Figs. S1 and S2).
Regarding to FDR estimate, there are several ways to calcu-
late it. Because MS/MS peak list data have not been searched
against a decoy database, Scaffold calculated the FDR with a
probabilistic method used by the TPP and the Protein Prophet
algorithm, based on the assigned protein probabilities.After validation, a good agreement in proteins identified in
the three different experimental replicates of the single CL
formulation was obtained (see Supplementary Table S1).
Most of the 117 proteins common to the three CL formula-
tions are involved in cellular process, biological regulations,
response to stimulus, and metabolic processes (Fig. 2).
3.4. Protein quantitative analysis and relation with CL
membrane charge density
Identification and quantification of the proteins that bind to
CLs in biological environments, i.e. the protein corona, can
provide insights into their biocompatibility and biodistribu-
tion in vivo. It is now emerging the concept that it is the pro-
tein relative abundance within protein corona which is the
most important outcome of the protein-nanoparticle binding.
It is thus essential to quantify both major and minor particle-
associated proteins. Such knowledge will constitute the basis
for future efforts to establish mathematical models for pre-
dicting nanoparticle surface chemistry interactions.
For protein quantitative analysis, Scaffold software allows
the normalization of the SC (NSC) and offers various statistical
tests to identify significant abundance differences in two or
more categories. Quantitative data showed that CLs with
Φ=0.3 and Φ=0.5 had a similar protein abundance for almost
all the identified proteins (see Fig. 3 and Supplementary
Table S3). This finding means that the composition of these
two CL formulations is roughly the same. On the other side,
the comparison between the abundance of proteins bound to
the coronas of CLs with Φ=0.3 and Φ=0.7 showed relevant dif-
ferences. Therefore, in the following text, discussion of results
will be restricted to the comparison of CLs with Φ=0.3 and
Φ=0.7.
For the two CL formulations considered, the mean value of
NSCs obtained in the three experimental replicates for each
protein was further normalized to the protein mass (MWNSC)
Fig. 2 – Pie chart showing the biological processes in which the 117 common proteins identified in all the three cationic
liposome formulations are involved. One protein can belong to more than one biological process.
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following equation:
MWNSCk ¼
NSC=MWð Þk
Pn
i¼1
NSC=MWð Þi
0
BBB@
1
CCCA 100 ð1Þ
where MWNSCk is the percentage molecular weight normal-
ized NSC for protein k (i.e. the relative protein abundance in
the ‘hard corona’ [12]), and MW is the molecular weight in
kDa for protein k. This correction takes into account the pro-
tein size and evaluates the actual contribution of each protein
to the hard corona composition [12]. By using Eq. (1), the rela-
tive protein abundance for the CL formulations selected (i.e.
CLs with Φ=0.3, and 0.7) could be calculated (Supplementary
Table S4).
It isworthmentioning that protein abundance does not nec-
essarily reflect the biological impact. Indeed, a less abundant
protein with high affinity and specificity may be a key player
in several biological processes. However, proteins whose rela-
tive protein abundance is extremely low are not expected to
be a determining factor for the fate and impact of the particles
[12–14]. To make data interpretation simpler and more mean-
ingful, the analysis was thereby restricted to those proteins
whose MWNSCk was ≥1 either in the corona of CLs with Φ=0.3
or in that of CLs with Φ=0.7. Relative protein abundance of pro-
teins satisfying such criterion is reported in Fig. 4. As Fig. 4clearly shows, the relative protein abundance was found to be
strictly dependent on the CL formulation. According to previous
findings [12–14], size and chemical surface properties are
among the most relevant influential factors of nanoparticle
bound protein abundance. In this regard, while both the size
and the zeta potential of CLs with Φ=0.3 and 0.7 are pretty sim-
ilar (Table 1), the lipid compositions of these formulations are
really different from each other. Given the remarkable differ-
ences in the relative protein abundance shown in Fig. 4, it
appeared that, under the experimental conditions of this
study, the lipid composition of the nanoparticle surface was
more impactful on the protein absorption than did their size.
Tobetter decipher data,we calculated the relativeprotein abun-
dance ratio, R, defined as R=MWNSCk(Φ=0.3)/MWNSCk(Φ=0.7)
(Fig. 5). Finally, we considered significant only R>2 and R<0.5.
Fig. 5 clearly shows that fibrinogen displays higher rate of asso-
ciation with the surface of CLs with Φ=0.3 (R>2) with respect to
all other identified proteins. On the other side, apolipoproteins
and C4b-binding protein alpha chain are the proteins most
abundantly associated in the corona of CLs with Φ=0.7 (R<0.5).
Bearing in mind that CLs with Φ=0.7 are definitely richer in
DOPE than that their counterpart with Φ=0.3, we corroborate
previous findings showing that phospholipid-lipoprotein bind-
ing is a general feature of lipid-based nanoparticles under phys-
iological conditions. Accordingly, our findings suggest that
apolipoproteins have hydrophilic groups of phospholipids that
can more favorably interact with the phospholid moiety of
DOPE rather than with the less hydrophilic head group of DC-
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poprotein phospholipids play a critical role in the normal func-
tioning and integrity of the lipid transport system [33].It is important to underline that such a remarkable differ-
ence in the composition of the coronas of CLs with Φ=0.3
and Φ=0.7 may have a deep biological impact. Indeed, it has
been recently hypothesized that adsorbed protein layer may
affect cellular uptake and may affect trafficking, while in
vivo, specific binding of proteins influences biodistribution
and blood clearance. Adsorption of opsonins like fibrinogen
(abundantly associated to CLs with Φ=0.3), IgG, and comple-
ment factors, is supposed to promote rapid clearance from
the bloodstream, while binding of dysopsonins like apolipo-
proteins (largely abundant in the corona of CLs with Φ=0.7)
etc. promotes prolonged circulation time in blood [12–14].
Apolipoproteins are also involved in the transportation of
lipids and cholesterol in the bloodstream and, as such, are
expected to greatly affect the intracellular trafficking, fate,
and transport of nanoparticles in cells and animals. It has
been also proposed that apolipoprotein enrichment on CL sur-
faces, as that observed in the case of CLs with Φ=0.7, might
stimulate interaction with low-density lipoprotein receptors,
resulting in transport across the blood–brain barrier. The be-
havior of C4b-binding protein, more adsorbed onto CLs with
Φ=0.7 than onto CLs with Φ=0.3, does not represent a contra-
diction to this scenario, considering the inhibitory role of the
protein in the complement system.
This specific adsorption of CLs, at different Φ is also con-
firmed observing the list of proteins detected only in the coro-
na of CLs with Φ=0.7 and the proteins detected only in the
protein coronas of CLs with Φ=0.3 (Supplementary Table S5).
Proteins bound to CLswithΦ=0.7 are expressed or synthesized
almost in the liver, and are involved in blood coagulation pro-
cess and complement pathway. The proteins that have been
found only in the coronas of CLs with Φ=0.3 have binding
functions and are localized mostly in cytoplasm. Therefore,
proteins expressed in an organ rich in lipids as the liver seem
to have a preferential adsorption on surface of CLs with
the major lipophilic characteristic (Φ=0.7). However, results
reported in Supplementary Table S5 shows that the relative
protein abundance of such ‘exclusive proteins’ is lower than
1% in both the coronas. As discussed above, such percentages
are too low to suppose such proteins are key players.Fig. 3 – Quantitative Scatterplot graph plotting each protein
as a point on a two dimensional Q–Q scatterplot. The x-axis
is the normalized spectral count (NSC) for the protein for all
samples in one category, and the y-axis is the NSC in a
second category: a) NSC for CLs with Φ=0.3 vs NSC for CLs
with Φ=0.5; b) NSC for CLs with Φ=0.3 vs NSC for CLs with
Φ=0.7; and c) NSC for CLs with Φ=0.5 vs NSC for CLs with
Φ=0.7. Proteins with similar abundances in both categories
are plotted as points near the 45 degree line. The two dashed
lines represent two standard deviations (depending on the
number of spectra), then proteins that plot outside these
lines are differentially expressed. Proteins plotted as red
points are those labeled as significantly different between
categories by quantitative analysis Fisher's Exact test.
Proteins plotted as blue points are those labeled as
insignificant.
Fig. 4 – Relative protein abundance of proteins (normalized to molecular weight, MWNSC) satisfying the criterion that
MWNSCk≥1 either in the corona of CLs with Φ=0.3 or in that of CLs with Φ=0.7.
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as a relevant factor determining the corona composition after
interaction with plasma proteins. Thus, we asked whether aFig. 5 – Relative protein abundance ratio, R, defined as the ratio b
CLs with Φ=0.3 and MWNSCk in CLs with Φ=0.7.correlation between the surface charge of CLs and the compo-
sition of the resulting protein coronas could actually exist. To
this end, the charges at pH 7.4 of the above mentionedetween relative protein abundance of protein k(MWNSCk) in
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scripps.edu/~cdputnam/protcalc.html). The charge of statisti-
cally significant proteins (those proteins with MWNSCk≥1 ei-
ther in the corona of CLs with Φ=0.3 or in that of CLs with
Φ=0.7) is reported in Supplementary Table S6. The relative
charge, a measure of the relative amount of the charge on
the protein corona, was calculated by multiplying the total
charge on the protein k, qk, for its relative protein abundance,
MWNSCk. It reads:
Q Φð Þ ¼
Xn
k¼1
qk MWNSCk Φð Þ: ð2Þ
By applying Eq. (2) we found that: (i) The relative charge of
both the coronas is negative; (ii)Q(Φ=0.3)<Q(Φ=0.7). The former
result is quite obvious in that it confirms that the cationic sur-
face of CLs preferably interacts with negatively charged pro-
teins. On the other hand, considering that CLs at Φ=0.3 are
more positively charged with respect to their counterpart with
Φ=0.7, the latter finding indicates that the charge of the protein
corona and the membrane charge density of cationic lipid
membranes are strongly related to each other. The low mem-
brane charge density of CLs at Φ=0.7 (rich in the neutral DOPE
and poor in cationic DC-Chol) could result in a low electrostatic
repulsion barrier that could be overcome by basic proteins with
the result that short-range attractive van der Waals forces pre-
vail on electrostatic repulsion thereby inducing membrane ag-
gregation and nanoparticle clustering. Such suggestion is in
very good agreement with the results of Table 1 showing that,
upon interaction with human plasma, CLs with Φ=0.7 largely
aggregate. Aside from clarifying the molecular mechanisms of
opsonization, the present results are likely to indicate that the
molar fraction of DOPE in theCL formulationsmayhave a deter-
minant role by regulating both the surface properties and the
membrane charge density of cationic membranes.4. Conclusions
Because nanoparticle interactions with plasma proteins
strongly affect the distribution of the vectors into the body,
understanding of these interactions could be useful in devel-
oping nanocarriers with surface, size and shape able to drive
them to target organs. The employment of a quantitative
strategy to determine the proteins adsorbed onto the surface
of three CLs formulations, characterized by a different lipid
composition and membrane charge density, has shown a
preferential absorption for some classes of proteins. Our re-
sults indicate that, for lipid gene vectors as those used in the
present study (e.g., cationic liposomes, lipid nanoparticles),
lipid composition does control the surface properties of nano-
particles that, in turn, is able to entirely change the nature of
the biologically active proteins in the corona, and thereby pos-
sibly also the biological impacts. The role of these proteins in
driving nanoparticle biodistribution is not completely clear.
Nevertheless, the proposed approach is applicable to other
nanoparticle typologies, and can support in designing and
testing new carriers for possible clinical employment.
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1. INTRODUCTION
Gene delivery holds great promise as a therapeutic agent for a
vast array of disorders such as cancer and genetic and acquired
diseases. Among the most promising nonviral candidates, cationic
liposomes/DNA complexes (lipoplexes) have beenwidely used13
because of their low immunogenicity, safety, ability to package large
DNAmolecules, and ease of preparation.Over the last two decades,
consistent efforts have been made with respect to the development
of lipoplex formulations that would exhibit cell specificity, minimal
immune response, the efficient release of DNA into cells, and a
large DNA capacity. Unfortunately, a deep knowledge of the
physicalchemical properties of these systems in simple solvents
did not result in the formulation of lipid vectors that were as
efficient as their viral counterparts. This may be due to the main
difference existing between the nanocarrier and itsmodified version
after interacting with biological media. Recently, a series of
pioneering studies48 have radically changed our way of thinking
about nanocarries for in vitro and in vivo gene delivery applications.
It has been shown that the effective unit of interest in the cell
nanomaterial interaction is not the nanoparticle itself but the
particle and its hard corona of associated proteins from plasma or
other bodily fluids. This corona of proteins at the surface of the
particle is sufficiently long-lived that actually the entity is “seen” and
processed by living cells. In a recent seminal paper,9Monopoli et al.
demonstrated that the composition of the hard corona of silica
nanoparticles at low protein concentration (appropriate to in vitro
cell studies) can be very different with respect to its counterpart
at high protein concentration (typical of in vivo studies). This is a
key issue that has broad implications for in vitroin vivo extra-
polations9 and will determine the future roadmap of nanomedicine
and perhaps impact the overall field of nanoscience.4
Here we investigate the compositional evolution of the protein
corona of 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)
cationic liposomes (CLs) and DOTAP/DNA lipoplexes as a
function of increasing plasma concentration. According to recent
findings,10 CLs are excellent model systems of lipid nanoparticles
(LNP) in which a DNA/polycation core is coated with a lipid
envelope.1113 This study allowed us to elucidate more quanti-
tatively the degree to which the protein corona of lipid gene
vectors can change, depending on the biological environment.
Although the hard corona of lipoplexes is quite stable, we find
that the hard corona of CLs can evolve quite considerably as one
passes from protein concentrations appropriate to in vitro cell
studies to those present in in vivo studies. As a consequence, the
biological identity of lipid gene vectors whose surfaces are entirely
lipidic (e.g., LNP) may change dramatically as the amount of
protein in the environment changes. This result may have deep
biological implications for the application of lipid-based gene
vectors both in vitro and in vivo.410
2. EXPERIMENTAL SECTION
2.1. Liposome and Lipoplex Preparation. Cationic DOTAP
was purchased from Avanti Polar Lipids (Alabaster, AL) and used
without further purification. Calf thymus (CT) DNAwas obtained from
Sigma-Aldrich (St. Louis, MO) and was used without further purifica-
tion. A solution of CT-DNA (1 mg/mL) was sonicated for 15 min to
produce fragments with typical length distributions of between 500 and
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1000 base pairs as determined by electrophoresis on agarose gels.
Unilamlellar DOTAP CLs (1 mg/mL) were prepared according to
standard protocols.14 Positively charged DOTAP/DNA lipoplexes were
prepared by mixing 100 μL of DOTAP CLs with 50 μL of CT-DNA at a
cationic lipid/DNA charge ratio of F = 1.15
2.2. Sizing and ζ-Potential Measurements. All sizing and ζ-
potential measurements weremade on a Zetasizer Nano ZS90 (Malvern,
U.K.) at 25 C with a scattering angle of 90. Sizing measurements were
made on the neat vesicle dispersions, whereas the samples were diluted
1:10 with distilled water for the zeta potential experiments to obtain
reliable and accurate measurements. For all of the samples investigated,
the data show a unimodal distribution and represent the average of at
least five different measurements carried out for each sample. More
accurate experimental details can be found in ref 10.
2.3. Synchrotron Small-Angle X-ray Scattering Measure-
ments. Synchrotron small-angle X-ray scattering (SAXS) measure-
ments were performed at the Austrian SAXS station of the ELETTRA
synchrotron light source (Trieste, Italy).16 SAXS patterns were recorded
with gas detectors based on the delay line principle covering the q ranges
from qmin = 0.4 nm
1 to qmax = 5 nm
1 with a beam size at the sample
position of 5  103 nm1 (fwhm). The angular calibration of the
detectors was performed with silver behenate powder (with a d spacing
of 5.838 nm). The data have been normalized for variations in the
primary beam intensity and corrected for the detector efficiency, and the
background has been subtracted. Exposure times were typically 300 s.
No evidence of radiation damage was observed in the X-ray diffraction
patterns. In both experimental sessions, the sample was held in a 1 mm
glass capillary (Hilgenberg, Malsfeld, Germany) and the measurements
were performed at 25 C with a precision of 0.1 C.
2.4. Proteomics Experiments. Human plasma was prepared as
described elsewhere.17 Both CLs and lipoplex suspensions (final lipid
concentration for both suspensions 0.75 mg/mL) were incubated in
different plasma concentrations (2.5, 5, 10, 20, 50, and 80%) in a saline
buffer (pH 7.4). After incubation, the samples were centrifuged to pellet
the particle/protein complexes. The pellet was resuspended in the saline
buffer, transferred into a new vial, and centrifuged again to pellet the
particle/protein complexes; this procedure was repeated twice.18 For
separation by 1D polyacrilamide gel electrophoresis (1D-PAGE), the
proteins were eluted from the particles by adding sodium dodecyl sulfate
(SDS)-PAGE sample buffer to the pellet and boiling the solution. A 12%
polyacrylamide gel was employed to separate the proteins as reported
elsewhere.19 Coomassie PhastGel Blue R-350 was used to stain the gels
with gentle agitation, in accordance with the manufacturer’s manual
(GEHealthcare, Milan, Italy). All experiments were conducted four times
to ensure the reproducibility of the particle/protein complex pellet sizes,
general pattern, and band intensities on the 1D gels. To determine the
molecular weights (MWs) of proteins after an electrophoretic run,
protein molecular weight markers were used. The molecular weights
were finally obtained by means of Kodak dedicated software (Rochester,
NY). For protein identification by liquid chromatography-tandem mass
spectrometry (LC-MS/MS), the pellet nanoparticlesproteins were
resuspended in ureaNH4HCO3 buffer. Afterward, the proteic solution
was handled and enzimatically digested with trypsin as described in
previous work.18,19 The resulting peptide mixture was analyzed by LC-
MS/MS, and the protein identity was assigned by employing Mascot
(v2.2.04, Matrix Science) as a database search engine. Protein identity
statistical validation and relative quantitative analysis were performed
with Scaffold software (v. 3.1.2, Proteome Software).
3. RESULTS AND DISCUSSION
To investigate the protein coronananoparticle complex better,
we performed a preliminary physicalchemical characterization
of both DOTAP CLs and DOTAP/DNA lipoplexes. Sizing and
ζ-potential measurements showed that DOTAP CLs are small,
positively charged vesicles (hydrodynamic radius, RH = 61.2 (
2.5 nm; ζ potential = 55.1( 1.2 mV). DOTAP/DNA lipoplexes
are larger with respect to neat DOTAP CLs (RH = 125.5 (
4.5 nm). DNA addition also results in a lowering of the surface
charge (ζ potential = 40.0 ( 1.1 mV).
Synchrotron SAXS was used to investigate the structure of
DOTAP CLs and DOTAP/DNA lipoplexes on the nanoscale.
Figure 1a shows the SAXS pattern of DOTAP CLs. The system
exhibited only pure diffuse scattering, and quasi-Bragg peaks
were not observed. Such a SAXS pattern is typical of uncorrelated
bilayers (e.g., unilamellar vesicles). The scattering intensity was
therefore fitted with a simple unilamellar vesicle model using the
Gaussian-type representation of the electron density profile (EDP)
as described in ref 20
IðqÞ ¼ 2π
2σH exp  σH
2q2
2
 !
cosðqzHÞ  σCF exp  σC
2q2
2
 !" #2
q2
ð1Þ
where σH is the half width at half-maximum of the Gaussian
representing the polar region that can be assumed to be a realistic
estimate of the headgroup size, zH is the distance between the
headgroup and the center of the bilayer, σC is the standard
deviation of the Gaussian at the center of the bilayer accounting
for the hydrocarbon chains, and F is the ratio of the methyl
terminus electron density amplitude to the headgroup. In Table 1,
we report the coefficient values obtained by fitting the SAXS
profile of DOTAP CLs to eq 1.
Figure 1. (a) SAXS pattern of DOTAP cationic liposomes. The pattern
has been fitted using eq 1 (solid line). (Inset) Electron density profile
calculated from the SAXS pattern reported in panel a. (b) SAXS pattern
of DOTAP/DNA lipoplexes. Bragg peaks arise from the multilayered
lipid membrane/DNA structure. The black arrow indicates the DNA
peak arising from the 1D DNADNA in-plane correlation.
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The resulting EDP was calculated as explained in ref 20 and is
given in the inset of Figure 1a. The more-electron-dense regions
(i.e., the two maxima in the EDP of Figure 1a) represent the
headgroup regions. The fwhm of the Gaussian representing
the headgroup has been assumed to be a realistic estimate of
the headgroup size, dH = 2σH.
20,21 According to this definition,
the bilayer thickness can be determined directly from the
electron density profile by dB =2(zH + σ0). From the EDP of
Figure 1a, the bilayer thickness, dB = 3.68 ( 0.2 nm, and the
extension of the headgroup region, dH = 0.54 ( 0.03 nm, were
determined.21
The SAXS pattern of Figure 1b shows that DOTAP/DNA
lipoplexes are multilamellar aggregates with a periodicity of d =
2π/q001 = 6.00( 0.01 nm. The lamellar periodicity, d, is the sum
of the bilayer thickness, dB, and the layer occupied by fully
hydrated DNA rods, dW (≈ 2.5 nm).14,15 As a consequence, the
bilayer thickness of the lipoplexes was calculated from dB = d 
dW = 3.5 nm. This value, within experimental error, is in good
agreement with the thickness of pure DOTAP bilayers estimated
from the EDP of Figure 1a. From the DNA peak (marked by an
arrow), an interhelical spacing of dDNA = 2π/qDNA = 4.01 nmwas
calculated. This indicates that the DNA rods are densely packed
within lamellar DOTAP/DNA lipoplexes. From the fwhm of the
first-order lamellar Bragg peaks, a lamellar domain size of about
Lm = 2π/fwhm≈ 200 nm could be estimated. Given the lamellar
repeat unit of d = 6.00 nm, this finding suggests that DOTAP/
DNA lipoplexes are multilamellar onionlike structures made of
more than 30 lipid bilayer/DNA monolayer repeat units. Within
experimental error, such a calculation gives a rough estimation of
the ratio of the exposed area of unilamellar DOTAP CLs to that
of multilamellar DOTAP/DNA lipoplexes.
Combined sizing, ζ-potential, and SAXS results well support
the accepted model of the DNA-induced restructuring of CLs
upon lipoplex formation.22 Taken together, these data confirm
the recent suggestion that lipoplexes are hybrid structures with
the lipid surface partially decorated by negatively charged DNA
chains.23 Such a nanostructure would have a deep impact on
the adsorption of plasma proteins, which is to a large extent an
electrostatically driven phenomenon.49
To focus on the evolution of the protein corona that forms
around both CLs and lipoplexes upon exposure to plasma, 1D
SDS/PAGE experiments were performed. Figure 2a,b shows 1D
SDS/PAGE gel results in which DOTAP CLs and DOTAP/
DNA lipoplexes were incubated in plasma concentrations from
2.5 to 80%. With increasing plasma concentration, the protein
pattern for DOTAP CLs changes considerably (Figure 2a),
whereas for lipoplexes the intensity of the protein bands seem to
increase monotonously with increasing plasma concentration
(Figure 2b). To provide insight into the evolution of the total
protein content as a function of the plasma concentration, the
total band intensities of proteins recovered from DOTAP CLs
(Figure 2c) and DOTAP/DNA lipoplexes (Figure 2d) were
Figure 2. One-dimensional SDS-PAGE gel of human plasma proteins obtained from (a) DOTAP cationic liposomeprotein complexes and
(b) DOTAP/DNA lipoplexprotein complexes following incubation at different plasma concentrations. The molecular weights of the proteins on the
standard ladder are reported on the left for reference. Histograms representing the total band intensity of proteins recovered from (c) DOTAP cationic
liposomes and (d) DOTAP/DNA lipoplexes incubated with 2.5, 5, 10, 20, 50, and 80% plasma concentration.
Table 1. Coefficient Values Obtained by Fitting the SAXS
Profile of DOTAP CLs Reported in Figure 1a with the
Unilamellar Vesicle Model Based on the Gaussian-Type
Representation of the Electron Density Profile (Equation 1)20
σH (nm) 0.27 ( 0.03
zH (nm) 1.57 ( 0.08
σC (nm) 1.02 ( 0.05
F 0.80 ( 0.07
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calculated.9 Figure 2c shows that, for DOTAP CLs, the total
amount of protein is maximized at ∼20% plasma and decreases
at lower and higher plasma concentrations. According to the
literature,49 this evolving trend may indicate that the most
abundant proteins (i.e., those having been bound first) are
progressively displaced by those with a higher affinity. Alterna-
tively, this could be an effect of the aggregation of CLs.6 In this
case, we underline that the results may be different from the
results reported in this article.
On the other side, the total band intensity of proteins
recovered fromDOTAP/DNA lipoplexes increases with increas-
ing plasma concentration (Figure 2d). This result is most likely to
suggest that more proteins of the same type bind at higher
concentrations. There are many factors influencing the detailed
nature of the biomolecule corona. Among them, the nanoparticle
size, surface charge, and surface curvature may affect protein
adsorption such that the coronas associated with nanoparticles of
the same material can vary in composition.49 Bearing in mind
that DOTAP CLs and DOTAP/DNA lipoplexes mainly differ in
the presence of DNA, we suggest that DNA molecules play a key
role in the formation of the protein corona of lipoplexes even at
low plasma concentration. This suggestion is supported by our
results that DNA is partially located at the lipoplex surface and
therefore available for protein adsorption.
We also observe that at fixed plasma concentrations the total
intensity of each lane is higher for CLs than for lipoplexes.
Because the signal intensity within each scan is proportional to
the vesicle surface area available to plasma protein adsorption,
this result indicates that the lipid membrane area of CLs that
is available for binding is larger than that of lipoplexes. This
finding is in agreement with the results of the physicalchemical
characterization showing that the lipoplex is a multilamellar
structure. Indeed, multilamellarity3,14,15 is known to reduce the
fraction of the lipid available on the outer surface of the vesicle
population for the initial binding of oppositely charged macro-
molecules. To give further support to such a conclusion, the total
intensity of each lane (i.e., at a fixed plasma concentration) from
the gel reported in Figure 2b was divided by the total intensity of
the corresponding lane from the gel reported in Figure 2d. The
calculated ratio, RI, is reported in Figure S1a. At the lowest
plasma concentration (2.5%), RI was found to be ∼25. Such a
value is in very good agreement with the ratio of the exposed
surface area of the DOTAP CLs to that of the DOTAP/DNA
lipoplexes. Even though the ratio of the exposed surface area of
the DOTAP CLs to that of the DOTAP/DNA lipoplexes was
constant in our experiments, RI was found to decrease with
increasing plasma concentration. To compare results, experi-
mental data should be collected by keeping the ratio of the
plasma concentration to the total particle surface area/mL, RCA,
the same.6 Although our data were collected at different RCA
ratios, the two investigated regions were practically contiguous
(Table S1). However, when the total intensity of each lane from
gels reported in Figure 2a,b is plotted against RCA, no clear trend
is found (Figure S1b). As evident, the interpretation of the data
reported in Figure S1a is not trivial and is complicated by the fact
that (i) the exposed surface area of CLs is roughly 30-fold higher
than that of lipoplexes and the effective area per protein decreases
with increasing protein concentration; (ii) the particle size, which
is known to affect the protein adsorption,6 of CLs and lipoplexes
is different; and (iii) the surfaces of CLs are completely
lipidic whereas those of lipoplexes are partially decorated with
DNA molecules. All of these observations suggest that, upon
interaction with plasma proteins, the compositions of the cor-
onas of CLs and lipoplexes can change in different ways from
each other. As a result, a quantitative comparison between the
coronas of CLs and lipoplexes is much less obvious than one
would expect.
To investigate the evolution of the protein corona of both CLs
and lipoplexes better, a semiquantitative densitometry analysis
was performed. In Figure 3a,b, we show the relative densitometry
results (the intensity of each protein band is divided by the total
intensity of the lane)9 of five major bands from the gels in
Figure 2a,b as a function of the plasma concentration during
incubation. Within the limits of gel separation methodologies,
this provides a semiquantitative description of the variations in
the band intensities that are visible in Figure 2. In Figure 3a, we
could distinguish both low-affinity (LA) proteins, whose relative
amount in the corona decrease, and competitive-binding (CB)
proteins, whose relative amount in the corona increases with
increasing plasma concentration. Aside from clarifying the exact
mechanism of protein corona formation, it is clear that the corona
composition of DOTAP CLs is not stable, with its composition
Figure 3. Relative amounts of the most abundant proteins (marked by
numbers in Figure 2) adsorbed in the hard corona complexes of (a)
DOTAP cationic liposomes and (b) DOTAP/DNA lipoplexes from
plasma solutions at different concentrations (legend) after 1 h of
incubation. The results are extracted as the relative intensities from
the gels shown in Figure 2a,b, respectively. Proteins whose relative
amounts in the corona decrease with increasing plasma concentration
are labeled as low-affinity (LA) proteins, and those whose relative
amounts in the corona increase are labeled as competitive-binding
(CB) proteins.
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probably being affected by a cooperative phenomenon.9 However,
for DOTAP/DNA lipoplexes, the relative intensities of all bands did
not change appreciably. This result indicates that the protein corona
of lipoplexes increases from 2.5 to 80% plasma whereas its protein
composition remained largely unchanged.
The compositional evolution of the coronas of CLs and
lipoplexes can be compared by calculating an average of standard
deviations for the relative band intensities reported in Figure 3a,
b. Each population consists of the five relative intensities at fixed
MW. To this end, we first calculated the standard deviation of
each intensity population, defined as
σ ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
∑
N
i¼ 1
ðxi  x̅Þ2
N  1
vuuut
ð2Þ
where xi is the ith band intensity of a given intensity population, x
is the average of an intensity population, and N is the number of
elements in the population. Standard deviations calculated for
DOTAP CLs were much larger than those obtained from the
intensity populations of DOTAP/DNA lipoplexes (Figure S1).
The average of the standard deviations calculated for DOTAP
CLs (Æσæ = 0.11) was about 5-fold higher than its counterpart
calculated for DOTAP/DNA lipoplexes (Æσæ = 0.02).
The identities of the proteins were last determined by mass
spectrometry analysis of selected bands cut from the gels re-
ported in Figure 2a,b. Identified proteins are reported in Table S1.
Even though an accurate protein quantification is beyond the
scope of the present study and is currently in progress, some
systematic effects were detected. The most abundant plasma
proteins such albumin, fibrinogen (alpha, beta, and gamma
chains), complement C5, apolipoprotein A-I, transferrin, vitro-
nectin, and fibronectin were identifed on both coronas. On the
other side, the corona of DOTAP/DNA lipoplexes was found to
be richer in immunoglobulins (Ig) than was that of DOTAPCLs.
In particular, a large number of Ig gamma proteins (Ig-Gs) were
identified by their mass. Ig-Gs are involved in many processes
(e.g., immunity responses). In particular, it has been reported that
Ig-Gs can promote the phagocytosis of DNA-loaded nanovectors
by macrophages and other phagocytic cells such as hepatic
Kupffer cells. This is consistent with several observations that
lipoplexes primarily accumulate in the liver following intravenous
administration.2426 Because Ig-Gs are mainly basic proteins
(i.e., with pK >7), proteomics results suggest that the surface
charge of lipoplexes may locally deviate from being positively
charged. This suggestion is supported by sizing, ζ-potential, and
SAXS results showing that a fraction of DNA is adsorbed at the
lipoplex membrane and can interact electrostatically with catio-
nic molecules. Another class of plasma proteins exclusively found
in the lipoplex corona was histones. Histones are alkaline
proteins found in eukaryotic cell nuclei that package and order
the DNA into structural units called nucleosomes. In particular,
histones H1.4, H3.1, H4, and H2B type 1-K were identified
(Table S2). Histone H1 is one of the most abundant proteins in
the nucleus of eukaryotic cells. It has long been known as the
linker histone because it links the chromatosomal DNA that goes
between the nucleosomes. Histone H2B type 1-K is one of the
proteins involved in the structure of chromatin in eukaryotic
cells. Finding such proteins in the lipoplex corona may confirm
our suggestion that some plasma proteins can specifically recog-
nize the DNA molecule at the lipoplex surface. The proteins
normally found inside the nucleus should not be found in a
significant amount in plasma. Thus, we cannot exclude the
possibility that the commercial calf thymus DNA was contam-
ined by histones.
The biochemical rationale for protein corona formation is still
unclear. Recent studies2729 have shown that the nanoparticle
protein corona can evolve over time. This temporal evolution
might cause consequences at the level of liposomes to target cell
interaction and needs further investigation to predict the actual
biological identity of the proteinLNP complex as far as the
protein layer is built up.
4. CONCLUSIONS
It is now clearly emerging that the primary defining element of
nanoparticles in biological media is their protein corona that
dictates the biodistribution and final fate in vivo, which is the
entity actually seen by target cells both in vitro and in vivo. We
have combined studies on the composition of the protein
corona at different plasma concentrations (mimicking in vitro
and in vivo conditions) with structural data on the complexes.
We have shown that the protein corona of CLs is made of both
low-affinity and competitive-binding proteins whose relative
abundance changes with the plasma concentration. Such effects
may be so striking that the biological identity of lipid gene vectors
with DNA cargo confined in the interior space (e.g., LNP) may
change dramatically as the amount of protein in the environment
changes. In particular, nanoparticleprotein complexes in vitro
(at low serum dilutions) may poorly correlate with those that
exist in vivo. On the other side, passing from low to high plasma
concentrations, the protein corona of lipoplexes changes in
abundance but not in composition. By correlating such evolution
trends with the distinctive physicalchemical properties of
lipoplexes, we conclude that the evolution of the protein corona
passing from in vitro to in vivo conditions is severely affected by
the presence of DNA. This aspect should be carefully considered
for the rational design of lipid gene vectors.
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Gene therapy research is still problematic owing to a paucityof acceptable vector systems to deliver nucleic acids to
patients for therapy.13 Viral vectors are efficient but may be
dangerous for routine clinical use. Synthetic nonviral vectors are
fundamentally safer but are currently not efficient enough to be
clinically viable. A possible solution for gene therapy lies with
improved synthetic nonviral vectors based upon well-established
platform technologies and a thorough understanding of the
barriers to efficient gene delivery and expression (transfection)
relevant to clinical applications of interest. One of the most
common nonviral gene delivery vectors are DNAcationic lipid
complexes (lipoplexes). On the basis of freezefracture electron
micrographs and X-ray diffraction studies, it was suggested that
lipoplexes are multilamellar onion-like systems with DNA sand-
wiched between opposing lipid bilayers.48 Once inside the cell,
such multilamellar structure offers protection from DNA degra-
dation but do not often allow for an adequate DNA release from
endosomal compartments. If gene payload is not released from
endosomes, it is shuttled to the lysosomes, where it is degraded
by the abundant nucleases and transfection may fail.911 To
overcome this problem, lipid/DNA/polycation (LDP) com-
plexes, in which plasmid DNA (pDNA) condensed with a
polycation is encapsulated by a lipid envelope, have recently
been developed.12 Kogure et al.12 demonstrated that the lucifer-
ase activity of a DNApoly-L-lysine complex (DPC) with a lipid
envelope was 10 times higher than only DPC in NIH 3T3 cells,
suggesting that the lipid coating is important and critical for
efficient gene delivery. Recent studies showed superiority of
LPD-mediated gene transfer over conventional liposomes for
delivering a gene to the liver.13 Over the past few years several
efforts to improve the delivery efficiency of LPD systems have
been made.1418 The composition of the lipid envelope of LPD
systems has been modified with novel chemical compounds,
while the surface has been functionalized with several polymers
and ligands. In a recent study a new lysine based cationic lipid
containing a guanidine group that serves simultaneously as a
delivery component and a therapeutic agent was reported.16 Such
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ABSTRACT: The utility of using a protammine/DNA complex coated with a lipid
envelope made of cationic 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)
for transfecting CHO (Chinese hamster ovary cells), HEK293 (human embryonic
kidney cells), NIH 3T3 (mouse embryonal cells), and A17 (murine cancer cells) cells
was examined. The widely used DOTAP/DNA lipoplex was employed as a reference.
In all the tested cell lines lipid/protamine/DNA (LPD) nanoparticles were more
efficient in transfecting cells than lipoplexes even though the lipid composition of the
lipid envelope was the same in both devices. Physicalchemical properties were found to control the ability of nanocarriers to
release DNA upon interaction with cellular membranes. LPD complexes easily release their DNA payload, while lipoplexes remain
largely intact and accumulate at the cell nucleus. Collectively, these data explain why LPD nanoparticles often exhibit superior
performances compared to lipoplexes in trasfecting cells and represent a promising class of nanocarriers for gene delivery.
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novel formulation resulted in enhanced cellular uptake, gene
silencing, and tumor growth inhibition. Systemic tumor-targeted
delivery remains the most challenging issue in the drug delivery
field. In vivo data of tissue distribution demonstrated the
potential of surface-modified LPD nanoparticles for tumor
targeting.15 Whether the superior performance of LPD systems
over the consolidated lipoplex strategy does correlate with
distinct physicalchemical properties of LPD complexes is an
open question that needs to be answered. Generally, lipoplex
dispersions are heterogeneous and polydisperse, consisting of a
variety of structures in dynamic equilibrium. Recently, the
existence of hybrid structures made of multilamellar lipoplexes
stuck together by DNA has been reported.19 Because physical
chemical properties of gene vectors may determine their inter-
action with cells and tissues, a precise knowledge of these
properties may be important for predicting their biological
response both in vitro and in vivo. Comparative studies of
pDNA-encapsulation type and lipoplex type gene vectors would
therefore provide useful information to decipher the relationship
between the physicalchemical properties of gene vectors and
their mechanisms of interaction with the cell’s components. This
knowledge is expected to drive the rational design of highly
efficient gene delivery systems.
In the present study, we show that the transfection effi-
ciency (TE) of protammine/DNA complexes coated with a lipid
envelope made of cationic 1,2-dioleoyl-3-trimethylammonium
propane (DOTAP) is from 3 to 20 times higher than that of
DOTAP/DNA lipoplexes. We asked whether such remarkable
difference in TE did correlate with particulate features of com-
plexes. To answer this question, we investigated complex forma-
tion, DNA protection ability, surface properties, nanostructure,
ability to release DNA upon interaction with cellular lipids, and
intracellular trafficking. We present findings showing that the
superior efficiency of LPD complexes over lipoplexes does
correlate with their distinctive physicalchemical properties.
’RESULTS
Complex Formation.Gel retardation assay was carried out to
evaluate the condensing ability of P/DNA, LPD complexes, and
lipoplexes.2024 The complete retardation of the binary P/DNA
complex can be observed when the P/DNAweight ratio, RW, was
above 0.5 (Figure 1, top part). Starting from RW= 0.75, the molar
fraction of plasmid DNA completely protected by protamine,
XDNA (Figure 1, bottom part), was maximum (i.e., XDNA = 1).
P/DNAcomplex formation was investigated by measuring the
average hydrodynamic radius, RD, and the electrophoretic mo-
bility of the diffusing complexes in the solution. The combined
use of these two techniques allowed us to study both of the two
typical phenomena occurring in these systems, namely, the
reentrant condensation and the charge inversion effect.25,26 In
Figure 2 the average dimensions and the ζ-potential of P/DNA
particles are plotted against RW. As can be seen, with the increase
in RW, complex formation begins and the diameter of complexes,
DH, gradually increases until a maximum is reached at RW ≈ 1.
Our results are in good agreement with previous studies show-
ing that P/DNA particles show a neutral charge at RW = 0.9.
27
Further increase in the P content determines the formation of
decreasing-size complexes until the size of the original P/DNA
core is approximately reached again (reentrant condensation).
Aggregates also undergo the charge inversion effect, documented
by the ζ-potential values whose sign changes for 0.5 < RW <1,
differentiating negatively and positively charged aggregates. On
the basis of these results, P/DNA complex at RW = 0.75 was
therefore chosen because it guaranteed complete DNA protec-
tion, exhibited negative charge (20 mV), and had appropriate
dimensions (260 nm) with the minimum P content. Then the
preassembled negatively charged P/DNA core was coated with a
Figure 2. (A) Diameter of P/DNA complexes, DH, as a function of the
P/DNA weight ratio, RW. This behavior is typical of the reentrant
condensation effect. (B) ζ-Potential of P/DNA complexes as a function
of RW. The charge inversion effect occurring for 0.5< RW <1 changes the
overall charge of the aggregates from negative (DNA excess) to positive
(protamine excess).
Figure 1. (Top) Digital photograph of protammine/DNA complexes
(P/DNA) with increasing P/DNA weight ratio RW: RW = 0.1 (lane 1),
RW = 0.5 (lane 2), RW = 1 (lane 3), RW = 2 (lane 4), RW = 3 (lane 5),
RW = 5 (lane 6), RW = 10 (lane 7), and control DNA (lane 8). Experiments
revealed two major bands for naked DNA (lane 8). The high-mobility
band was attributed to the most compact (supercoiled) form, and the
less-intense one was considered to be the non-super-coil content in the
plasmid preparation. (Bottom) Molar fraction of plasmid DNA pro-
tected by protamine, XDNA, against the P/DNA weight ratio, RW.
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lipid envelope through membrane fusion of positively charged
DOTAP small unilamellar vesicles (SUVs) (55 mV, RH =
61.2 nm), triggered by the electrostatic attraction around the
negatively charged core. The main results are summarized in
Figure 3 where we show the diameter DH (part A, triangles) and
the ζ-potential ζp (part B, triangles) of DOTAP/PDNA LPD
complexes as a function of the lipid/DNA volume ratio, RV. As can
be seen, with the increase of RV, complexation begins and the size
of the complexes gradually increases until a maximum is reached
(DH≈ 500 nmatRV = 0.5). Increasing the lipid content (RV > 0.5)
results in the formation of decreasing-size complexes. Aggregates
also undergo the charge inversion effect, recognizable by the ζ-
potential values (Figure 3b, triangles) whose sign changes around
RV = 0.5, differentiating negatively and positively charged aggre-
gates. This trend shows three different ζ potential regions: (i) the
region where the net charge of LPD complexes is negative and
almost constant at (31 mV); (ii) the region where the inversion
of ζ potential sign takes place (around RV = 0.5); and (iii) the
region where the net charge of the LPD complexes is positive
(47.8 mV). We observe that condensed P/DNA core (260 nm) is
larger in size than the final LPD complex (∼220 nm). This finding
suggests that the P/DNA core is partly disassembled upon
DNAlipid interaction. Upon disassembling, some free DNA
may give rise to a minor fraction of lipoplexes, if any, in the final
dispersion. Even though the polydispersity index was low (pdi
<0.25), this possibility cannot be excluded. In Figure 3DH (part A,
circles) and ζp, (part B, circles) of DOTAP/DNA lipoplexes
plotted against RV are also reported. As evident, both the re-
entrant condensation and the charge inversion effect occurred, but
at RV values larger than those observed in the case of LPD
complexes. Dynamic investigation of size and ζ potential showed
that both LPD nanoparticles and lipoplexes were fairly stable over
24 h (Supporting Information). The LPD complex at RV = 2 was
finally chosen because it exhibited positive charge (47.8 mV) as
well as the lowest colloidal dimensions (220 nm) and the lowest
polydispersity index (pdi = 0.22).
DNA condensation was also investigated by UVvis absorp-
tion measurements by which the binding constants for both LPD
complexes and lipoplexes were estimated (KLPD = (2.1( 0.5)
104M1 andKLipoplex = (1.3( 0.3) 104M1; details are given
in the Supporting Information). A slightly stronger lipid/DNA
interaction for LPD systems was observed. Since the stability of
lipidDNA complexes is related to charge neutralization, our
findings are most likely to indicate that protammine contributes
to a better DNA charge neutralization.28
DNA Protection Ability. The DNA protection ability of both
LPD nanoparticles and lipoplexes was investigated by electropho-
resis on agarose gel. In Figure 4A we report the molar fraction of
DNA protected by either lipoplexes and LPD nanoparticles,XDNA,
over the incubation period with cells. The starting point
(t = 0) refers to the time when lipid vectors are usually given to
cells, i.e., about 20 min of incubation after lipidDNA mixing. At
t = 0, the protection ability of LPD is almost complete while some
free DNA is present in the lipoplex formulation (XDNA ≈ 0.25).
Such values of protection remained the same over 3 h of incuba-
tion. The presence of serum in the transfection media has been
found to be inhibitory to gene transfer.29 This inhibition has been
mainly attributed to serumlipid membrane interaction resulting
in destabilization of the lipid structure. Such structural degradation
is often accompanied by lipidDNA dissociation and release
leading to a decrease in the DNA protection ability of complexes.
We therefore investigated the protection ability of both LPD
nanoparticles and lipoplexes in serum. As can be seen in
Figure 4B, no relevant changes in the molar fraction of protected
DNA, XDNA, occurred. This indicates that the DNA-protection
capacity of complexes was not modified by serum.
Figure 4. Molar fraction of DNA protected, XDNA, by LPD nanopar-
ticles and lipoplexes over incubation with buffer (A) and serum (B).
Figure 3. (A) Diameter of LPD complexes (triangles) and lipoplexes
(circles) as a function of the lipid/DNA volume ratio, RV. (B)
ζ-Potential of LPD complexes (triangles) and lipoplexes (circles) as a
function of RV.
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Surface Properties. Recent pioneering studies3034 have
reported on the existence of a rich protein layer associated with
the surface of nanoparticles after treatment with biological fluids
(e.g., human plasma, HP). Here we perform proteomics experi-
ments to investigate the “protein corona” associated with the
surface of DOTAP cationic liposomes (CLs), LPD complexes,
and lipoplexes after interaction with HP. Figure 5 (top part)
shows one-dimensional sodium dodecyl sulfatepolyacrylamide
gel electrophoresis (1D SDSPAGE) (12% gels) of plasma
proteins retrieved from DOTAP CLs (lanes 1 and 2), DOTAP/
DNA lipoplexes (RV = 2) (lanes 3 and 4), and LPD complexes
(RV =2) (lanes 5 and 6). As Figure 5 shows, 1D SDSPAGE
experiments were highly reproducible. Even though an accurate
protein analysis is beyond the scope of the present study and will
be given in detail elsewhere, some systematic effects were
detected. We observe that the intensities of almost all protein
bands of CLs (lanes 1 and 2) were higher than those of both
lipoplexes (lanes 3 and 4) and lipid nanoparticles (lanes 5 and 6).
Since the signal intensity within each scan is proportional to the
vesicle surface available to plasma protein adsorption, this result
indicates that the lipid membrane area of CLs that is available for
binding is larger than that of lipoplexes and lipid nanoparticles.
To find a surface similarity between the different surfaces, the
intensity of each protein band identified in the patterns of both
lipid nanoparticles, ILPD, and lipoplexes, ILipoplex, was compared
to that of the corresponding band identified in the patterns of
DOTAP CLs, IDOTAP. A comparative intensity analysis is re-
ported in Figure 5 (bottom part) where the intensity ratios
(ILPD/IDOTAP) and (ILipoplex/IDOTAP) are plotted against the
molecular weight of several protein bands, MW. In the case of
LPD complexes a series of approximately uniform intensity ratios
was observed (Figure 5, bottom part, triangles). On the other
hand, intensity ratios of lipoplexes (Figure 5, bottom part,
circles) exhibited a random variation. This finding is most likely
to suggest that the surface of LPD complexes has a high degree of
similarity with that of pure DOTAP CLs, while that of lipoplexes
has not. Furthermore, a protein band observed in the protein
pattern of lipoplexes (indicated by black arrow in Figure 5, top
part) was not detected in the pattern of CLs or in that of LPD
nanoparticles. This high-intensity band was centered around
23 kDa. In this band a large number of Ig-Gs were identified by
their mass (proteomics data not reported). Ig-Gs are basic
proteins involved in many processes such as immunity
response.33 This finding indicates that the surface charge of
lipoplexes differs, at least locally, from being positive. The latter
observation is most likely to suggest that negatively charged
DNA is adsorbed at the lipoplex surface and can interact with
basic plasma proteins. In summary, our findings suggest that (i)
the surface area of LPD complexes available to protein adsorp-
tion resembles that of DOTAPCLs (i.e., it is mainly lipidic) but it
is smaller than that of pure DOTAP SUVs; (ii) the surface of
lipoplexes is partly decorated with DNA molecules, while that of
LPD is not.
We therefore asked ourselves whether the observed differ-
ences in the surface properties of lipoplexes and LPD nanopar-
ticles may also affect their size and ζ-potential upon inter-
action with plasma proteins. To model the interaction of
complexes with plasma proteins, albumin from bovine serum
Figure 5. (Top) Photograph of an SDSPAGE (12% gel) of human
plasma proteins retrieved from DOTAP CLs (lanes 1 and 2), LPD
complexes (lanes 3 and 4), and lipoplexes (lanes 5 and 6). Lane 7 is a
protein molecular weight marker. The black arrows indicate the bands of
human plasma proteins that were found to be much more abundantly
associated with lipoplexes than with cationic liposomes. (Bottom)
Intensity of protein band identified in the patterns of both lipid
nanoparticles, ILPD, and lipoplexes, ILipoplex, compared to the that of
corresponding band identified in the patterns of DOTAP CLs, IDOTAP.
Intensity ratios (ILPD/IDOTAP, triangles) and (ILipoplex/IDOTAP, circles)
are plotted against the molecular weight of several protein bands,MW. In
the case of LPD complexes approximately uniform intensity ratios were
observed, whereas intensity ratios of lipoplexes exhibited a random
variation.
Figure 6. (A) Diameter of LPD complexes (triangles) and lipoplexes
(circles) as a function of albumin concentration,CALB. (B) ζ-Potential of
LPD complexes (triangles) and lipoplexes (circles) as a function of
albumin concentration, CALB.
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(Sigma-Aldrich, St. Louis, MO) was employed. Albumin is the
main protein of HP and is negatively charged at physiological pH.
Size and ζ-potential of complexes were investigated as a function
of increasing albumin concentration, CALB, from zero up to
its typical concentration in plasma (35 mg/mL). Figure 6A
shows that upon interaction with albumin, the size of both
lipoplexes and LPD nanoparticles increased with increasing
albumin concentration, passed throughout a maximum, and
finally reached a plateau value. On the other side, the ζ potential
(Figure 6B) changed from positive (∼40 mV) to negative values
(about20 mV). Even though albumin changed the ζ-potential
of lipoplexes and LPD nanoparticles to negative, gel electro-
phoresis showed that albumin was never able to release pDNA
from the complexes (data not shown). Such finding is in very
good agreement with the results of Figure 4B showing that the
DNA protection ability of complexes is not affected by serum.
Nanostructure. Figure 7A shows the synchrotron SAXS
pattern of LPD complexes (RV = 2). As evident, two broad
Bragg peaks, corresponding to a periodicity d = 2π/q001 =
7.10 nm, were detected. The large peak width, which is char-
acteristic of a system with a short scattering correlation length, is
an indication that the bilayers are weakly bound. Further, the
lamellar periodicity, d, is larger than that commonly observed in
most DOTAP/DNA complexes (typically 5.56.2 nm).47 This
suggests that the lipid membranes are in a highly swollen state
due to electrostatic repulsion between adjacent charged DOTAP
bilayers. From the full width at half-maximum (fwhm) of the
first-order lamellar Bragg peaks, a domain lamellar size of Lm =
2π/fwhm ≈ 70 nm could be estimated. These observations are
consistent with a model of LPD complexes made of a P/DNA
core coated with a lipid envelope made of about 10 DOTAP
bilayers.
We next examined the nanostructure of DOTAP/DNA lipo-
plexes. Figure 5, top, shows the SAXS pattern of DOTAP/DNA
lipoplexes (RV = 2). The sharp periodically spaced peaks at q001
are caused by alternating lipid bilayerDNAmonolayer struc-
ture with periodicity d = 2π/q001 = 6.01( 0.01 nm. This result is
in agreement with previous experimental evidence of the DNA-
induced liposome restructuring upon lipoplex formation pro-
vided by different techniques such as X-ray diffraction and
cryoelectron microscopy.48 The middle peak (marked by an
arrow) results from one-dimensional (1D) ordering of the DNA
sandwiched between the lipid bilayers.23,24 It is usually referred to
as “DNA peak” and corresponds to a DNA interhelical spacing
dDNA = 2π/qDNA = 4.01 nm. From the fwhm of the first-order
lamellar Bragg peaks, a domain lamellar size of about Lm =
2π/fwhm ≈ 200 nm could be estimated. Given the lamellar
d-spacing, d = 6.00 nm, this finding suggests that DOTAP/DNA
lipoplexes are multilamellar onion-like structures made of more
than 30 repeating lipid bilayer/DNA monolayer repeat units.48
Transfection Efficiency. To compare the ability of LPD
nanoparticles and lipoplexes (RV = 2) to deliver plasmid DNA,
TE experiments were performed in NIH 3T3, CHO, Hek293,
and A17 cells. TE results are reported in Figure 8. According to
the literature, TE was found to be dependent on the given cell
line. The CHO cell line was much more easily transfected than
the A17 one, while intermediate levels of transfection were
obtained with Hek 293NIH 3T3 and cells. Even though different
cell lines exhibited varying levels of TE, Figure 8 clearly shows the
superior performance of LPD nanoparticles over lipoplexes in all
the tested cell lines. TE was found to increase by a factor of∼3 in
A17, ∼4 in CHO, ∼8 in Hek293, and ∼20 in NIH 3T3 cells.
Interaction with Cellular Lipids. A viewpoint now emerging
is that a critical factor in the lipid-mediated gene delivery is the
structural evolution of lipoplexes upon interaction and mixing
with anionic cellular lipids.20,21,3538 Such a structural rearrange-
ment is supposed to play a central role in the DNA escape
process, i.e., in how DNA dissociates from lipoplexes and is
released into the cytoplasm and eventually into the nucleus.
Thus, we were particularly interested in whether theDNA release
from complexes upon interaction with cellular lipids might
correlate with the TE data reported in Figure 8. Electrophoretic
experiments (digital photographs not reported for space con-
sideration) allowed us to quantify the molar fraction of DNA that
Figure 7. (A) Synchrotron SAXS pattern of LPD complexes at a lipid/
DNA volume ratio, RV = 2. Two broad Bragg peaks, corresponding to a
periodicity d = 2π/q001 = 7.10 nm, were detected and larger than those
commonly observed in most DOTAP/DNA complexes (typically
5.56.2 nm). (B) Synchrotron SAXS pattern of DOTAP/DNA lipo-
plexes (RV = 2). The sharp periodically spaced peaks at q001 are caused
by alternating lipid bilayerDNAmonolayer structure with periodicity
d = 2π/q001 = 6.01( 0.01 nm. The middle peak (marked by an arrow)
results from one-dimensional (1D) ordering of the DNA sandwiched
between the lipid bilayers and corresponds to aDNA interhelical spacing
dDNA = 2π/qDNA = 4.01 nm.
Figure 8. Transfection efficiency of LPD complexes and lipoplexes at
the same lipid/DNA ratio (RV = 2). Luciferase activity is expressed as
relative light units/mg of protein in the cell lysate.
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is no longer electrostatically associated with cationic lipids,
1  XDNA, as a function of the anionic/cationic charge ratio R
upon interaction with DOPG (Figure 9A) and DOPA
(Figure 9B) cellular lipids. At the lowest R (R = 0.5), DNA is
almost completely dissociated from LPD complexes (1  XDNA
≈ 1), while a large fraction of DNA is still protected by lipoplexes
(1  XDNA of ∼0.35 and ∼0.45 for DOPG and DOPA,
respectively). Figure 9 also shows that DNA released from
lipoplexes, 1  XDNA, increases with increasing R and reaches
1 at R≈ 10. These findings suggest that a much lower amount of
anionic lipids (ALs) is needed to promote complete DNA
dissociation from LPD complexes.
Size and ζ-potential of lipoplexes and LPD nanoparticles upon
interaction with cellular lipids are reported in Figure 10. Addition
of ALs to cationic complexes results in a marked increase in size
until a maximum is reached (at R of ∼0.5 and ∼1 for lipoplexes
and LPD systems, respectively). Upon further addition of anionic
charge, vesicle size reverted to control values. The observed
increase in size of complexes for R < 1 can be either associated
with van der Waals attractions overcoming weak electrostatic
repulsions (reentrant condensation) or to vesicle fusion. Aggre-
gates also undergo the charge inversion effect, documented by
the ζ-potential values whose sign changes for 0.5 < R < 1,
differentiating positively and negatively charged aggregates. Size
and ζ-potential of complexes after interaction with ALs were
pretty stable over 24 h (data not reported for space consider-
ation). On the basis of the analysis reported in Figure 10, it is
difficult to correlate the extent of DNA release (Figure 9) with
the size and ζ-potential of complexes emerging from interaction
with cellular lipids. Electrophoresis results (Figure 9) show that
for R < 0.5 DNA is almost completely released from LPD
systems, while it is still largely protected by lipoplexes. As a
whole, these results indicate that the size and ζ-potential of
complexes interacting with cellular lipids are mainly regulated by
the anionic/cationic charge ratio, R, while the ability of the
investigated formulations to release DNA is controlled by factors
other than R. The DNA release ability may be connected with the
membrane fusion rate of complexes with cellular membranes that
is, in turn, inversely related to the multilamellarity of lipid
aggregates. Such suggestion is in good agreement with SAXS
findings (Figure 7) showing that lipoplexes are multilamellar
systems, while LPD nanoparticles are made of a few membranes
and are therefore more disposed to fuse with ALs mimicking
cellular membranes and to release their gene cargo.
Cell Imaging. Confocal images of CHO-K1 cells 4 h after
incubation with LPD complexes and DOTAP/DNA lipoplexes
(RV = 2) are shown in Figure 11. We observe that green
fluorescence from lipids forming LPD nanoparticles was clearly
localized, while DNA (red fluorescence) had visibly spread into
the cytoplasm (Figure11A). It may be reasonable to judge such
spreading red regions as due to plasmid DNA exiting from the
endosomal or lysosomal stage into the cytoplasm. Over the same
time scale, CHO-K1 cells incubated with DOTAP/DNA lipo-
plexes were mainly distributed throughout the cytoplasm and to
some extent at the cell periphery (Figure 11B). Complexes
appeared almost devoid of cytoplasmic plasmid DNA, suggesting
that such binary formulation is defective in facilitating endosomal
escape of nucleic acids, resulting in entrapment of plasmid DNA
in endosomes. Since there is a possibility that lipoplexes exhibit
DNA release with different kinetics than LPD complexes, the
distribution was followed at various time points (4, 6, 8, 10, 12,
24, 36, and 48 h). Over such time scale, significant cytosolic DNA
release from lipoplexes as that observed for LPD nanoparticles
was not detected.
’DISCUSSION
This study represents a direct comparison between a pDNA-
encapsulated system (LPD) and a complex system (lipoplex) on
Figure 9. Molar fraction of DNA, 1  XDNA, that is no longer
electrostatically associated with LPD complexes and lipoplexes after
interaction with DOPG (A) and DOPA (B) cellular lipids of as a
function of the anionic/cationic charge ratio, R.
Figure 10. (A) Diameter of LPD complexes (triangles) and lipoplexes
(circles) upon interaction with DOPG as a function of the anionic/
cationic charge ratio, R. (B) ζ-Potential of LPD complexes (triangles)
and lipoplexes (circles) upon interaction with DOPG as a function of the
anionic/cationic charge ratio, R. (C) Diameter of LPD complexes
(triangles) and lipoplexes (circles) upon interaction with DOPA as a
function of the anionic/cationic charge ratio, R. (D) ζ-Potential of LPD
complexes (triangles) and lipoplexes (circles) upon interaction with
DOPG as a function of the anionic/cationic charge ratio, R.
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the basis of the same lipid composition. Crucial to the mecha-
nism of gene delivery is likely the relative ease by which the gene
and amphiphile dissociate. Insight into parameters that deter-
mine stabilization and destabilization of these complexes, which
are intricately related to their efficiency in gene delivery, requires
an understanding of factors that govern amphiphileDNA
interaction and subsequent complex formation. Upon complex
formation, reentrant condensation and charge inversion20,21
occurred in both systems (Figure 3). Both charge inversion
and charge and size saturation of LPD complexes were found to
occur at RV values smaller than those observed when lipoplexes
were used. This finding means that complete encapsulation of
protammine/DNA core by a lipid envelope requires a lower
amount of cationic lipid than that needed to condense the same
amount of DNA by a lipoplex system. Toxicity of the complex, as
described for many such complexes, may depend upon the
amount of cationic lipid used to transfect cells. Pertinent to
sustaining such toxicity effects may be their biodegradability and
the cell’s capacity to eliminate cationic lipids. Thus, LPD com-
plexes, because of the lower amount of cationic lipid needed to
protect DNA, are potentially less toxic than lipoplexes.
We found that TE of LPD nanoparticles was higher than that of
lipoplexes in all the tested cell lines (Figure 8). DNA complexes
must overcome a series of barriers to gain access to the membrane
surface, cytoplasmic compartment, and nucleus of a target cell and
to translate transgenes into protein. As particles encounter each of
these barriers, they are subject to a certain probability of success
or failure in overcoming each. The cumulative probability of
success for the entire journey is reflected in the transfection
efficiency for a given system.39 A number of physicalchemical
properties of lipoplexes have been proposed as factors regulating
success in overcoming such transfection barriers such as
size,4043 ζ-potential,44,45 nanostructure,22,46 propensity to
be disintegrated by anionic lipids,20,21,3538,47 and ability to
release DNA both in the cytosol and in the nucleus.
Upon arrival near the cell, complexes associate electrostatically
with mammalian cells, which contain surface proteoglycans with
negatively charged sulphated groups. Since the first interaction
between nanocarriers and cells is charge-mediated and not
specific, complexes with high ζ-potential are supposed to be
better internalized. A preferential binding should result in sub-
sequent efficient cellular internalization of the carrierDNA
complex that is crucial to nonviral gene transfer. However,
ζ-potential of LPD complexes and lipoplexes were found to be
roughly the same (ζp = 47.5 and 44.4 mV, respectively). Thus,
charge-mediated efficient binding played a minor role, if any, in
differentiating efficiency levels of the two carriers.
Nonviral vectors can be transported to the cytoplasmic
compartment by a diversity of endocytic mechanisms.39 Each
of these pathways may support a different level of transfection
mediated by a given delivery system. An emerging paradigm for
the design of effective gene carriers is the modification of
particulate parameters to encourage entry via a preferable
endocytic pathway.48,49 The endocytic machinery and cell mem-
brane have well-defined geometries and flexibility that may
restrict entry of incompatibly large or small particles.4043
Recently, a size-dependent mechanism of lipoplex internalization
has been proposed.41 Accordingly, complexes with a size of
approximately 200 nm or less are supposed to enter cells basically
via the clathrin-coated pathway, while larger complexes are
internalized via caveolae-mediated pathways. OurDLS data show
that both LPD complexes and lipoplexes used in the present
study are larger than 200 nm in size. Even though a precise
determination of the internalization mechanisms of LPD com-
plexes and lipoplexes is beyond the scope of the present study, we
claim that potential differences in their internalization efficiency,
if any, should not be size regulated. In summary, size and surface
charge of complexes could not be taken into account to justify
differences in TE.
It is the surface of the gene delivery system that is recognized
and processed by cells, and this has important implications for
safety considerations and the practice of nanomedicine.3033
From this point of view, surface properties of LPD complexes
and lipoplexes were found to be largely different from each other.
Figure 11. Confocal microscopy of CHO-K1 cells 4 h after treatment with LPD complexes (A) and lipoplexes (B). Green fluorescence fromNBD lipids
forming LPD complexes was clearly localized, while DNA (red fluorescence) had visibly spread into the cytoplasm. DOTAP/DNA lipoplexes were
distributed throughout the cytoplasm and to some extent at the cell periphery. Colocalization of green and red fluorescence signals suggests that
lipoplexes are intact with DNA trapped within.
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Proteomics experiments (Figure 5, top) showed that surface of
LPD complexes resembles that of pure DOTAP CLs while that
of lipoplexes is partly decorated with adsorbed DNA molecules.
The latter finding is in very good agreement with the recent
suggestion that the position of the negatively charged DNA is not
controlled in the lipoplex system.19 This aspect is potentially
detrimental for in vivo application because interactions between
negatively charged DNA and positively charged serum compo-
nents have been found to result in the formation of large
aggregates and would also result in undesirable lung accumula-
tion. On the other side, encapsulating pDNA in the lipid
envelope would be an ideal strategy to shield the mutual
interactions between DNA and basic serum proteins.10,1218
When in the cytosol, the ability of a nonviral vector to escape
from the endosomal compartment determines the carrier’s
transfection ability. Exposure to the acidic and degradative
lysosomal compartment reduces the transfection efficiency of
nonviral vectors. Therefore, enhanced escape from the acidic
endosomes by the proton sponge effect50 or by chemical and
physical endosomolytic agents51 has been pursued to help
surmount this cytoplasmic barrier. Most lipid/DNA complexes
are ordered structures. In cells, they may be presumed to interact
with a number of cellular membranes, during which DNAmay be
released gradually only after the lipoplex has acquired enough
anionic lipids to neutralize the cationic charge and to rearrange
into a structure from which the DNA can escape. Thus, inter-
mixing of cellular lipids with lipoplex lipids is presumed to be a
necessary step in transfection.52 Upon nanocarriercellular
membrane interaction, anionic cellular lipids laterally diffuse into
the complex and locally neutralize cationic lipids.52 Formation of
cationic/anionic mixed bilayers is expected to weaken the
electrostatic attraction between cationic lipoplex lipids and
anionic DNA molecules. Only when the membrane charge
density of cationic membranes is completely neutralized by
anionic lipids does DNA start to escape from complexes
appreciably.53 SAXS measurements showed that DNA is not
present in the lipid envelope of LPD complexes, but it is confined
in the central core. Thus, anionic cellular lipids can interact with
cationic lipids of LPD complexes without competing with DNA
molecules. According to electrostatic interaction models,52,53 we
hypothesize that the absence of electrostatic competition be-
tween ALs and DNA molecules would result in the high
incorporation efficiency of ALs within LPD membranes, result-
ing in the efficient DNA cytoplasmic release observed by con-
focal microscopy experiments (Figure 11). Numerous contacts
visualized by electron microscopy between lipoplexes and var-
ious cellular membranes54 support a concept of gradual lipoplex
peeling and DNA release. SAXS measurements reported in
Figure 7 show that LPD complexes are made of about 10 lipid
layers in a highly swollen state, while lipoplexes are well ordered
multilamellar structures made of more than 30 alternating lipid/
DNA layers. Given the need for intermixing of anionic cellular
lipids and cationic carrier lipids,5258 our findings take on a
particular significance because the ability of ALs to initiate DNA
release could depend on the extent of membrane fusion (strictly,
lipid mixing) between anionic cellular membranes and lipid
carriers. All these suggestions are well supported by results
reported in Figure 9 showing a plain correlation between
complexes and their ability to release DNA upon interaction
with cellular lipids.
Figure 12 summarizes our present understanding of mecha-
nisms occurring upon complexcell interaction. Because of
similar size and ζ-potential, as well as identical lipid composition,
it is reasonable that complexes enter the cell using similar
internalization mechanisms. However, after complex internaliza-
tion within cells, both LPD complexes and lipoplexes must fuse
with the negatively charged cellular membrane to escape endo-
somes. LPD complexes are more fusogenic than lipoplexes, a
phenomenon that is presumably related to higher interaction
between cationic and anionic cellular lipids due to the absence of
competingDNA in the lipid envelope and to the lower number of
lipid layers to be peeled off. If poor DNA release from lipoplexes
proves to be a critical attribute of poor transfection, an intelligent
strategy to achieve efficient dissociation of pDNA is desirable.
Collectively, these data support the hypothesis that the encapsu-
lation of pDNA in the lipid envelope has a distinct advantage for
releasing DNA in the cytosol. As for intranuclear disposition of
the DNA cargo, coating the core with the minimum number of
fusogenic lipid envelopes ensuring complete DNA protection is
ideal for decoating and for facilitated release.
’CONCLUSIONS
The findings reported herein indicate that a LPD system is
more efficient in transfecting cells if compared to the consoli-
dated lipoplex strategy. Such a system has evident advantage in
terms of endosomal escape and DNA release. Encapsulating
Figure 12. Because of comparable size and ζ-potential, as well as
identical lipid composition, it is reasonable to judge that LPD complexes
and lipoplexes enter the cell using similar internalization mechanisms.
However, after complex internalization, both LPD complexes and
lipoplexes fuse with the negatively charged endosomal membrane.
LPD complexes are more fusogenic than lipoplexes, a phenomenon
that is presumably related to higher interaction between cationic and
anionic cellular lipids due to the absence of competing DNA in the lipid
envelope and to the lower number of lipid layers to be peeled off. DNA
release from endosomes is not a relevant barrier for LPD complexes,
while DOTAP/DNA lipoplexes remained largely intact and accumu-
lated at the nuclear membrane without releasing DNA abundantly.
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pDNA in the lipid envelope would also be an ideal strategy to
shield the mutual interactions between DNA and basic serum
proteins for in vivo applications as well as to better investigate the
interaction between nanocarriers and cellular compartments.
The findings reported in this study promise to be useful for the
development of efficient gene delivery systems for both in vitro
and in vivo applications. In the near future, the very same
packaging strategy will be applied to develop a proper LPD
system equipped with functional devices to control intracellular
fate and intranuclear DNA release. This functionalized envelope-
type system will be able to compete with the efficiency of viral
vectors.
’EXPERIMENTAL SECTION
Liposomes. Cationic 1,2-dioleoyl-3-trimethylammonium propane
(DOTAP) and fluorescently labeled NBD-DOTAP were purchased
from Avanti Polar Lipids (Alabaster, AL) and used without further
purification. DOTAP cationic liposomes (CLs) were prepared accord-
ing to standard protocols.59 In brief, the proper amount of DOTAP was
dissolved in chloroform and the solvent was evaporated under vacuum
for at least 24 h. The obtained lipid films were hydrated with the
appropriate amount of Tris-HCl buffer solution (102 M, pH 7.4) to
achieve the desired final concentration (1 mg/mL). The same experi-
mental protocol was used to prepare negatively charged liposomes made
of anionic lipids dioleoylphosphatidylglycerol (DOPG) and dioleoyl-
phosphatidic acid (DOPA). Liposome dispersions were sonicated to
clarity to prepare SUVs.
LPD Complexes. Protamine sulfate salt (P) from salmon (MW =
5.1 kDa) was purchased from Sigma-Aldrich (St. Louis, MO). For
dynamic light scattering, synchrotron small-angle X-ray scattering
(SAXS), and electrophoresis experiments, calf thymus DNA was used.
For confocal fluorescence microscopy experiments, Cy3-labeled 2.7 kbp
plasmid DNA (Mirus Bio Corporation, Madison, WI) was used.
Positively charged P/DNA microspheres were prepared at seven
protamine/DNA weight ratios RW = 0.25, 0.5, 1, 2, 3, 5, and 10.
Positively charged P/DNA microspheres at RW = 0.5 were mixed with
DOTAP SUVs at nine lipid/DNA volume ratios, RV = 0.25, 0.5, 1, 1.25,
1.75, 2, 3, 5, and 10.
Lipoplexes. When adequate amounts of the DNA solutions were
mixed with suitable volumes of DOTAP liposome dispersions, self-
assembled DOTAP/DNA lipoplexes at nine volume ratios RV = 0.25,
0.5, 1, 1.25, 1.75, 2, 3, 5, and 10 were obtained.
Size and ζ-Potential. The size and size distribution of CLs, LPD,
and lipoplexes were measured at 25 C by a Malvern NanoZetaSizer
spectrometer equipped with a 5 mW HeNe laser (wavelength λ =
632.8 nm) and a digital logarithmic correlator. The normalized intensity
autocorrelation functions were detected at 90 and analyzed by using the
CONTINmethod, which analyzes the autocorrelation function through
an inverse Laplace transform60,61 in order to obtain the distribution of
the diffusion coefficient D of the particles. This coefficient is converted
into an effective hydrodynamic radius RH by using the StokesEinstein
relationship RH = KBT/(6πηD), where KBT is the thermal energy and η
the solvent viscosity. Our clusters invariably show a size distribution, and
the values of the radii reported here correspond to the so-called
“intensity weighted” average.62 The electrophoretic mobility measure-
ments were carried out by means of the laser Doppler electrophoresis
technique, the same apparatus used for size measurements. The mobility
u was converted into the ζ-potential using the Smoluchowski relation
ζ = uη/ε, where η and ε are the viscosity and the permittivity of the
solvent phase, respectively.
One-Dimensional Polyacrylamide Gel Electrophoresis
(1D-PAGE). Human plasma was prepared as described elsewhere.63
An amount of 100 μL of CL, LPD, and lipoplex suspensions (1 mg/mL)
were incubated with 100 μL of plasma on ice. The samples were
centrifuged to pellet the particleprotein complexes. The pellet was
resuspended in phosphate buffered saline (PBS), transferred into a new
vial, and centrifuged again to pellet the particleprotein complexes; this
procedure was repeated twice. The proteins were eluted from the
particles by adding sodium dodecyl sulfate (SDS) sample buffer to the
pellet and boiling the solution. Then the proteins were separated by 10%
1D SDSPAGE gels. Coomassie PhastGel Blue R-350 was used to stain
the gels with gentle agitation, in accordance with the manufacturer’s
manual (GE Healthcare, Milan, Italy). All experiments were conducted
four times to ensure reproducibility of the particleprotein complex
pellet sizes, general pattern, and band intensities on the 1D gels. To
determine molecular weights of proteins after electrophoretic run,
protein molecular weight markers were used. The molecular weights
were finally obtained by means of the dedicated software Kodak
(Rochester, NY).
Synchrotron Small Angle X-ray Scattering. SAXS measure-
ments were performed at the Austrian SAXS station of the synchrotron
light source ELETTRA (Trieste, Italy).64 SAXS patterns were recorded
with gas detectors based on the delay line principle covering the q-ranges
from qmin = 0.04 Å
1 to qmax = 0.5 Å
1 with a resolution of 5 104 Å1
(fwhm). The angular calibration of the detectors was performed with
silver behenate powder (d-spacing of 58.38 Å). The data have been
normalized for variations of the primary beam intensity, corrected for the
detector efficiency, and the background has been subtracted. Exposure
times were typically 300 s. No evidence of radiation damage was
observed in the X-ray diffraction patterns. In both experimental sessions
the sample was held in a 1 mm glass capillary (Hilgenberg, Malsfeld,
Germany) and the measurements were performed at 25 C with a
precision of 0.1 C.
Transfection Efficiency. Transfection efficiency is evaluated by
the expression of reporter firefly luciferase gene and measured by the
luciferase reporter assay. Fibroblasts 3T3 NIH, CHO, Hek293, and
A1765 cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) with GlutaMAX-I (Invitrogen) supplemented with 10% fetal
bovine serum (FBS, Invitrogen) at 37 C and 5% CO2 atmosphere,
splitting cells every 24 days to maintain monolayer coverage. Twenty-
four hours before transfection 150 000 cells were seeded per well into
24-well culture plates in order to reach 7080% confluence during
transfection. For transfection experiments, plasmid DNA (pGL3 control
vector, which codifies for firefly luciferase under the control of SV40
promoter) (Promega, Madison, WI) was employed. Both LPD nano-
particles and lipoplexes were prepared at a fixed lipid/DNA volume
ratio, RV = 2. This value was chosen because it corresponds to a typical
plateau value. LPD complexes and lipoplexes were prepared inOptimem
(Invitrogen) by mixing, for each well of 24-well plates, 0.5 μg of pDNA,
condensed or not with protamine, with 10 μL of sonicated lipid
dispersion (0.5 mg/mL). These complexes were left for 20 min at room
temperature before adding them to the cells. The cells were incubated
with lipoplexes in Optimem (Invitrogen) for 3 h to permit transient
transfection before they were incubated in 1 mL of growth medium for
24 h. Finally, cells were whashed in PBS and harvested in 200 μL of 1
reporter lysis buffer (Promega). Of the cell suspension 20 μLwas diluted
in 100 μL of luciferase reaction buffer (Promega), and the luminescence
was measured after 10 s using a luminometer (Berthold). Results were
espressed as relative light units per mg of cell proteins as determined by
Bio-Rad protein assay dye reagent (Bio-Rad). Each condition was
performed in quadruplicate and repeated three times.
Electrophoresis on Agarose Gels. Electrophoresis studies
were conducted on 1% agarose gel containing ethidium bromide in
TrisborateEDTA (TBE) buffer as elsewhere described.58 LPD com-
plexes and lipoplexes were prepared by mixing 4 μg of pDNA, condensed
or notwith protamine,with 45μLof lipid dispersion (1mg/mLDOTAP).
These complexes were left for 20 min at room temperature before
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incubating them with (i) Tris-HCl buffer solution (incubation time
03 h), (ii) fetal bovine serum (FBS) (incubation time 03 h), and
negatively charged liposomes (DOPA, DOPG) (incubation time 1 h).
Naked plasmid DNA, P/DNA microspheres, LPD complexes, and
lipoplexes (upon interaction with Tris-HCl buffer solution, serum,
and cellular lipids at differentR values) were analyzed by electrophoresis.
For this purpose, 10 μL of each sample was mixed with 2 μL of loading
buffer (glycerol 30%, bromophenol blue 0.25%) and subjected to
agarose gel electrophoresis for 1 h at 80 V. The electrophoresis gel
was visualized and digitally photographed using a Kodak image station,
model 2000 R (Kodak, Rochester, NY). Digital photographs were
enhanced using dedicated software (Kodak MI, Kodak).66
Confocal Fluorescence Microscopy Experiments. Chinese
hamster ovary (CHO-K1) cells were cultured and maintained in a
humidified, 5%CO2 atmosphere at 37 C inDulbecco’smodified Eagle’s
medium (Gibco, Paisley, U.K.) supplemented with 10% fetal bovine
serum and nonessential amino acids, splitting the cells every 24 days to
maintain monolayer coverage. For transfection experiments, lipoplexes
were prepared in PBS (Invitrogen, Carlsbad, CA) by mixing 0.5 μg of
Cy3-labeled plasmid DNA with 10 μL of sonicated lipid dispersions.
These complexes were left for 20 min at room temperature before
adding them to the cells. Confocal fluorescence microscopy experiments
were performed with the Olympus Fluoview 1000 (Olympus, Melville,
NY) confocal microscope.
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A shotgun proteomics approach was used to characterize and compare the proteins that lead to the
formation of a rich ‘‘protein corona’’ adsorbed onto the surfaces of cationic liposomes (CLs), lipoplexes,
and lipid/polycation/DNA (LPD) complexes, when they come into contact with plasma. After separation
of the nanoparticle–protein complex from plasma, the protein mixture was digested, and peptides were
analyzed by nanoliquid chromatography–Orbitrap LTQ-XL mass spectrometry. The number of proteins
bound to lipoplexes was double that of those identified in the corona of CLs (208 vs 105), while 77 pro-
teins were common to both coronas. The number of proteins bound to the surface of the LPD complexes
(158, 133 of which are common to lipoplexes) is intermediate between those found in the protein corona
of both CLs and lipoplexes. About half of them were found in the protein corona of CLs. By overlapping the
three formulations, it can be seen that only 12 proteins are peculiar to LPD complexes. These results may
help in designing gene delivery systems capable of binding the minimum possible quantity of proteins
that influence transfection negatively, binding selectively proteins capable of helping in steering
in vivo the vector toward the target, and obtaining more efficient and effective gene therapy.
 2011 Elsevier Inc. All rights reserved.One of the most important requirements in gene therapy is the
development of safe and efficient gene delivery systems. Retrovi-
ruses, adenoviruses, and adeno-associated viruses are viral vectors
that have shown a high transfection efficiency and are used in
many clinical trials, but may be dangerous for routine clinical
use [1]. In the past two decades, because of the advantages of their
nonimmunogenicity, convenience of handling, and high capability
for the delivery of genetic materials [2,3], nonviral vectors have
attracted a growing interest in the scientific community. Cationic
liposomes (CLs)1 have been extensively studied as nonviral vectors
since the first lipofection was reported in 1987 [4]. One of the most
common nonviral gene delivery vectors is the DNA–cationic lipid
complex (lipoplex). Much work has been done, with different exper-
imental techniques, toward determining the lipoplex microstructure
and stability, as well as on its transfection efficiency [5–14]. The
cationic lipids used as transfection agents are indeed readily andll rights reserved.
Chimica, Sapienza Università
185 Rome, Italy. Fax: +39 06
lia).
us; DOTAP, 1,2-dio-leoyl-3-
l; IAA, iodoacetamide; LPD,
stem; SUVs, small unilamellar
ethyl)aminomethane.easily metabolized by the target tissues [15–17]. One critical ele-
ment for efficient gene delivery is the lipid composition of cationic
liposomes, and many quaternary ammonium surfactants have been
tried, including compounds with alkyl, ether, and ester bonds.
Monocationic lipids are widely used to make most cationic carri-
ers [17–19], and 1,2-dio-leoyl-3-trimethylammonium-propane
(DOTAP), a double chain quaternary ammonium surfactant, is the
most popular cationic lipid used in lipoplex formation. When cat-
ionic lipids are used as carriers of nucleic acids (RNA, DNA), periodic
multilayer structures with DNA chains adsorbed between lipid
membranes are often formed [7,20]. This multilayer structure offers
protection from DNA degradation inside the cell; on the other hand,
the DNA is not properly released from endosomal compartments.
Recently, this problem was overcome by developing the lipid/poly-
cation/DNA (LPD) complex, where the plasmid DNA (pDNA) is
condensed with a polycation and encapsulated by a lipid envelope
[21]. It has been shown that the gene transfer mediated by the
LPD complex works better than the conventional gene transfer using
liposomes for delivering a gene into the liver [22]. Medical adminis-
tration of these gene delivery vectors is frequently carried out by
parenteral injection. Therefore, on exposure to biological media,
the administered gene delivery vectors are immediately covered
by plasma proteins that lead to the formation of a rich ‘‘protein cor-
ona’’ [23–25]. Recent studies have shown that the binding of plasma
Protein corona on cationic nanoparticles surface / A.L. Capriotti et al. / Anal. Biochem. 419 (2011) 180–189 181proteins to nanoparticles, such as gene delivery vectors, is a critical
step in determining their fate in vivo [26,27]. Moreover, plasma pro-
teins play an important role in the identification of foreign bodies in
the bloodstream. Macrophages of the mononuclear phagocytic sys-
tem (MPS) remove unprotected nanoparticles from the bloodstream
within seconds of intravenous administration, thus rendering them
ineffective as site-specific drug delivery devices [28]. Several meth-
ods have been developed to camouflage or mask nanoparticles,
allowing them to temporarily bypass recognition by the MPS and in-
crease their blood circulation half-life [28–30]. From these examples
it is clear that nanoparticle–protein interactions are important for
understanding the circulation, clearance rates, blood half-life, stabil-
ity, immunogenicity, and organ biodistribution of nanoparticles.
Moreover, in order to fully realize the biomedical value of the gene
delivery vectors it is important to improve their functionality in
the biological environment by studying the nanoparticle–protein
interactions.
In the present study, we compare the binding of human plasma
proteins onto the surface of DOTAP CLs, DOTAP/DNA lipoplexes,
and DOTAP/protamine/DNA complexes. For this purpose, we have
employed a shotgun proteomics approach based on centrifugation
for separating the nanoparticle–protein complex, followed by
‘‘in-solution’’ proteolytic digestion of the whole protein mixture,
and determination of the resulting peptides by nano-high-perfor-
mance liquid chromatography (nano-HPLC) coupled with a high-
resolution Orbitrap LTQ-XL mass spectrometer.
To the authors’ best knowledge, this is the first study using this
approach to characterize the protein corona of cationic liposomes,
lipoplexes, and lipid/polycation/DNA complexes. We found that
these nanoparticles are capable of binding different plasma protein
categories with important biological functions, such as lipopro-
teins, immunoglobulins, acute-phase proteins, proteins which play
an essential role in protein synthesis, proteins strongly related to
cellular activity, and proteins involved in complement pathways
and coagulation. These results could help in designing gene deliv-
ery systems capable of binding selectively certain proteins rather
than others, and of steering their biodistribution in vivo so as to ob-
tain a more efficient and effective gene therapy.Materials and methods
Reagents and chemicals
DOTAP was purchased from Avanti Polar Lipids (Alabaster, AL),
and used without further purification. Calf thymus (CT) Na–DNA
and protamine sulfate salt (P) from salmon (MW = 5.1 kDa) were
purchased from Sigma–Aldrich (St. Louis, MO). Tris(hydroxy-
methyl)aminomethane (Tris), sodium chloride, polyacrylamide
ethylenediaminetetraacetic acid (EDTA), iodoacetamide (IAA),
1,4-dithiothreitol (DTT), ammonium bicarbonate, and Coomassie
PhastGel Blue R-350 were purchased from GE Healthcare (Amer-
sham Biosciences, Uppsala, Sweden). All organic solvents were
the highest grade available from Carlo Erba Reagents (Milan, Italy).
Ultrapure water was produced from distilled water by a Milli-Q
system (Millipore Corporation, Billerica, MA, USA). Protein LoBind
tubes were obtained from Eppendorf (Hamburg, Germany). Porcine
trypsin (modified, sequencing grade) was commercialized by
Promega (Madison, WI, USA).Human plasma collection, preparation, and storage
Human whole blood was obtained from the Experimental
Medicine Department (Sapienza University of Rome) by venipunc-
ture of healthy volunteers aged 20–40 years, by means of a BD P100
Blood Collection System (Franklin Lakes, NJ, USA), with proteaseinhibitors cocktail and K2EDTA anticoagulant. Each tubewas turned
upside down 10 times to ensure mixing of blood with the K2EDTA
and, immediately after sediment formation, centrifuged for
10 min at 1000g for 5 min to pellet the blood cells. After verifying
the absence of hemolysis, the supernatant plasma was removed
and pooled to reduce the overall subject-to-subject variation and
to reduce differences between individuals. The pooled plasma
was split into 200-lL aliquots, and stored at 80 C in labeled
Protein LoBind tubes to ensure plasma stability during storage.
When plasma was used for experiments, aliquots were thawed at
4 C and then allowed to warm at room temperature (RT).
Liposomes
DOTAP CLs were prepared according to standard protocols [31].
Briefly, 5 mg of DOTAP was dissolved in 100 lL of chloroform and
then evaporated under vacuum for at least 24 h. Then the lipid
films obtained were hydrated with 5 mL of 10 mmol L1 Tris–HCl
(pH 7.4), 150 mmol L1 NaCl, 1 mmol L1 EDTA to achieve the
desired final lipid concentration (1 mg mL1). Small unilamellar
liposomes (SUVs), with mean diameter around 100 nm, were
produced by sonication to clarity.
Lipoplexes
Self-assembled DOTAP/DNA lipoplexes, at a single lipid/DNA
volume ratio (Rv) (Rv = DOTAP/DNA (vol/vol) = 1) were obtained
by mixing 20 lL of the 1 mg mL1 CT DNA solution to 100 lL of
CLs SUVs dispersion. At this volume ratio, lipoplexes exhibited
the lowest colloidal dimensions (about 200 nm, data not reported)
and were positively charged (about 50 mV, data not reported) [32].
LPD complexes
Negatively charged P/DNA microspheres were prepared at a
protamine/DNA weight ratio (Rw) of 0.5 [32]. LPD complexes were
prepared by mixing P/DNA microspheres with DOTAP SUVs at a
single lipid/DNA volume ratio (Rv = DOTAP/DNA (vol/vol) = 1). At
this volume ratio, LPD systems exhibited the lowest colloidal
dimensions (about 200 nm, data not reported), and were positively
charged (about 45 mV, data not reported).
Incubation of CLs, lipoplexes, and LPD complexes with plasma and
centrifugation
The incubation procedure was conducted as previously de-
scribed [32], with minor modifications. Two hundred microliters
of CL suspension (1 mg mL1) was added to 200 lL of plasma in
the dissolving buffer and incubated at 37 C for 1 h to promote
aggregation of the plasma proteins onto the surface of nanoparti-
cles. The same procedure was used for lipoplexes and LPD com-
plexes. The samples were centrifuged at 15,000g for 10 min to
pellet the nanoparticle–protein complexes. The pellet was washed
three times with 250 lL of the dissolving buffer, using a vortex
mixer, and then the sample was transferred into a new Protein
LoBind tube and centrifuged again to pellet the nanoparticle–
protein complexes. The tubes were changed after each washing
step to minimize contamination from plasma proteins bound to
the tube walls, and plasma without nanoparticles was used as a
control to ensure there was no protein precipitation.
In-solution trypsin digestion
The enzymatic digestion procedure was conducted as previ-
ously described [32]. Briefly, the nanoparticle–protein complexes
were resuspended in 40 lL of 8 mol L1 urea solution in
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incubated at 37 C for 1 h under slight agitation to denature pro-
teins adsorbed onto the nanoparticle surface. Afterward, 8 lL of
200 mmol L1 IAA was added to the samples that were then incu-
bated at RT for 1 h in the dark. Subsequently, 8 lL of 200 mmol L1
DTT was added and incubated at 37 C for 1 h, under slight agita-
tion, to consume any leftover alkylating agent and to avoid trypsin
alkylation. The sample solutions were then diluted with
50 mmol L1 NH4HCO3 to obtain a final urea concentration of
1 mol L1. Reconstituted trypsin solution (20 lg mL1 in
50 mmol L1 NH4HCO3) was added to ensure a minimum en-
zyme-to-substrate ratio of 1/20. The samples were allowed to di-
gest rotating overnight at 37 C. The digestion was quenched by
adding HCOOH. Digested samples were desalted by using an SPE
C18 column (Bond Elut 1CC LRC-C18, Varian, Palo Alto, CA, USA)
conditioned with acetonitrile and rinsed with 0.1% TFA. Peptides
were eluted from the SPE column with 0.5 mL of CH3CN/H2O
(50/50, v/v) containing 0.05% TFA and were dried in a Speed-Vac
SC 250 Express (Thermo Savant, Holbrook, NY, USA). Each sample
was reconstituted with 500 lL of the 0.1% HCOOH solution.
Digested samples were stored at 80 C until analysis. Three
experimental replicates were performed for each type of nanopar-
ticle, CLs, lipoplexes, and LPD complexes, to identify the proteins
adsorbed on their surface forming the protein corona, and to allow
assessment of the reproducibility and reliability of this approach.
Nano-HPLC–mass spectrometry analysis
A Dionex Ultimate 3000 nano-LC system (Sunnyvale, CA, USA)
connected to a linear quadrupole ion trap-orbitrap (LTQ-Orbitrap
XL) mass spectrometer (Thermo Scientific, Bremen, Germany)
equipped with a nanospray ion source was used to analyze tryptic
peptides. Peptide mixtures were enriched injecting a 5-lL aliquot
of the sample on a 300 lm i.d.  5 mm Acclaim PepMap 100 C18
(5 lm particle size, 100 Å pore size) l-precolumn (Dionex),
employing a premixed mobile phase H2O/CH3CN 98/2 (v/v) (phase
C) containing 0.1% (v/v) HCOOH at a flow rate of 10 lL min1.
Peptides were separated on a Biobasic 18 (5 lm particle size,
300 Å pore size) 75 lm i.d.  100 mm, 15 lm tip picofrit column
(Thermo Scientific, Bellefonte, PA, USA) connected in series with
the concentrator column and operated at a flow rate of
250 nL min1. LC gradient was optimized to detect the largest set
of peptides using H2O/HCOOH (99.9/0.1, v/v) as phase A and
CH3CN/HCOOH (99.9/0.1, v/v) as phase B. A 120-min gradient was
used; after an isocratic step at 5% B for 5 min, B was linearly in-
creased to 30% within 75 min; afterward, B was increased to 80%
within 5 min, and to 95% within the following 10 min to rinse the
column. Finally, B was restored to 5% over 1 min and the column
reequilibrated for 24 min. The mass spectrometer was operated in
data-dependent mode to automatically switch between Orbitrap-
MS and LTQ-MS/MS acquisition (m/z range 350–1800, resolution
60,000) using the ‘‘TOP5 strategy.’’ In brief, a scan cycle was initi-
ated with a full scan of high mass accuracy in the Orbitrap analyzer
and followed byMS/MS scans in the linear ion trap on the five most
intense precursor ions with dynamic exclusion of previously se-
lected ions. This dynamic exclusion consisted of twoMS/MS spectra
acquisitions of the most abundant ions during a period of 30 s, and
then the exclusion of these ions for the followed fragmentations for
100 s. The activation type used was CID with a normalized collision
energy set at 35 V. Therefore, a total of five LC-MS/MS runs for each
sample (CLs, lipoplexes, and LPD complexes) were analyzed.
Data processing and statistical validation
Raw data files, obtained from Xcalibur software, were submit-
ted in Mascot Deamon (2.2.04 version, Matrix Science, London,UK) for database search using the ThermoFinnigan LCQ/DECA
RAW file data import filter. Data were searched against human
entries in the SwissProt protein database (57.15 version, 20266
sequences). Trypsin was specified as the proteolytic enzyme with
a maximum of two missed cleavages, and fixed modification
(carbamidomethyl) on cysteine (+57.0215 Da), and variable modi-
fications (oxidation) on methionine (+15.9949 Da) were set for all
searches. The monoisotopic mass tolerance for precursor ions
and fragmentation ions were set to 10 ppm and 0.8 Da, respec-
tively. Charge states of +2, +3, or unknown were selected as precur-
sor ions. Peptide identification and protein assignment were
statistically validated submitting the Mascot result files (.dat) in
the statistical open source Trans-Proteomic Pipeline (TPP) software
(Seattle Proteome Center, SPC, Proteomics Tools: http://tools.pro-
teomecenter.org/software.php). After conversion of the output
Mascot files (.dat) in the .pepXML format files, the PeptideProphet
and ProteinProphet tools [33–35], included in TPP, were employed.Results and discussion
Sample preparation
The nanoparticle–protein complex, formed by the protein
corona and the nanoparticle in the plasma, is the unit actually con-
cerned in biodistribution of the nanoparticles throughout the body
[25]. Therefore, the method used to separate the nanoparticle–pro-
tein complex from excess plasma proteins must not destroy the
complex or induce additional protein binding. For this reason, we
used centrifugation for the separation of the nanoparticle–protein
complex. This approach was chosen in accordance with previous
findings showing that, if performed under controlled conditions
of washing and centrifugation, it does not destroy the complex,
and does not induce the binding of additional proteins [32]. Since
we are working on proteins strongly adsorbed onto liposomes,
the so-called ‘‘hard corona,’’ the nanoparticle–protein complex pel-
let was washed vigorously three times in 250 lL of 10 mmol L1
Tris–HCl, pH 7.4, 150 mmol L1 NaCl, and 1 mmol L1 EDTA, using
a vortex mixer to remove all unbound proteins. We also used a
short centrifugation time (2 min), to avoid sedimentation of large
proteins, formation of protein aggregates, and coprecipitation. De-
spite the stringent washing conditions and the rapid spin a large
number of proteins remained bound to the nanoparticle surface
as components of the protein corona.LC-MS/MS and data analysis
We performed experimental and technical replicates to assess
the accuracy, reproducibility, and reliability of identification of
the protein corona adsorbed onto the surface of CLs, lipoplexes,
and LPD complexes by a shotgun proteomics approach. Three
experimental replicates were performed for each type of nanopar-
ticle. The experimental design provided five LC-MS/MS runs on the
same sample. The runs, called technical replicates, allow the
assessment of the additional variation introduced by the experi-
mental procedure. Then Mascot output files were submitted to
TPP software. To validate the peptide and protein identifications,
two new statistical tools of TPP, namely Peptide Prophet and Pro-
tein Prophet, were applied. The peptide and protein probability
thresholds for running Peptide Prophet and Protein Prophet were
set at 0.75 and 0.90, respectively. Table 1 shows the values of sen-
sitivity (percentage of total correct identifications after restricting
data at a given probability threshold) and error rate (percentage
of total false identifications) of each experimental replicate (5 LC
runs) for each system investigated. Sensitivity and error rate for
any dataset are both affected by the probability threshold, and
Table 1
Protein identification sensitivity and error rate determined by TPP of each experi-
mental replicate (5 LC runs) for each system investigated, calculated with peptide
probabilityP 0.75 and protein probabilityP 0.90.
Experimental replicate Sensitivity Error rate
CLs experimental replicate 1 (5 LC runs) 95.4% 0.3%
CLs experimental replicate 2 (5 LC runs) 92.5% 0.5%
CLs experimental replicate 3 (5 LC runs) 93.7% 0.4%
Lipoplexes experimental replicate 1 (5 LC runs) 88.8% 0.6%
Lipoplexes experimental replicate 2 (5 LC runs) 91.2% 0.6%
Lipoplexes experimental replicate 3 (5 LC runs) 94.2% 0.7%
LPD complexes experimental replicate 1 (5 LC runs) 87.5% 0.8%
LPD complexes experimental replicate 2 (5 LC runs) 81.0% 0.7%
LPD complexes experimental replicate 3 (5 LC runs) 86.2% 0.7%
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of CLs), the chosen thresholds resulted in a low false-positive rate
(error rate of 0.3%), and in an extremely high percentage of correct
identifications (95.4%). On the other hand, in the worst instance
(experimental replicate 2 of LPD complexes), the false-positive rate
was 0.7%, and a good percentage of correct identifications was still
achieved (81.0%). The results show a high degree of reproducibility
with very similar sensitivities, as well as similar values of the error
rate for all sets of analyses. Since the goal of this study is the differ-
ential proteomic analysis of the protein corona adsorbed onto the
surface of the three different lipid-based systems, the acquisition
of an accurate protein profile of each corona is a key step toward
the correct interpretation of the data. When using a proteomic ap-
proach for studying protein mixtures, the reanalysis of the same
sample under the same experimental conditions can lead to the
identification of a different set of proteins from that previously
identified [36–38]. The degree of overlap between two chromato-
graphic runs of the same sample varies depending on the complex-
ity of the sample, ranging from 100% overlap (actually very rare) in
not very complex samples to about 20% overlap in very complex
samples. So the presence (or absence) of a protein in a sample
can be due simply to an incomplete determination rather than to
a biological difference between samples. With this in mind we
decided to perform three experimental replicates, and five techni-
cal replicates. This procedure allowed us to increase the number of
identified proteins for each protein corona of the three investigated
systems. Moreover, in order to increase the confidence of the dif-
ferential proteomics analysis, proteins identified by a single unique
peptide were not considered. Comparing the data obtained
(Table 2) with those found in the literature [39,40], we can affirm
that the percentage of these proteins can be considered low. This
observation makes us confident that relevant biological informa-
tion was not missed, neglecting protein identified with a single
peptide. Lastly, the protein identification in the three experimental
replicates, each of them achieved from the five technical replicates,
was compared.Table 2
Summary of proteins identified in the ‘‘protein corona’’ for each single experimental replic
peptide is included).
Experimental replicate 1 Exper
Proteins onto CLs Total proteins 110 Total
Proteins with 1 unique Pep 20 Prote
% Proteins with 1 unique Pep 18.2% % Pro
Proteins onto lipoplexes Total proteins 234 Total
Proteins with 1 unique Pep 58 Prote
% Proteins with 1 unique Pep 24.2% % Pro
Proteins onto LPD complexes Total proteins 168 Total
Proteins with 1 unique Pep 33 Prote
% Proteins with 1 unique Pep 19.6% % ProTable 3 shows the overlap between the proteins identified on
the surface of the three systems in the three experimental repli-
cates, and the percentage of proteins identified in each experimen-
tal replicate versus the total proteins of the three combined
experimental replicates. The latter parameter (percentage) ranges
from 69.6% (experimental replicate 2 of LPD complexes) to 90.5%
(experimental replicate 2 of CLs). A more thorough reading of the
data shown in Table 3 prompts two relevant observations. First,
the number of proteins overlapping, among the proteins identified
on the surface of the three systems in the three experimental rep-
licates, is very high. This is certainly due to the low complexity of
protein mixtures, combined with the high number of chromato-
graphic runs. Second, the variation in the percentage of proteins
identified was found to be larger in the case of LPD complexes. This
result indicates that the type of proteins that bind onto the surface
of LPD complexes changes slightly between experimental repli-
cates. This is probably due to the presence of protamine that could
make the nanoparticles dynamically unstable. On the other hand,
neither CLs nor lipoplexes contain protamine and are supposed
to be more stable systems. Accordingly, the percentages of overlap
among the three experimental replicates are very close to each
other.
In Fig. 1, a Venn diagram showing the relationship among the
proteins identified in the corona of CLs, lipoplexes, and LPD nano-
particles is reported. We observed that lipoplexes bind a number of
proteins larger than those identified on the liposome surface. This
finding can be explained considering that a fraction of DNA is lo-
cated on the surface of nanoparticles. DNA molecules can bind
additional proteins, such as DNA-binding proteins and/or basic
proteins that do not interact with cationic lipid membranes. We
also observed that the number of proteins bound to the surface
of the LPD complexes is intermediate between those found in the
protein corona of both CLs and lipoplexes. In principle, LPD com-
plexes protect inside them the DNA carried; in fact, plasmid DNA
is condensed with protamine and encapsulated by a lipid envelope.
However, the possibility cannot be ruled out that, when CLs are
added to the protamine/DNA dispersion, a fraction of precon-
densed DNA is subtracted by cationic lipids with the result that
some intermediate structures with DNA available to protein
adsorption are formed. This suggestion is further supported by
the observation that the largest percentage of overlap is observed
for lipoplexes and LPD complexes, probably because both these
systems contain DNA. Further information on protein identifica-
tion is provided in supporting data were also the proteins identi-
fied on just one unique peptide are shown.Proteins identified on the surfaces of CLs, lipoplexes, and LPD
complexes
Identified proteins are reported in Table 4. Proteins bound to
lipoplexes were twice the amount of those identified in the coronaate of the three systems (the percentage of proteins identified with only one unique
imental replicate 2 Experimental replicate 3
proteins 118 Total proteins 114
ins with 1 unique Pep 23 Proteins with 1 unique Pep 20
teins with 1 unique Pep 19.5% %Proteins with 1 unique Pep 17.5%
proteins 236 Total proteins 233
ins with 1 unique Pep 50 Proteins with 1 unique Pep 65
teins with 1 unique Pep 21.2% % Proteins with 1 unique Pep 27.9%
proteins 127 Total proteins 137
ins with 1 unique Pep 17 Proteins with 1 unique Pep 21
teins with 1 unique Pep 13.4% % Proteins with 1 unique Pep 15.3%
Table 3
Overlap of identified proteins on the surface of the three systems in the three experimental replicates, each of them achieved from the five technical replicates (the percentage of
proteins identified in each experimental replicate versus the total proteins of the three experimental replicates combined is also reported).
Experimental
replicate 1
Experimental
replicate 2
Experimental
replicate 3
Combined Overlap Not
Overlap
Only
experimental
replicate 1
Only
experimental
replicate 2
Only
experimental
replicate 3
Proteins onto CLs 90 (85.7%) 95 (90.5%) 94 (89.5%) 105 82 13 1 5 7
Proteins onto
Lipoplexes
176 (84.6%) 186 (89.4%) 168 (80.8%) 208 140 26 9 10 7
Proteins onto
LPD
complexes
135 (85.4%) 110 (69.6%) 116 (73.4%) 158 92 47 26 6 15
Fig.1. Venn diagram representing the total number of proteins identified on
nanoparticle surfaces, and their respective overlaps.
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(see also Fig. 1). The majority of them were apolipoproteins, which
interact with lipids forming lipoproteins; immune response-
related proteins, such as complement system proteins, which are
part of the innate immune system; immunoglobulins; acute-phase
proteins; coagulation-related proteins; and cell adhesion proteins.
Most of the proteins found were secreted, but there were some
proteins coming from cellular compartments. Among the proteins
exclusively present in the protein corona of CLs, kininogen1 was
found. Kininogen1 is a multidomain and multifunctional glycopro-
tein, mainly known as precursor of kinins and bradykinin,
important mediators of inflammatory responses [41]. It has been
recently shown that a fragment within D3 has antibacterial activity
and a fragment within D5 possesses cell-binding and heparin-
binding sites, and may be a modulator of the innate immunity
system [42]. Also Lumican was found. Lumican is a glycoprotein,
which contains 4 sulfotyrosin; thus its adsorption might be sec-
ondary to kininogen1 (heparin is a sulfate-rich glycosaminogly-
can), although a ‘‘role of lumican’’ in the innate immune system
has been also hypothesized [43]. Mannan-binding lectine serine
protease1 exerts its function in the lectin pathway of complement,
which performs a key role in the innate immunity system.
It is interesting to observe that most of the proteins specifically
bound to lipoplex were low-abundance proteins, either secreted or
coming from cellular compartments. These proteins are related to
immune response, inflammatory response, blood coagulation,
acute phase, and stress, and they cover most aspects of the cellularfunctions and processes, including cell cycle control, cell motility,
nucleotide metabolism, DNA replication, protein synthesis, glycol-
ysis, and transport. Some groups of metabolically related proteins
found together seem to outline an unexpected scenario. Actin is
one of the most abundant proteins present in multicellular organ-
isms and is the monomeric subunit of microfilaments, one of the
major components of cytoskeleton, which play a very important
role in cytokinesis, cell motility, cell signaling, cell division, etc.
Several studies have revealed a plethora of actin-binding proteins
controlling the variety of actin-based processes [44,45]. Many of
these proteins have been found only in the lipoplexes protein cor-
ona (Table 4), while alpha actinin-1 and pleckstrin are present also
in CLs. In the lipoplexes protein corona, proteins related to DNA
replication, proteins related to nucleotide and RNA synthesis,
DNA or RNA binding, and cell cycle control are also present (Ta-
ble 4). All these proteins are strongly related to cellular activity.
While the majority are nonsecreted proteins, many of them are
typically nuclear or nuclear/cytosolic proteins and are expected
to be present in human plasma at very low levels. This could mean
that a complex interaction among proteins and the DNA carried by
lipoplexes takes place. In addition to histones and other proteins
involved in chromatin dynamic-like nucleophosmin [46], proteins
that play an essential role in protein synthesis, like the elongation
factors [47], are also present.
The surface of LPD complexes was found to bind 158 proteins,
the largest part of which (133) were common to lipoplexes. About
half of them were found in the protein corona of CLs (81). By over-
lapping the three formulations, it can be seen that only 12 proteins
are peculiar to LPD complexes (see also Fig. 1 for these data).
Among them, keratin type1 cuticolar may be a contamination,
and ceruloplasmin, a protein able to bind up to 7 copper ions,
may co-complex Cu2+ with protamine. The remaining 10 proteins
were identified by only two peptides. By comparing the number
of peptides per protein, which is related to the protein concentra-
tion [48], we have concluded that the LPD complexes protein cor-
ona composition is about half way between the two formulations.Conclusion
A wide range of nanostructured systems, both viral and nonvi-
ral, capable of delivering any type of genetic material of different
size is available to date. Among nonviral gene carriers, CLs have
been extensively studied. However, there is still an open question
about the mechanisms of their biodistribution in the body. A key
role in determining the biodistribution of any nanostructured
system is surely played by the plasma proteins adsorbed onto their
surface. Although the exact role of each of the proteins adsorbed
onto the surface of the nanoparticles in the clearance and biodistri-
bution is still not clear, it is essential to identify the plasma
proteins of the protein corona that forms when the nanoparticles
are in contact with body fluids such as plasma. Therefore, studies
aimed at characterizing the protein corona are fundamental for
Table 4
Identified proteins on nanoparticle surface (the three systems in the three experimental replicates, each of them achieved from the five technical replicates); proteins identified
by a single unique peptide are not considered.
Protein Protein
probability
Percentage
coverage
Unique
peptides
Description CLs Lipoplexes LPD
complexes
A6NIZ1|RP1BL_HUMAN 1 7.6 2 Ras-related protein Rap-1b-like protein X X
B2RPK0|HGB1A_HUMAN 0.9967 12.8 3 Putative high mobility group protein B1-like 1 X
O00299|CLIC1_HUMAN 0.9999 15.8 3 Chloride intracellular channel protein 1 X
O14791|APOL1_HUMAN 0.9302 6.5 2 Apolipoprotein L1 X X X
O14818|PSA7_HUMAN 0.9999 13.3 2 Proteasome subunit alpha type-7 X
O14950|ML12B_HUMAN 0.9999 16.4 2 Myosin regulatory light chain 12B X
O15144|ARPC2_HUMAN 0.9988 14.3 2 Actin-related protein 2/3 complex subunit 2 X X
O43707|ACTN4_HUMAN 0.9873 3.4 2 Alpha-actinin-4 X
O43866|CD5L_HUMAN 1 32.9 4 CD5 antigen-like X
O60234|GMFG_HUMAN 0.9822 19 2 Glia maturation factor gamma X
O60361|NDK8_HUMAN 0.999 13.9 2 Putative nucleoside diphosphate kinase X
O60814|H2B1K_HUMAN 1 38.1 7 Histone H2B type 1-K X X
O75083|WDR1_HUMAN 1 17.3 3 WD repeat-containing protein 1 X X
O75874|IDHC_HUMAN 0.9999 8.9 2 Isocitrate dehydrogenase [NADP] cytoplasmic X
O76009|KT33A_HUMAN 0.9977 9.9 3 Keratin, type I cuticular Ha3-I X
O95445|APOM_HUMAN 1 26.1 4 Apolipoprotein M X
P00450|CERU_HUMAN 0.9994 8.1 4 Ceruloplasmin X
P00488|F13A_HUMAN 0.999 6 2 Coagulation factor XIII A chain X X
P00558|PGK1_HUMAN 1 26.1 8 Phosphoglycerate kinase 1 X X
P00734|THRB_HUMAN 1 60.6 73 Prothrombin X X X
P00736|C1R_HUMAN 1 9.1 2 Complement C1r subcomponent X X
P00738|HPT_HUMAN 1 29.6 5 Haptoglobin X X X
P00739|HPTR_HUMAN 0.9997 9.8 2 Haptoglobin-related protein X
P00740|FA9_HUMAN 1 47.9 21 Coagulation factor IX X X
P00742|FA10_HUMAN 1 36.1 17 Coagulation factor X X
P00747|PLMN_HUMAN 1 33.6 10 Plasminogen X X
P00751|CFAB_HUMAN 1 25.1 12 Complement factor B X X X
P01009|A1AT_HUMAN 1 41.4 16 Alpha-1-antitrypsin X X X
P01011|AACT_HUMAN 1 14.7 2 Alpha-1-antichymotrypsin X X
P01023|A2MG_HUMAN 0.9984 3 2 Alpha-2-macroglobulin X X X
P01024|CO3_HUMAN 1 72.2 154 Complement C3 X X X
P01031|CO5_HUMAN 1 14.5 15 Complement C5 X X X
P01042|KNG1_HUMAN 1 32.1 33 Kininogen-1 X X
P01591|IGJ_HUMAN 0.9996 23.3 2 Immunoglobulin J chain X
P01620|KV302_HUMAN 0.9991 31.2 2 Ig kappa chain V-III region SIE X X
P01625|KV402_HUMAN 0.9986 23.7 2 Ig kappa chain V-IV region Len X
P01765|HV304_HUMAN 1 16.5 2 Ig heavy chain V-III region TIL X X
P01766|HV305_HUMAN 1 16 2 Ig heavy chain V-III region BRO X
P01834|IGKC_HUMAN 1 82.1 11 Ig kappa chain C region X X X
P01842|LAC_HUMAN 1 65.7 7 Ig lambda chain C regions X X X
P01857|IGHG1_HUMAN 1 41.5 10 Ig gamma-1 chain C region X X X
P01859|IGHG2_HUMAN 1 39 6 Ig gamma-2 chain C region X X
P01860|IGHG3_HUMAN 1 53.1 3 Ig gamma-3 chain C region X X
P01861|IGHG4_HUMAN 1 39.1 2 Ig gamma-4 chain C region X X
P01871|IGHM_HUMAN 1 44.5 16 Ig mu chain C region X X X
P01876|IGHA1_HUMAN 1 34.8 10 Ig alpha-1 chain C region X X X
P02647|APOA1_HUMAN 1 41.2 11 Apolipoprotein A-I X X X
P02649|APOE_HUMAN 1 50.5 16 Apolipoprotein E X X X
P02652|APOA2_HUMAN 1 69 13 Apolipoprotein A-II X X X
P02654|APOC1_HUMAN 0.9998 24.1 2 Apolipoprotein C-I X X
P02655|APOC2_HUMAN 1 52.5 7 Apolipoprotein C-II X X X
P02656|APOC3_HUMAN 1 58.6 8 Apolipoprotein C-III X X X
P02671|FIBA_HUMAN 1 49.2 73 Fibrinogen alpha chain X X X
P02675|FIBB_HUMAN 1 75.6 81 Fibrinogen beta chain X X X
P02679|FIBG_HUMAN 1 62 55 Fibrinogen gamma chain X X X
P02730|B3AT_HUMAN 0.9998 5.5 2 Band 3 anion transport protein X
P02735|SAA_HUMAN 1 27.9 2 Serum amyloid A protein X X X
P02741|CRP_HUMAN 0.9784 11.2 3 C-reactive protein X
P02745|C1QA_HUMAN 1 41.2 19 Complement C1q subcomponent subunit A X X
P02746|C1QB_HUMAN 1 49.8 22 Complement C1q subcomponent subunit B X X
P02747|C1QC_HUMAN 1 50.6 15 Complement C1q subcomponent subunit C X X
P02748|CO9_HUMAN 1 18.6 9 Complement component C9 X X X
P02749|APOH_HUMAN 1 22 4 Beta-2-glycoprotein 1 X X
P02751|FINC_HUMAN 1 3.3 4 Fibronectin X X X
P02760|AMBP_HUMAN 1 25.3 7 Protein AMBP X X X
P02763|A1AG1_HUMAN 0.9994 12.4 3 Alpha-1-acid glycoprotein 1 X
P02765|FETUA_HUMAN 0.9993 19.3 3 Alpha-2-HS-glycoprotein X X X
P02766|TTHY_HUMAN 1 68 9 Transthyretin X X X
P02768|ALBU_HUMAN 1 69 63 Serum albumin X X X
P02774|VTDB_HUMAN 0.9998 5.5 2 Vitamin D-binding protein X X
P02775|CXCL7_HUMAN 0.9988 30.5 3 Platelet basic protein X X X
P02776|PLF4_HUMAN 1 35.6 3 Platelet factor 4 X X
(continued on next page)
Protein corona on cationic nanoparticles surface / A.L. Capriotti et al. / Anal. Biochem. 419 (2011) 180–189 185
Table 4 (continued)
Protein Protein
probability
Percentage
coverage
Unique
peptides
Description CLs Lipoplexes LPD
complexes
P02787|TRFE_HUMAN 1 15 6 Serotransferrin X X X
P02788|TRFL_HUMAN 0.998 3 2 Lactotransferrin X
P02790|HEMO_HUMAN 0.9999 7.4 3 Hemopexin X X
P04003|C4BPA_HUMAN 1 62.5 37 C4b-binding protein alpha chain X X X
P04004|VTNC_HUMAN 1 44.1 34 Vitronectin X X X
P04070|PROC_HUMAN 1 31.2 13 Vitamin K-dependent protein C X
P04075|ALDOA_HUMAN 0.9999 16.2 4 Fructose-bisphosphate aldolase A X
P04114|APOB_HUMAN 1 34.8 112 Apolipoprotein B-100 X X X
P04196|HRG_HUMAN 1 10.5 4 Histidine-rich glycoprotein X X
P04220|MUCB_HUMAN 1 44 2 Ig mu heavy chain disease protein X X
P04264|K2C1_HUMAN 1 13.2 8 Keratin, type II cytoskeletal 1 X X X
P04275|VWF_HUMAN 0.9994 1.1 2 von Willebrand factor X
P04350|TBB4_HUMAN 1 11.5 2 Tubulin beta-4 chain X X
P04406|G3P_HUMAN 1 7.2 2 Glyceraldehyde-3-phosphate dehydrogenase X X X
P05090|APOD_HUMAN 1 10.1 4 Apolipoprotein D X X
P05106|ITB3_HUMAN 0.9903 3.2 2 Integrin beta-3 X X
P05154|IPSP_HUMAN 0.9953 6.2 2 Plasma serine protease inhibitor X
P05546|HEP2_HUMAN 1 60.3 28 Heparin cofactor 2 X X X
P06396|GELS_HUMAN 1 44.4 25 Gelsolin X X X
P06576|ATPB_HUMAN 1 9.1 2 ATP synthase subunit beta, mitochondrial X
P06702|S10A9_HUMAN 0.9993 13.2 2 Protein S100-A9 X
P06727|APOA4_HUMAN 1 51.5 18 Apolipoprotein A-IV X X X
P06733|ENOA_HUMAN 1 34.6 10 Alpha-enolase X X
P06744|G6PI_HUMAN 1 2.7 2 Glucose-6-phosphate isomerase X
P06748|NPM_HUMAN 0.9999 7.1 2 Nucleophosmin X X
P06753|TPM3_HUMAN 1 5.2 2 Tropomyosin alpha-3 chain X X X
P07195|LDHB_HUMAN 1 20.7 6 L-lactate dehydrogenase B chain X X
P07225|PROS_HUMAN 1 46.9 31 Vitamin K-dependent protein S X X X
P07339|CATD_HUMAN 0.9996 11.2 2 Cathepsin D X X
P07355|ANXA2_HUMAN 0.9999 8.8 2 Annexin A2 X
P07357|CO8A_HUMAN 1 5.1 2 Complement component C8 alpha chain X X X
P07358|CO8B_HUMAN 0.9997 9.1 2 Complement component C8 beta chain X X X
P07360|CO8G_HUMAN 1 33.2 4 Complement component C8 gamma chain X X X
P07437|TBB5_HUMAN 1 18.9 4 Tubulin beta chain X X X
P07737|PROF1_HUMAN 1 44.3 8 Profilin-1 X X
P07900|HS90A_HUMAN 1 34.8 18 Heat shock protein HSP 90-alpha X X
P07996|TSP1_HUMAN 1 6 4 Thrombospondin-1 X X X
P08134|RHOC_HUMAN 0.9998 13.5 2 Rho-related GTP-binding protein RhoC X
P08514|ITA2B_HUMAN 1 6.9 3 Integrin alpha-IIb X X X
P08519|APOA_HUMAN 1 43.9 27 Apolipoprotein(a) X X X
P08567|PLEK_HUMAN 1 13.7 4 Pleckstrin X X
P08571|CD14_HUMAN 1 14.7 4 Monocyte differentiation antigen CD14 X X
P08603|CFAH_HUMAN 1 9.2 7 Complement factor H X X
P08697|A2AP_HUMAN 0.9999 14.7 3 Alpha-2-antiplasmin X X
P08709|FA7_HUMAN 1 14.2 4 Coagulation factor VII X
P08758|ANXA5_HUMAN 0.9989 9.7 2 Annexin A5 X
P09429|HMGB1_HUMAN 1 23.3 4 High mobility group protein B1 X X
P09651|ROA1_HUMAN 1 25.3 5 Heterogeneous nuclear ribonucleoprotein A1 X X
P09871|C1S_HUMAN 1 48 29 Complement C1s subcomponent X X
P09874|PARP1_HUMAN 1 7.3 4 Poly [ADP-ribose] polymerase 1 X
P0C0L4|CO4A_HUMAN 1 45 60 Complement C4-A X
P0C0L5|CO4B_HUMAN 1 45 61 Complement C4-B X X X
P10412|H14_HUMAN 1 13.1 4 Histone H1.4 X X
P10643|CO7_HUMAN 1 14.7 8 Complement component C7 X X X
P10809|CH60_HUMAN 0.9993 7.5 2 60 kDa heat shock protein, mitochondrial X
P10909|CLUS_HUMAN 1 41.4 33 Clusterin X X X
P11021|GRP78_HUMAN 1 10.1 4 78 kDa glucose-regulated protein X
P11142|HSP7C_HUMAN 1 38.4 19 Heat shock cognate 71 kDa protein X X
P11597|CETP_HUMAN 0.9785 8.7 2 Cholesteryl ester transfer protein X X X
P11908|PRPS2_HUMAN 0.9913 10.4 2 Ribose-phosphate pyrophosphokinase 2 X
P12004|PCNA_HUMAN 1 16.1 3 Proliferating cell nuclear antigen X X
P12259|FA5_HUMAN 1 15.5 21 Coagulation factor V X
P12814|ACTN1_HUMAN 1 12.8 9 Alpha-actinin-1 X
P13639|EF2_HUMAN 1 21.6 9 Elongation factor 2 X X
P13645|K1C10_HUMAN 1 18.5 6 Keratin, type I cytoskeletal 10 X X X
P13671|CO6_HUMAN 1 6.6 3 Complement component C6 X X X
P13796|PLSL_HUMAN 1 12 3 Plastin-2 X X
P14618|KPYM_HUMAN 1 41.1 18 Pyruvate kinase isozymes M1/M2 X X
P14625|ENPL_HUMAN 1 7.2 2 Endoplasmin X
P15311|EZRI_HUMAN 0.9991 16.6 4 Ezrin X
P17987|TCPA_HUMAN 0.9992 12.9 2 T-complex protein 1 subunit alpha X
P18206|VINC_HUMAN 0.9995 6.7 4 Vinculin X X
P18428|LBP_HUMAN 1 29.9 12 Lipopolysaccharide-binding protein X X X
P19338|NUCL_HUMAN 0.9999 9.4 2 Nucleolin X X
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Table 4 (continued)
Protein Protein
probability
Percentage
coverage
Unique
peptides
Description CLs Lipoplexes LPD
complexes
P19823|ITIH2_HUMAN 1 48.7 52 Inter-alpha-trypsin inhibitor heavy chain H2 X X X
P19827|ITIH1_HUMAN 1 41.9 39 Inter-alpha-trypsin inhibitor heavy chain H1 X X X
P20618|PSB1_HUMAN 0.9982 15.8 2 Proteasome subunit beta type-1 X
P20851|C4BPB_HUMAN 1 30.2 7 C4b-binding protein beta chain X X
P21333|FLNA_HUMAN 0.9995 0.9 2 Filamin-A X X X
P21926|CD9_HUMAN 0.9991 15.4 2 CD9 antigen X
P22314|UBA1_HUMAN 0.9999 7.5 5 Ubiquitin-like modifier-activating enzyme 1 X
P22626|ROA2_HUMAN 1 10.2 2 Heterogeneous nuclear ribonucleoproteins A2/B1 X
P22891|PROZ_HUMAN 1 23.5 9 Vitamin K-dependent protein Z X
P23528|COF1_HUMAN 1 31.9 4 Cofilin-1 X X
P25787|PSA2_HUMAN 1 26.5 5 Proteasome subunit alpha type-2 X X
P26038|MOES_HUMAN 1 35.7 15 Moesin X X
P27169|PON1_HUMAN 1 74.1 33 Serum paraoxonase/arylesterase 1 X X X
P27797|CALR_HUMAN 0.9974 18 3 Calreticulin X X
P27918|PROP_HUMAN 1 19.8 10 Properdin X X X
P28066|PSA5_HUMAN 1 12.9 2 Proteasome subunit alpha type-5 X
P28838|AMPL_HUMAN 0.9999 7.7 3 Cytosol aminopeptidase X X
P29401|TKT_HUMAN 0.9937 7.7 2 Transketolase X
P30101|PDIA3_HUMAN 1 12.5 4 Protein disulfide-isomerase A3 X
P31146|COR1A_HUMAN 1 23.9 7 Coronin-1A X X
P31939|PUR9_HUMAN 1 8.4 2 Bifunctional purine biosynthesis protein PURH X
P31946|1433B_HUMAN 0.9779 8.9 2 14-3-3 protein beta/alpha X
P32119|PRDX2_HUMAN 0.9899 14.6 3 Peroxiredoxin-2 X
P34096|RNAS4_HUMAN 0.9993 21.8 2 Ribonuclease 4 X
P35443|TSP4_HUMAN 1 5.9 2 Thrombospondin-4 X
P35527|K1C9_HUMAN 1 17.8 6 Keratin, type I cytoskeletal 9 X X X
P35542|SAA4_HUMAN 0.9772 17.7 2 Serum amyloid A-4 protein X X X
P35579|MYH9_HUMAN 1 8.2 10 Myosin-9 X X X
P35908|K22E_HUMAN 1 12.8 5 Keratin, type II cytoskeletal 2 epidermal X X X
P36873|PP1G_HUMAN 0.9894 10.8 2 Serine/threonine-protein phosphatase PP1-gamma
catalytic subunit
X
P37802|TAGL2_HUMAN 1 32.7 4 Transgelin-2 X
P40227|TCPZ_HUMAN 0.9991 7.5 2 T-complex protein 1 subunit zeta X
P40925|MDHC_HUMAN 0.9999 15 3 Malate dehydrogenase, cytoplasmic X
P46777|RL5_HUMAN 1 11.8 2 60S ribosomal protein L5 X
P47756|CAPZB_HUMAN 1 24.5 4 F-actin-capping protein subunit beta X X
P48740|MASP1_HUMAN 1 18.5 7 Mannan-binding lectin serine protease 1 X
P49720|PSB3_HUMAN 1 25.9 5 Proteasome subunit beta type-3 X X
P49747|COMP_HUMAN 1 15.5 7 Cartilage oligomeric matrix protein X X
P50395|GDIB_HUMAN 1 18.9 8 Rab GDP dissociation inhibitor beta X X
P51884|LUM_HUMAN 1 36.4 14 Lumican X
P51991|ROA3_HUMAN 0.9971 9 2 Heterogeneous nuclear ribonucleoprotein A3 X
P52209|6PGD_HUMAN 0.9999 4.8 2 6-phosphogluconate dehydrogenase,
decarboxylating
X
P52907|CAZA1_HUMAN 1 22 4 F-actin-capping protein subunit alpha-1 X X
P55056|APOC4_HUMAN 0.9896 20.5 2 Apolipoprotein C-IV X
P55058|PLTP_HUMAN 1 15.8 4 Phospholipid transfer protein X X
P55209|NP1L1_HUMAN 1 17.1 3 Nucleosome assembly protein 1-like 1 X
P59665|DEF1_HUMAN 0.9129 20.2 2 Neutrophil defensin 1 X
P60174|TPIS_HUMAN 1 18.1 3 Triosephosphate isomerase X X
P60660|MYL6_HUMAN 1 19.2 3 Myosin light polypeptide 6 X X
P60709|ACTB_HUMAN 1 60.5 10 Actin, cytoplasmic 1 X X X
P60900|PSA6_HUMAN 1 15.9 3 Proteasome subunit alpha type-6 X X
P60953|CDC42_HUMAN 0.9962 25.7 2 Cell division control protein 42 homolog X
P61158|ARP3_HUMAN 1 19.9 4 Actin-related protein 3 X X
P61204|ARF3_HUMAN 0.9995 9.9 2 ADP-ribosylation factor 3 X
P61224|RAP1B_HUMAN 1 35.3 4 Ras-related protein Rap-1b X X
P61978|HNRPK_HUMAN 1 9.5 2 Heterogeneous nuclear ribonucleoprotein K X
P62805|H4_HUMAN 1 41.7 5 Histone H4 X X
P62937|PPIA_HUMAN 1 58.8 10 Peptidyl-prolyl cis-trans isomerase A X X
P63104|1433Z_HUMAN 1 29 5 14-3-3 protein zeta/delta X X
P67936|TPM4_HUMAN 1 29 5 Tropomyosin alpha-4 chain X
P68104|EF1A1_HUMAN 1 46.8 11 Elongation factor 1-alpha 1 X X
P68363|TBA1B_HUMAN 0.9995 7.1 2 Tubulin alpha-1B chain X X
P68366|TBA4A_HUMAN 0.9991 7.4 2 Tubulin alpha-4A chain X
P68431|H31_HUMAN 0.9985 19.9 3 Histone H3.1 X
P68871|HBB_HUMAN 1 82.3 9 Hemoglobin subunit beta X X X
P69905|HBA_HUMAN 1 76.8 11 Hemoglobin subunit alpha X X X
P78371|TCPB_HUMAN 0.998 12 2 T-complex protein 1 subunit beta X
P78386|KRT85_HUMAN 0.9999 14.2 10 Keratin, type II cuticular Hb5 X
Q00839|HNRPU_HUMAN 1 12.7 7 Heterogeneous nuclear ribonucleoprotein U X X
Q01105|SET_HUMAN 0.9992 8.3 2 Protein SET X
Q01518|CAP1_HUMAN 1 26.3 6 Adenylyl cyclase-associated protein 1 X
Q06033|ITIH3_HUMAN 1 41.3 42 Inter-alpha-trypsin inhibitor heavy chain H3 X X
(continued on next page)
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Table 4 (continued)
Protein Protein
probability
Percentage
coverage
Unique
peptides
Description CLs Lipoplexes LPD
complexes
Q06830|PRDX1_HUMAN 1 31.2 5 Peroxiredoxin-1 X X
Q09028|RBBP4_HUMAN 0.9999 17.2 4 Histone-binding protein RBBP4 X
Q12905|ILF2_HUMAN 1 9.5 2 Interleukin enhancer-binding factor 2 X
Q13103|SPP24_HUMAN 1 17.5 3 Secreted phosphoprotein 24 X X
Q13201|MMRN1_HUMAN 1 3.7 3 Multimerin-1 X
Q13418|ILK_HUMAN 0.9632 11.7 2 Integrin-linked protein kinase X
Q13790|APOF_HUMAN 1 24.4 8 Apolipoprotein F X X
Q14103|HNRPD_HUMAN 0.9997 9.9 2 Heterogeneous nuclear ribonucleoprotein D0 X X
Q14520|HABP2_HUMAN 1 34.1 22 Hyaluronan-binding protein 2 X X X
Q14624|ITIH4_HUMAN 1 9 4 Inter-alpha-trypsin inhibitor heavy chain H4 X X
Q15404|RSU1_HUMAN 0.9996 24.2 2 Ras suppressor protein 1 X
Q16658|FSCN1_HUMAN 0.9937 4.5 2 Fascin X X
Q6Q788|APOA5_HUMAN 0.9999 15.6 3 Apolipoprotein A-V X
Q86UX7|URP2_HUMAN 1 16.6 5 Fermitin family homolog 3 X
Q92688|AN32B_HUMAN 1 25.1 4 Acidic leucine-rich nuclear phosphoprotein 32
family member B
X X
Q92928|RAB1C_HUMAN 0.9998 8.5 2 Putative Ras-related protein Rab-1C X
Q92954|PRG4_HUMAN 0.9994 3.6 2 Proteoglycan 4 X
Q96KN2|CNDP1_HUMAN 1 60.9 28 Beta-Ala-His dipeptidase X
Q96PD5|PGRP2_HUMAN 1 12.3 3 N-acetylmuramoyl-L-alanine amidase X
Q99832|TCPH_HUMAN 1 8.7 2 T-complex protein 1 subunit eta X X
Q9BTT0|AN32E_HUMAN 0.996 12.3 2 Acidic leucine-rich nuclear phosphoprotein 32
family member E
X X
Q9BWP8|COL11_HUMAN 1 18.8 4 Collectin-11 X X
Q9BXR6|FHR5_HUMAN 1 32 7 Complement factor H-related protein 5 X X
Q9H299|SH3L3_HUMAN 0.999 31.2 2 SH3 domain-binding glutamic acid-rich-like protein
3
X
Q9H4B7|TBB1_HUMAN 1 14 3 Tubulin beta-1 chain X
Q9HBI1|PARVB_HUMAN 0.9998 8 2 Beta-parvin X
Q9NQ79|CRAC1_HUMAN 0.999 6.5 2 Cartilage acidic protein 1 X
Q9UK55|ZPI_HUMAN 1 21.4 4 Protein Z-dependent protease inhibitor X X
Q9UQ80|PA2G4_HUMAN 1 18 3 Proliferation-associated protein 2G4 X
Q9Y490|TLN1_HUMAN 1 11.1 14 Talin-1 X X X
Total proteins 105 208 158
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adsorbed protein corona and the complex biodistribution in vivo.
Such investigations can therefore help those who are engaged in
the construction of gene delivery nanocarriers. When the relation-
ship between the physical–chemical properties of nanovectors and
the composition of the adsorbed corona is elucidated, it will be
possible to design gene delivery vectors capable of binding selec-
tively certain proteins rather than others. In this way, it will be
possible to steer their biodistribution in order to carry out efficient
and effective gene therapy.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.ab.2011.08.003.References
[1] E. Marshall, Gene therapy. What to do when clear success comes with an
unclear risk?, Science 298 (2002) 510–511
[2] T.I. Kim, M. Ou, M. Lee, S.W. Kim, Arginine-grafted bioreducible poly(disulfide
amine) for gene delivery systems, Biomaterials 30 (2009) 658–664.
[3] M.A. Mintzer, E.E. Simanek, Nonviral vectors for gene delivery, Chem. Rev. 109
(2009) 259–302.
[4] P.L. Felgner, T.R. Gadek, M. Holm, R. Roman, H.W. Chan, M. Wenz, J.P. Northrop,
G.M. Ringold, M. Danielsen, Lipofection: a highly efficient, lipid-mediated
DNA-transfection procedure, Proc. Natl. Acad. Sci. USA 84 (1987) 7413–7417.
[5] H. Gershon, R. Ghirlando, S.B. Guttman, A. Minsky, Mode of formation and
structural features of DNA-cationic liposome complexes used for transfection,
Biochemistry 32 (1993) 7143–7151.
[6] J. Gustafsson, G. Arvidson, G. Karlsson, M. Almgren, Complexes between
cationic liposomes and DNA visualized by cryo-TEM, Biochim. Biophys. Acta
Biomembr. 1235 (1995) 305–312.
[7] I. Koltover, T. Salditt, J.O. Radler, C.R. Safinya, An inverted hexagonal phase of
cationic liposome–DNA complexes related to DNA release and delivery,
Science 281 (1998) 78–81.[8] D.D. Lasic, H. Strey, M.C.A. Stuart, R. Podgornik, P.M. Frederik, The structure of
DNA–liposome complexes, J. Am. Chem. Soc. 119 (1997) 232–233.
[9] J.O. Radler, I. Koltover, T. Salditt, C.R. Safinya, Structure of DNA–cationic
liposome complexes: DNA intercalation in multilamellar membranes in
distinct interhelical packing regimes, Science 275 (1997) 791–792.
[10] H.E.J. Hofland, L. Shephard, S.M. Sullivan, Formation of stable cationic lipid/
DNA complexes for gene transfer, Proc. Natl. Acad. Sci. USA 93 (1996) 7305–
7309.
[11] N. Ballas, N. Zakai, I. Sela, A. Loyter, A. Loyter, Liposomes bearing a quaternary
ammonium detergent as an efficient vehicle for functional transfer of TMV-
RNA into plant protoplasts, Biochim. Biophys. Acta Biomembr. 939 (1988) 8–
18.
[12] B. Li, S. Li, Y. Tan, D.B. Stolz, S.C. Watkins, L.H. Block, L. Huang, Lyophilization of
cationic lipid–protamine–DNA (LPD) complexes, J. Pharm. Sci. 89 (2000) 355–
364.
[13] K. Hong, W. Zheng, A. Baker, D. Papahadjopoulos, Stabilization of cationic
liposome–plasmid DNA complexes by polyamines and poly(ethylene glycol)-
phospholipid conjugates for efficient in vivo gene delivery, FEBS Lett. 400
(1997) 233–237.
[14] P.C. Ross, M.L. Hensen, R. Supabphol, S.W. Hui, Multilamellar cationic
liposomes are efficient vectors for in vitro gene transfer in serum, J.
Liposome Res. 8 (1998) 499–520.
[15] R. Leventis, J.R. Silvius, Interactions of mammalian cells with lipid dispersions
containing novel metabolizable cationic amphiphiles, Biochim. Biophys. Acta
Biomembr. 1023 (1990) 124–132.
[16] J.K. Rose, L. Buonocore, M.A. Witt, A new cationic liposome reagent mediating
nearly quantitative transfection of animal cells, BioTechniques 10 (4) (1991)
520–525.
[17] X. Gao, L. Huang, A novel cationic liposome reagent for efficient transfection of
mammalian cells, Biochem. Biophys. Res. Commun. 179 (1991) 280–285.
[18] P.L. Felgner, T.R. Gadek, M. Holm, R. Roman, H.W. Chan, M. Wenz, J.P. Northrop,
G.M. Ringold, N. Danielsen, Lipofection: a highly efficient, lipid-mediated DNA-
transfection procedure, Proc. Natl. Acad. Sci. USA 84 (1987) 7413–7417.
[19] J.H. Felgner, R. Kumar, C.N. Sridhar, C.J. Wheeler, Y.J. Tsai, R. Border, P. Ramsey,
M. Martin, P.L. Felgner, Enhanced gene delivery and mechanism studies with a
novel series of cationic lipid formulations, J. Biol. Chem. 269 (1994) 2550–
2561.
[20] G. Caracciolo, R. Caminiti, D. Pozzi, M. Friello, F. Boffi, A.C. Castellano, Self-
assembly of cationic liposomes–DNA complexes: a structural and
thermodynamic study by EDXD, Chem. Phys. Lett. 351 (2002) 222–228.
[21] K. Kogure, R. Moriguchi, K. Sasaki, M. Ueno, S. Futaki, H. Harashima,
Development of efficient packaging method of oligodeoxynucleotides by a
Protein corona on cationic nanoparticles surface / A.L. Capriotti et al. / Anal. Biochem. 419 (2011) 180–189 189condensed nano particle in lipid envelope structure, J. Controlled Release 98
(2004) 317–323.
[22] J. Yamauchi, Y. Hayashi, K. Kajimoto, H. Akita, H. Harashima, Comparison
between a multifunctional envelope-type nano device and lipoplex for
delivery to the liver, Biol. Pharm. Bull. 33 (2010) 926–929.
[23] T. Cedervall, I. Lynch, S. Lindman, T. Berggard, E. Thulin, H. Nilsson, K.A.
Dawson, S. Linse, Understanding the nanoparticle–protein corona using
methods to quantify exchange rates and affinities of proteins for
nanoparticles, Proc. Natl. Acad. Sci. USA 104 (2007) 2050–2055.
[24] B. Sahoo, M. Goswami, S. Nag, S. Maiti, Spontaneous formation of a protein
corona prevents the loss of quantum dot fluorescence in physiological buffers,
Chem. Phys. Lett. 445 (2007) 217–220.
[25] I. Lynch, K.A. Dawson, Protein–nanoparticle interactions, NanoToday 3 (2008)
40–47.
[26] I. Lynch, T. Cedervall, M. Lundqvist, C. Cabaleiro-Lago, S. Linse, K.A. Dawson,
The nanoparticle–protein complex as a biological entity: a complex fluids and
surface science challenge for the 21st century, Adv. Colloid Interface Sci. 134/
135 (2007) 167–74.
[27] D.E. Owens III, N.A. Peppas, Opsonization, biodistribution, and
pharmacokinetics of polymeric nanoparticles, Int. J. Pharm. 307 (2006) 93–
102.
[28] R. Gref, Y. Minamitake, M.T. Peracchia, V. Trubetskoy, V. Torchilin, R. Langer,
Biodegradable long-circulating polymeric nanospheres, Science 263 (1994)
1600–1603.
[29] L. Illum, S.S. Davis, The organ uptake of intravenously administered colloidal
particles can be altered using a non-ionic surfactant (Poloxamer-338), FEBS
Lett. 167 (1984) 79–82.
[30] G. Kaul, M. Amiji, Long-circulating poly(ethylene glycol)-modified gelatin
nanoparticles for intracellular delivery, Pharm. Res. 19 (2002) 1061–1067.
[31] G. Caracciolo, D. Pozzi, R. Caminiti, Lipid mixing upon deoxyribonucleic acid-
induced liposomes fusion investigated by synchrotron small-angle X-ray
scattering, Appl. Phys. Lett. 87 (2005) 133901–133903.
[32] A.L. Capriotti, G. Caracciolo, C. Caruso, D. Pozzi, R. Samperi, A. Laganà, Analysis
of plasma protein adsorption onto DC-Chol-DOPE cationic liposomes by HPLC-
CHIP coupled to a Q-TOF mass spectrometer, Anal. Bional. Chem. 389 (2010)
2777–2894.
[33] A. Keller, A.I. Nesvizhskii, E. Kolker, R. Aebersold, Empirical statistical model to
estimate the accuracy of peptide identifications made by MS/MS and database
search, Anal. Chem. 74 (2002) 383–392.
[34] A. Keller, J. Eng, N. Zhang, X.J. Li, R. Aebersold, A uniform proteomics MS/MS
analysis platform utilizing open XML file formats, Mol. Syst. Biol. 1 (2005) 1–8.
[35] A.I. Nesvizhskii, A. Keller, E. Kolker, R. Aebersold, A statistical model for
identifying proteins by tandem mass spectrometry, Anal. Chem. 75 (2003)
4646–4658.[36] E.C. Yi, M. Marelli, H. Lee, S.O. Purvine, R. Aebersold, J.D. Aitchison, D.R.
Goodlett, Approaching complete peroxisome characterization by gas-phase
fractionation, Electrophoresis 23 (2002) 3205–3216.
[37] C.S. Spahr, M.T. Davis, M.D. McGinley, J.H. Robinson, E.J. Bures, J. Beierle, J.
Mort, P.L. Courchesne, K. Chen, R.C. Wahl, W. Yu, R. Luethy, S.D. Patterson,
Towards defining the urinary proteome using liquid chromatography-tandem
mass spectrometry. I. Profiling an unfractionated tryptic digest, Proteomics 1
(2001) 93–107.
[38] E.C. Koc, W. Burkhart, K. Blackburn, M.B. Moyer, D.M. Schlatzer, A. Moseley, L.L.
Spremulli, The large subunit of the mammalian mitochondrial ribosome.
Analysis of the complement of ribosomal proteins present, J. Biol. Chem. 276
(2001) 43958–43969.
[39] N.V. Welham, M. Yamashita, S.H. Choi, C. Ling, Cross-sample validation
provides enhanced proteome coverage in rat vocal fold mucosa, PLoS One 6
(2011) e17754.
[40] P.D. von Haller, E. Yi, S. Donohoe, K. Vaughn, A. Keller, A.I. Nesvizhskii, J. Eng, X.
Li, D.R. Goodlett, R. Aebersold, J.D. Watts, The application of new software
tools to quantitative protein profiling via isotope-coded affinity tag (ICAT)
and tandem mass spectrometry, Mol. Cell. Proteomics 2 (2003)
428–442.
[41] J.N. Sharma, G.J. Al-Sherif, The kinin system: present and future
pharmacological targets, Am. J. Biomed. Sci. 3 (2) (2011) 156–169.
[42] G. Lalmanach, C. Naudin, F. Lecaille, H. Fritz, Kininogens: more than
cysteine protease inhibitors and kinin precursors, Biochimie 92 (2010)
1568–1579.
[43] F. Wu, N. Vij, L. Roberts, S. Lopez-Briones, S. Joyce, S. Chakravarti, A novel role
of the lumican core protein in bacterial lipopolysaccharide-induced innate
immune response, J. Biol. Chem. 282 (2007) 26409–26417.
[44] A. Disanza, A. Steffen, M. Hertzog, E. Frittoli, K. Rottnerd, G. Scita, Actin
polymerization machinery: the finish line of signaling networks, the starting
point of cellular movement, Cell. Mol. Life Sci. 62 (2005) 955–970.
[45] J. Saarikangas, H. Zhao, P. Lappalainen, Regulation of the actin cytoskeleton-
plasma membrane interplay by phosphoinositides, Physiol. Rev. 90 (2010)
259–289.
[46] S.S. Gadad, P. Senapati, S.H. Syed, R.E. Rajan, J. Shandilya, V. Swaminathan, S.
Chatterjee, E. Colombo, S. Dimitrov, P.G. Pelicci, U. Ranga, T.K. Kundu, The
multifunctional protein nucleophosmin (NPM1) is a human linker histone H1
chaperone, Biochemistry 50 (2011) 2780–2789.
[47] R. Jørgensen, A.R. Merrill, G.R. Andersen, The life and death of translation
elongation factor 2, Biochem. Soc. Trans. 34 (2006) 1–6.
[48] Y. Ishihama, Y. Oda, T. Tabata, T. Sato, T. Nagasu, J. Rappsilber, M. Mann,
Exponentially modified protein abundance index (emPAI) for estimation of
absolute protein amount in proteomics by the number of sequenced peptides
per protein, Mol. Cell Proteomics 4 (2005) 1265–1272.
 
  
VII 
 
ORIGINAL PAPER
Label-free quantitative analysis for studying the interactions
between nanoparticles and plasma proteins
Anna Laura Capriotti & Giulio Caracciolo &
Giuseppe Caruso & Chiara Cavaliere & Daniela Pozzi &
Roberto Samperi & Aldo Laganà
Received: 24 October 2011 /Revised: 19 December 2011 /Accepted: 21 December 2011
# Springer-Verlag 2012
Abstract A shotgun proteomics approach was used to com-
pare human plasma protein binding capability with cationic
liposomes, DNA–cationic lipid complexes (lipoplexes), and
lipid–polycation–DNA (LPD) complexes. Nano-high-
performance liquid chromatography coupled with a high-
resolution LTQ Orbitrap XL mass spectrometer was used to
characterize and compare their protein corona. Spectral
counting and area under curve methods were used to per-
form label-free quantification. Substantial qualitative and
quantitative differences were found among proteins bound
to the three different systems investigated. Protein variety
found on lipoplexes and LPD complexes was richer than
that found on cationic liposomes. There were also signifi-
cant differences between the amounts of protein. Such
results could help in the design of gene-delivery systems,
because some proteins could be more selectively bound
rather than others, and their bio-distribution could be driven
in vivo for more efficient and effective gene therapy.
Keywords Label-free quantification . Proteomics .Mass
spectrometry . Protein corona . Liposome . Lipoplexes .
DOTAP. Gene delivery
Introduction
A major objective of gene therapy is to obtain targeted
vectors that could efficiently transfer genes to specific cell
types. Unfortunately, until now, the lack of such delivery
systems has impeded the introduction of gene therapy into
clinical applications. Ideally, a gene-delivery system should
be stable, biocompatible, nontoxic, and cost effective, and it
should be able to transfer exogenous highly anionic genetic
materials to a tissue-specific site. Viral vectors, including
retroviruses, adenoviruses, and adeno-associated viruses,
have high transfection efficiency and have been used in
multiple clinical trials, but may ultimately be too dangerous
for routine clinical use [1].
In the past two decades, much attention has been devoted
to non-viral vectors: cationic liposomes (CLs) have been
extensively studied [2], and DNA–cationic lipid complexes
(lipoplexes) are among the favourite non-viral gene-delivery
vectors. Monocationic lipids are widely used for fabrication
of cationic carriers [3–5]. 1,2-Dioleoyl-3-trimethylammo-
niumpropane (DOTAP), a double chain quaternary ammo-
nium surfactant, is the most popular for lipoplex formation.
X-ray scattering techniques suggest that when cationic lipids
are used as carriers of nucleic acids (DNA), periodic multi-
layer structures are often formed with DNA chains adsorbed
between lipid membranes [6, 7]. Once inside the cell, such
multilayer structures offer protection from DNA degradation,
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but often prevent adequate DNA release from the endosomal
compartments. To overcome this problem, lipid–polycation–
DNA (LPD) complexes, in which plasmid DNA (pDNA)
condensed with a polycation is encapsulated by a lipid enve-
lope, have recently been developed [8]. Recent studies have
demonstrated the superiority of LPD-mediated gene transfer
over conventional liposomes in delivering a gene to the liver
[9].
Both lipoplexes and LPD complexes are frequently given
via parenteral administration. As with any foreign material,
the body mounts a biological response to such administered
gene-delivery vectors. Upon contact with human plasma,
lipid–DNA complexes are immediately coated by proteins,
and a protein corona is formed around the complexes
[10–12]. Recently, the binding of plasma proteins to nano-
particles, for example gene-delivery vectors, has been iden-
tified as a critical step in determining their fate in vivo [13,
14]. First experiments were directed at isolation and identi-
fication of particle-associated proteins. These studies pro-
vided information about relevant issues, for example
opsonization, suggesting possible strategies for suppressing
immune responses. More recent findings [15] have revealed
that the average composition of the protein corona does not
reflect the relative abundance of proteins in human plasma.
Over time, those with higher affinity may displace the more
abundant proteins, and the resulting biomolecule “hard co-
rona” may contain only a few proteins in a relatively im-
mobile layer, with a more loosely bound layer that is less
well understood. This is a point of substantial general inter-
est because the most abundantly associated proteins do not
necessarily have the most profound effect. Instead, a less
abundant protein with high affinity and specificity for a
particular receptor may be extremely important. Information
on binding affinities and stoichiometry for different combi-
nations of protein corona and nanoparticles would be highly
relevant to classification of the biological effect of the com-
plexes. Furthermore, ranking of the affinities of proteins that
coexist in specific bodily fluids or cellular compartments
would add valuable information. Such accurate quantitative
determination could be the basis for the establishment of a
correlation between protein-adsorption pattern and in vivo
fate of intravenously administered nanoparticles. As a result,
protein quantification is the only strategy we have to reveal
the molecular basis of cell–nanoparticle interactions.
The development of non-gel-based shotgun proteomic
techniques, for example multidimensional protein identifi-
cation technology, has provided powerful tools for studying
large scale protein expression and characterization of com-
plex biological systems [16]. Because of the development of
mass spectrometers with high resolution and high mass
accuracy, label-free quantification of liquid chromatogra-
phy–mass spectrometry (LC–MS) data has become a very
appealing approach for quantitative analysis of biological
samples. Tandem mass spectrometry (MS–MS) label-free
quantification can be performed by two distinct methods:
1. spectral counting, in which the number of spectra
matched to peptides from a protein is used as a surro-
gate measure of protein abundance; and
2. area under the curve (AUC) or signal intensity measure-
ment, in which protein abundance is derived from the
extracted ion chromatograms.
The spectral counting method relies on the simple con-
cept that an increase in protein abundance can increase the
number of its detectable proteolytic peptides, i.e. the total
number of MS–MS spectra that are acquired for that pep-
tide. Liu et al. have demonstrated a linear relationship be-
tween the spectral count and relative protein abundance over
a dynamic range of two orders of magnitude [17]. The AUC
method, based on precursor ion signal intensity, compares
the chromatographic peaks of peptide precursor ion meas-
urements belonging to a specific protein extracted from an
LC–MS–MS run [18–20].
In this study we used a shotgun proteomics approach to
characterize differences between the binding of human plas-
ma proteins to the surface of DOTAP CLs, DOTAP–DNA
lipoplexes, and LPD complexes [21]. LC–MS–MS was
selected as the most suitable method for analysis of the
protein adsorption patterns. This method has been used
successfully in areas such as protein analysis of cell and
body fluids in general and, subsequently, in clinical diagno-
sis. Recently, LC–MS–MS was established for analysis of
adsorbed proteins on nanoparticles for gene delivery [22].
Nano-high-performance liquid chromatography (nano-
HPLC) coupled with a high-resolution LTQ Orbitrap XL
(Thermo Fisher Scientific) mass spectrometer was used for
SC and AUC label-free relative quantification of the inves-
tigated samples. Label-free comparative proteomics is a
relatively new approach that has been used successfully
for different systems (humans, yeast, fly, etc.) [23–26]; as
far as we are aware its application to nanoparticle–protein
interactions has not yet been investigated.
Experimental
Chemicals and reagents
DOTAP cationic lipid was purchased from Avanti Polar
Lipids (Alabaster, AL, USA) and used without further puri-
fication. Calf thymus (CT) Na-DNA and protamine sulfate
salt (P) from salmon (m.w.05.1 kDa) were purchased from
Sigma–Aldrich (St Louis, MO, USA). Ethylenediaminete-
traacetic acid (EDTA), tris(hydroxymethyl)aminomethane
(TRIS), sodium chloride, polyacrylamide, 1,4-dithiothreitol
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(DTT), iodoacetamide (IAA), ammonium bicarbonate, pro-
tein molecular weight standards, and Coomassie PhastGel
Blue R-350 were all purchased from GE Healthcare (Amer-
sham Biosciences, Uppsala, Sweden). All organic solvents
were the highest grade available from Carlo Erba Reagents
(Milan, Italy). Ultrapure water was produced from distilled
water by use of a Milli-Q system (Millipore Corporation,
Billerica, MA, USA). Protein LoBind tubes were obtained
from Eppendorf (Hamburg, Germany). Porcine trypsin
(modified, sequencing grade) was obtained from Promega
(Madison, WI, USA).
Human plasma collection, preparation and storage
Human whole blood was provided by the Dipartimento di
medicina sperimentale of Sapienza Università di Roma.
Blood was extracted by venipuncture from healthy 20–40-
year-old volunteers, by use of the BD P100 Blood Collec-
tion System (Franklin Lakes, NJ, USA) with K2EDTA as
anticoagulant and a protease inhibitors cocktail. Immediate-
ly after blood extraction, each tube was inverted ten times to
ensure mixing of the components, and subsequently centri-
fuged for 10 min at 1,000g to pellet the blood cells. Super-
natant plasma was drawn and the absence of haemolysis was
checked. Plasma specimens were then mixed to reduce
differences between individuals and overall subject-to-
subject variation. Mixed plasma was split into 200-μL vol-
umes and stored at −80 °C in labelled Protein LoBind tubes,
to ensure plasma stability until further use. When used for
experiments, aliquots were thawed at 4 °C and then left to
warm at RT.
Liposomes
CLs were prepared in accordance with standard procedures
[27]. Chloroform (100 μL) was used to dissolve DOTAP
(5 mg) and was then removed under vacuum for 24 h. The
lipid films obtained were hydrated with 5 mL of a dissolving
buffer (Tris–HCl, pH 7.4, 10 mmol L−1; NaCl, 150 mmol L−1;
EDTA, 1 mmol L−1) to achieve a final concentration of
1 mg mL−1. Small unilamellar liposomes (SUVs) were pro-
duced by sonication to clarity (mean diameter approx. 100 nm)
[21].
Lipoplexes
Self-assembled DOTAP–DNA lipoplexes at a single lipid-
to-DNA volume ratio, RV01, were obtained by mixing 20
μL CT DNA solution (1 mg mL−1) with 100 μL of SUVs
dispersion. At this volume ratio, lipoplexes are positively
charged and have the lowest colloidal dimensions [21].
LPD complexes
Negatively charged P–DNA microspheres were prepared at
a protamine-to-DNA weight ratio RW00.5 [26]. P–DNA
microspheres were mixed with SUVs at a single lipid-to-
DNA volume ratio, RV01, to compare protein binding ca-
pacity of lipoplexes and LPD complexes properly. At this
volume ratio, LPD complexes are positively charged and
have the lowest colloidal dimensions [21].
CLs, lipoplexes, and LPD complexes incubation
with plasma and centrifugation
The incubation procedure was conducted as described else-
where [22]. Plasma-protein binding to CLs, lipoplexes, and
LPD complexes was investigated by incubating 200 μL of
each system, separately, with an equal amount of plasma in the
dissolving buffer at 37 °C for 1 h. Solutions were then centri-
fuged at 15,000g for 10 min to separate the nanoparticle–
protein complexes. Pellets were washed with 250 μL dissolv-
ing buffer, by use of a vortex mixer, transferred to a new
Protein LoBind tube, and centrifuged again. To reduce con-
tamination from plasma proteins bound to the tube wall, three
washings were performed for each pellet. To check the repro-
ducibility of nanoparticle–protein corona complex formation,
three experimental replicates were performed for each system.
A plasma aliquot not incubated with nanoparticles was sub-
jected to the same procedure as control, to verify the absence
of protein precipitation.
In-solution trypsin digestion
Protein denaturation and disulfide bonds reduction was
performed with a solution prepared with 40 μL urea
(8 mol L−1)–ammonium bicarbonate (50 mmol L−1) and
2 μL 1,4-dithiothreitol (200 mmol L−1), in which nanopar-
ticle–protein systems were suspended and kept in incubation
at 37 °C for 1 h under slight agitation. Carbamidomethylation
of thiol groups was accomplished by addition of iodoaceta-
mide (8 μL, 200 mmol L−1) and incubation at RT for 1 h in the
dark. Subsequently, to consume any leftover alkylating agent
and to avoid trypsin alkylation, 8 μL 1,4-dithiothreitol
(200 mmol L−1) was added and samples were incubated at
37 °C for 1 h, with slight agitation. Solutions were then diluted
with ammonium bicarbonate (50 mmol L−1) to obtain a final
urea concentration of 1 mol L−1, and were incubated overnight
at 37 °C with a solution of trypsin (20 μg mL−1)–ammonium
bicarbonate (50 mmol L−1) to ensure a minimum enzyme-to-
substrate ratio of 1:20. Enzymatic digestion was quenched
acidifying with formic acid.
Digested samples were desalted by use of an SPE C18
column (Bond Elut 1 cc LRC-C18; Varian, Palo Alto, CA,
USA) conditioned with acetonitrile and rinsed with 0.1% TFA.
Label-free quantitative analysis for studying the interactions
Peptides were eluted from the SPE column with 0.5 mL ace-
tonitrile–water (50:50, v/v) containing 0.05% TFA and were
dried in a Speed-Vac SC 250 Express (Thermo Savant, Hol-
brook, NY, USA). Each sample was re-constituted with formic
acid (500 μL, 0.1%) and stored at −80 °C until analysis.
Nano HPLC–mass spectrometric analysis
Tryptic peptides were analyzed by use of a Dionex (Sunny-
vale CA, USA) Ultimate 3000 nano-LC system connected
to a linear quadrupole ion-trap Orbitrap (LTQ Orbitrap XL)
mass spectrometer (ThermoScientific, Bremen, Germany)
equipped with a nanospray ion source.
Peptide mixtures were enriched by injecting 5 μL sample,
on-line, on to a 300 μm i.d.×5 mm Acclaim PepMap 100 C18
(5 μm particle size, 100 Å pore size) μ-precolumn (Dionex),
using a premixed mobile phase H2O–CH3CN 98:2 (v/v)
(phase C) containing 0.1% (v/v) HCOOH at a flow-rate of
10 μL min−1.
Peptides were separated on a Biobasic 18 (5 μm particle
size, 300 Å pore size) 75 μm i.d.×100 mm, 15 μm tip
picofrit column (Thermo Scientific, Bellefonte, PA, USA)
with a flow rate of 250 nL min−1. The LC gradient was
optimized to detect the largest set of peptides by using H2O–
HCOOH (99.9:0.1, v/v) as phase A and CH3CN–HCOOH
(99.9:0.1, v/v) as phase B. A 120-min gradient was used;
after an isocratic step at 5% B for 5 min, B was linearly
increased to 30% within 75 min; afterwards, B was in-
creased to 80% within 5 min, and to 95% within the follow-
ing 10 min to rinse the column. Finally, B was reduced to
5% over 1 min and the column re-equilibrated for 24 min.
The mass spectrometer was operated in the data-dependent
mode to automatically switch between Orbitrap-MS and
LTQ-MS–MS acquisition (m/z range 400–1,800, 60,000
resolution) using the data-dependant acquisition, DDA,
“TOP5 strategy”. In brief, each scan cycle begins with a
full scan at high resolution and high mass accuracy in the
Orbitrap analyzer, followed by MS–MS scans in the linear
ion trap on the five most intense precursor ions. Dynamic
exclusion consists of two MS–MS spectra acquisitions of
the most abundant ions during a period of 30 s and then
excluding the ion from subsequent fragmentations for 100 s.
The activation type used was CID with a normalized
collision energy set at 35 V. To assess the additional varia-
tion introduced into the measurements by the experimental
Table 1 Number of validated proteins found for each sample accord-
ing to Proteome Discoverer and Scaffold analysis
CLs Lipoplexes LPD
Complexes
Overall
Proteome Discoverer 104 227 186 306
Scaffold 110 231 189 268
Fig. 1 Venn diagram representing the distribution of (a) number of
validated proteins according to Proteome Discoverer, (b) number of
validated proteins according to Scaffold
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procedure and to increase the number of identified pro-
teins, the experimental design provided five replicate
(LC–MS–MS runs) for each of the three experimental
replicates.
Identification of proteins
Raw MS–MS data files from Xcalibur software (version
2.0.7 SP1; Thermo Fisher Scientific) were submitted to
Mascot Deamon (version 2.2.04, Matrix Science, London,
UK) for database search against the IPI human database
(version 3.79). A ThermoFinnigan LCQ/DECA RAW file
data import filter was used. In brief, two missed cleavages
were allowed and a precursor mass tolerance of 10 ppm was
used in combination with 0.8 Da fragment mass tolerance;
acetylation (N-term), oxidation (M), and deamidation (N, Q)
were used as dynamic modifications; carbamidomethylation
(C) was used as static modification. Mascot ion scores >25
on unique peptides were used for further processing, with a
significance threshold >0.05.
Proteome Discoverer and SIEVE analysis
Proteome Discoverer software (version 1.3.0.339; Thermo
Fisher Scientific) was used to validate identification of
Mascot proteins. Proteins containing at least two identified
peptides were accepted.
SIEVE software (version 1.3; Thermo Fisher Scientific)
was used to execute differential quantitative analysis on val-
idated proteins. Alignment and framing (peak detection) were
performed as follows: data were processed in the interval 13–
80 min of the chromatographic separation (also processed for
peptide identification), frames fromMS–MS scans were used,
a maximum of 200,000 frames was set together with 105 as
signal threshold, and peptides with MZStart 400 and MZStop
1,800, MZWidth 0.01, and RTWidth 2.5 were used.
Scaffold analysis
Scaffold [28] (version 3.1.2; Proteome Software, Portland,
OR, USA) was also used to validate MS–MS based peptide
Table 2 SIEVE relative quantitative analysis results showing protein
abundance (signal intensity) ratios for proteins having CV lower than
10%, P values lower than 0.001, Mascot scores higher than 25, pep-
tides unique assignment, and abundance ratio higher than 2 or lower
than 0.5 with a coefficient of variance lower than 0.33. Values in
parentheses refer to proteins that do not satisfy SIEVE’s restriction
but do satisfy Scaffold’s
Protein name Accession
no.
Lipoplexes/Cls
abundance ratio
LPD complexes/CLs
abundance ratio
LPD complexes/
lipoplexes abundance ratio
HSPA5 HSPA5 protein IPI00003362 0.20±0.04
SAA4 Serum amyloid A_4 protein IPI00019399 0.16±0.04
Prothrombin (Fragment) IPI00019568 0.010±0.003
PLG Plasminogen IPI00019580 4.5±1.5 0.44±0.09
C4BPA C4b_binding protein alpha chain IPI00021727 0.04±0.01
APOE Apolipoprotein E IPI00021842 (1.3±0.2) 0.29±0.03
APOA2 Apolipoprotein A_II IPI00021854 0.33±0.06
APOC2 Apolipoprotein C_II IPI00021856 0.7±0.1
APOB Apolipoprotein B_100 IPI00022229 2.7±0.1 (0.59±0.07) 0.29±0.02
C1QC Complement C1q subcomponent subunit C IPI00022394 0.003±0.001
C9 Complement component C9 IPI00022395 (1.8±0.3) 0.28±0.04
PF4 Platelet factor 4 IPI00022446 (1.6±0.4) 0.07±0.01
LPA Apolipoprotein(a) IPI00029168 2.2±0.2 0.49±0.06
Complement C5 IPI00032291 (2.6±1.0)
LBP Lipopolysaccharide_binding protein IPI00032311 3.0±0.6 0.20±0.06
PFN1 Profilin_1 IPI00216691 13±4 0.18±0.05
PON1 Serum paraoxonase/arylesterase 1 IPI00218732 (2.0±1.6) 0.010±0.003
THBS1 Thrombospondin_1 IPI00296099 0.12±0.02
VTN Vitronectin IPI00298971 (1.5±0.1) 0.15±0.01
TLN1 Talin_1 IPI00298994 2.1±0.3 0.09±0.01
HIST4H4 Histone H4 IPI00453473 0.33±0.07
C3 Complement C3 (Fragment) IPI00783987 2.1±0.4 (0.9±0.2)
C6 Complement component 6 precursor IPI00879709 0.45±0.06
Label-free quantitative analysis for studying the interactions
and protein identification, and to execute differential quan-
titative analysis. Peptide identifications were accepted if
they could be established at greater than 95% probability
as specified by the Peptide Prophet algorithm [29]. Protein
identifications were accepted if they could be established at
greater than 99.0% probability and contained at least two
identified peptides. Protein probabilities were assigned by
the Protein Prophet algorithm [30]. Proteins that contained
similar peptides and could not be differentiated on the basis
of MS–MS analysis alone were grouped to satisfy the prin-
ciples of parsimony. False discovery was found to be 0.1%
for proteins and 0.5% for peptides.
Unweighted spectrum count (USC) was used to assess
the consistency of experimental replicates in quantitative
analysis, and normalized spectrum count (NSC) was used
to retrieve protein abundance. The SC normalization is an
option available in Scaffold by means of which spectral
counts are multiplied by a fractional amount across samples,
so that the total number of spectra are the same within each
category and then across all categories. Fisher’s exact test
was used to identify significant differences and to calculate
P values. Ratios between NSCs were used to perform dif-
ferential quantitative analysis.
Gene ontology [31] (GO) terms for the validated proteins
were retrieved from the NCBI online database [32] by using
Scaffold’s built-in facility. GO uses a controlled vocabulary to
depict biological molecules or gene products in terms of bio-
logical process, molecular function, and cellular component.
Results and discussion
Sample preparation
The separation of the nanoparticle–protein complexes, the
effective unit of interest in biodistribution of the nanopar-
ticles throughout the body [12], from excess plasma proteins
must not destroy the complex or induce additional protein
binding. Therefore, centrifugation was chosen as separation
method to avoid such possibilities [22]. Furthermore, be-
cause our interest focuses on those proteins strongly
adsorbed on to nanoparticles, the so-called “hard corona”,
nanoparticle–protein complex pellet was washed vigorously
three times with 250 μL 10 mmol L−1 Tris–HCl, pH 7.4,
150 mmol L−1 NaCl, and 1 mmol L−1 EDTA, using a vortex
mixer to remove all unbound proteins, and centrifuging for a
short time (2 min), to avoid sedimentation of large proteins,
formation of protein aggregates, and co-precipitation.
Proteome Discoverer and SIEVE analysis results
Complete lists of the proteins validated by Proteome Dis-
coverer over the all fifteen MS–MS files for each sample are
available in the Electronic Supplementary Material (please
refer to the Supporting Excel file).
Fig. 2 Correlation between spectrum count in the three experiments
conducted on the lipoplexes sample: (a) experiment 2 vs experiment 1,
(b) experiment 3 vs experiment 1, and (c) experiment 3 vs experiment
2. Proteins with grouping ambiguity are not represented. In each plot,
Pearson’s product is indicated as r
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Three-hundred and six proteins were validated and ac-
cepted. The number of proteins found in each sample is
summarized in Table 1. Lipoplex protein coronas were the
richest in terms of qualitative composition, whereas that of
the CLs was the poorest. In fact, the number of proteins
found in the former is more than twice as large as that found
in the latter, and it is only approximately 20% greater than
the corresponding value for LPD complexes. On the other
hand, the number of proteins found in LPD complexes
“corona” is approximately 1.8 times the number found in
Table 3 Scaffold relative quantitative analysis results showing protein
abundance (NSC) ratios for proteins having no grouping ambiguity, a P
value smaller than 0.001, and abundance ratio higher than 2 or lower
than 0.5 with a coefficient of variance lower than 0.33. Proteins
containing peptide sequences identical with other isoforms are reported
as one accession number followed by parentheses containing the
relative number of isoforms. Values in parentheses refer to proteins
that do not satisfy Scaffold’s restriction but do satisfy SIEVE’s
Protein name Accession
no.
Lipoplexes/Cls
abundance ratio
LPD complexes/CLs
abundance ratio
LPD complexes/lipoplexes
abundance ratio
Complement component C8 gamma chain IPI00011261 3.8±0.6 2.1±0.6
Prothrombin (Fragment) IPI00019568 (0.01±0.004)
PLG Plasminogen IPI00019580 (1.6±0.5)
cDNA FLJ55673, highly similar to
Complem. fact. B
IPI00019591 (+2) 2.1±0.3 2.5±0.3
Properdin IPI00021364 2.39±0.23
C4b-binding protein alpha chain IPI00021727 0.09±0.01
Apolipoprotein A-I IPI00021841 2.3±0.5 5.1±0.7 2.3±0.3
Apolipoprotein E IPI00021842 3.0±0.6 3.4±0.6 (1.1±0.3)
Apolipoprotein C-III IPI00021857 (+1) 2.9±0.4 2.2±0.3
Isoform 1 of Fibrinogen alpha chain IPI00021885 0.13±0.03 0.26±0.02 2.0±0.4
Apolipoprotein B-100 IPI00022229 2.8±0.3 3.0±0.5 (1.6±0.5)
Complement C1q subcomponent subunit A IPI00022392 0.03±0.01
Complement C1q subcomponent subunit C IPI00022394 0.06±0.02
Complement component C9 IPI00022395 2.8±0.6 3.6±0.8 (1.3±0.3)
Protein AMBP IPI00022426 0.13±0.02
Platelet basic protein IPI00022445 4.8±0.5
Platelet factor 4 IPI00022446 4.2±0.8
Apolipoprotein(a) IPI00029168 2.4±0.2 4.0±0.4 (1.7±0.1)
Complement C5 IPI00032291 2.7±0.8
Lipopolysaccharide-binding protein IPI00032311 3.3±0.9 2.42±0.56
Isoform HMW of Kininogen-1 IPI00032328 0.14±0.03
PFN1 Profilin_1 IPI00216691 (0.4±0.1)
Isoform 2 of Phospholipid transfer protein IPI00217778 (+2) 0.48±0.06
Serum paraoxonase/arylesterase 1 IPI00218732 0.09±0.02 0.08±0.02
Isoform 1 of Vinculin IPI00291175 (+1) 3.1±0.1
Isoform 1 of Clusterin IPI00291262 (+2) 0.38±0.06 0.5±0.1
Inter-alpha-trypsin inhibitor heavy chain H1 IPI00292530 0.17±0.02 0.34±0.08
Inter-alpha-trypsin inhibitor heavy chain H1 IPI00292530 2.0±0.6
Vitamin K-dependent protein S IPI00294004 0.15±0.04
Isoform 1 of Integrin alpha-IIb IPI00295976 2.5±0.5
Fibrinogen beta chain IPI00298497 0.10±0.02 0.19±0.03
Thrombospondin-1 IPI00296099 2.4±0.4
Vitronectin IPI00298971 2.5±0.3 (0.5±0.1)
Talin-1 IPI00298994 3.9±0.7 (0.08±0.05)
Isoform 2 of Filamin-A IPI00302592 (+2) 10±2 0.18±0.06
Hyaluronan-binding protein 2 IPI00746623 (+1) 2.2±0.4
Complement C3 (Fragment) IPI00783987 (1.27±0.06) 2.4±0.1
Label-free quantitative analysis for studying the interactions
that of the CLs. The situation can be further clarified by
observing the distribution of the above numbers among
samples using Venn diagrams, as shown in Fig. 1a. If we
exclude the 59 proteins shared by all samples, protein over-
lap between lipoplexes and LPD complexes is 10 times and
approximately 5 times the protein overlap found between
lipoplexes and CLs, and between LPD complexes and CLs,
respectively.
Relative quantitative analysis was performed on two sam-
ples at a time, each time taking into account the shared proteins
only. For these proteins, the change in abundance was
expressed as the ratio of protein signal intensity measured for
one sample to the signal intensity measured for the other.
Changes were considered significant if the following condi-
tions were met: CV was lower than 10%, P value was lower
than 0.001, Mascot score was higher than 25, and peptides had
Fig. 3 Gene ontology
classification of validated
proteins found in (a) CLs, (b)
lipoplexes, and (c) LPD
complexes. Proteins with
grouping ambiguity were
excluded from the classification
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unique protein assignment. Moreover, signal intensity (abun-
dance) ratios had to be higher than 2 or lower than 0.5 with a
coefficient of variance lower than 0.33. The numbers of pro-
teins found to satisfy the above conditions in the analysis of
lipoplexes vs CLs, LPD complexes vs CLs, and lipoplexes vs
LPD complexes were 9, 2 and 17, respectively. Results are
shown in Table 2.
Fig. 4 Comparisons between relative abundance ratios as obtained by
SIEVE and by Scaffold. Solely validated proteins for which at least one
method has identified a significant relative ratio are shown. Pearson’s
product is indicated as r
Fig. 5 Comparisons between relative abundance ratios as obtained by
SIEVE and by Scaffold. Solely validated proteins for which both
methods have identified a significant relative ratio, irrespective of the
coefficient of variance, are shown. (a) From left to right: IPI00019568,
IPI00021727, IPI00029168, IPI00022229, IPI00032311, and
IPI00298994. (b) From left to right: IPI00022394, IPI00298994,
IPI00216691 and IPI00032291. Pearson’s product is indicated as r
Label-free quantitative analysis for studying the interactions
Scaffold analysis results
The fifteen MS–MS spectra acquired for each sample were
loaded and analyzed with Scaffold using the MuDPIT op-
tion (all spectra were combined in one analysis). A total of
268 proteins were validated. The complete list of identified
proteins is available in the Electronic Supplementary Mate-
rial (Table S1; also, for protein grouping ambiguities, num-
ber of assigned spectra, unique peptides and sequences
coverage).
In comparing the number of proteins found in each sam-
ple, as summarized in Table 1, it is found again that the
lipoplex protein corona is the richest in qualitative compo-
sition whereas that of the CLs is the poorest; protein number
ratios for one sample to another are also very close to those
found in Proteome Discoverer analysis. The distribution of
proteins among samples are shown by use of Venn diagrams
in Fig. 1b. Here we can see that—excluding the 82 proteins
shared by all the samples—protein overlap between lipo-
plexes and LPD complexes is approximately 20 times and 7
times protein overlap found between lipoplexes and CLs,
and between LPD complexes and CLs, respectively.
Proteins abundance was retrieved from spectral counts.
Each experimental replicate was analyzed independently,
combining all technical replicates in one analysis (using
Scaffold’s MuDPIT option). The consistency of replicate
experiments was checked by comparing, among replicates,
the unweighted spectrum count (USC) obtained for each
protein. Figure 2 shows the correlation found between the
three experiments carried out for the lipoplexes sample;
correlations for the two other samples are available in the
Electronic Supplementary Material (Figs. S1 and S2). Pear-
son’s product was calculated and the results indicate that
USCs obtained in the experimental replicates were highly
reproducible. Therefore, NSC mean value (with the
corresponding standard deviation) was calculated for each
protein and used to perform relative quantitative analysis.
Comparisons were made between two samples at a time, each
time taking into account shared proteins only. Ratios between
NSC mean values were calculated only for those proteins
having no grouping ambiguity and having a P value
smaller than 0.001. The numbers of proteins found to
have an NSC ratio higher than 2 or lower than 0.5, with
a coefficient of variance lower than 0.33, in the compar-
ison of lipoplexes vs CLs, LPD complexes vs CLs and
lipoplexes vs LPD complexes were 22, 17 and 12, re-
spectively. Results are reported in Table 3.
Validated proteins were also classified by GO to be reason-
ably representative of the various cellular compartments, bio-
logical processes, and molecular functions they are involved in.
Figure 3 summarizes GO classification for the (Fig. 3a) CLs,
(Fig. 3b) lipoplexes, and (Fig. 3c) LPD complexes samples.
Only small differences were found among samples in the
distributions of values for the biological processes and the
molecular functions. In fact, differences of 1–2% only are
observed among more represented terms. It might be worth
noticing that, among less represented biological process
terms—not reported in Fig. 3—“growth” was found sole-
ly in lipoplexes, a single item, whereas “viral reproduc-
tion” was found in lipoplexes and LPD complexes only,
7 and 6 items, respectively. Regarding terms for less
represented molecular functions, “electron carrier activi-
ty” occurred once in both lipoplexes and LPD com-
plexes, and “translation regulator activity” occurred,
respectively, twice and once; “transcription regulator ac-
tivity” was found—5 times—in lipoplexes only. In con-
trast, some consistent differences were found in the
distribution of the cellular component terms: “extracellu-
lar region” and “nucleus” have different representation in
CLs samples compared with lipoplexes and LPD com-
plexes, larger and smaller, respectively.
Conclusions
Proteome Discoverer and Scaffold analysis were found to
validate an almost equal number of proteins. In particular,
the number of identified proteins in each sample and the
relative overlaps, as obtained by the two software packages,
were found to be highly congruent.
CLs, lipoplexes, and LPD complexes protein coronas
seem to be different in terms of qualitative composition. It
was confirmed [33] that those of lipoplexes and LPD com-
plexes are more variable than those of CLs, whereas there
are small differences between those of lipoplexes and LPD
complexes.
Both NSC Scaffold and AUC SIEVE analysis revealed
there are quantitative differences also; approximately 10%
of the validated proteins differ significantly in their amounts
in the three coronas. Assuming the two methods of analysis
to be complementary [34], the relative amount (signal in-
tensity and abundance ratio) of validated proteins for which
at least one method has identified a significant difference are
compared in Fig. 4. A good correlation between ratios
obtained by the two analytical methods was found for
LPD complexes vs CLs and LPD complexes vs lipoplexes,
whereas a lower correlation was found for lipoplexes vs
CLs, as stated by Pearson’s product. On the other hand,
correlation is substantially increased by taking into account
only those proteins identified by both methods with a sig-
nificant difference, irrespective of the coefficient of vari-
ance, as shown in Fig. 5.
Such results could help in designing gene-delivery sys-
tems, because some proteins could be more selectively
bound than others, and their bio-distribution could be driven
in vivo for more efficient and effective gene therapy.
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